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ABSTRACT
Caloric restriction (CR) increases lifespan and promotes both longevity and
‘healthy-aging.’ CR’s benefits are dependent in part on NAD-dependent deacetylases
known as sirtuins. NAD levels increase with CR promoting sirtuin-mediated
deacetylation of lysine residues. Humans express seven sirtuin isoforms that localize to
specific sub-cellular compartments. Sirtuins and acetylation affect numerous cellular
processes including mitochondrial function. Sirt3 is the major mitochondrial deacetylase
and regulates mitochondrial function namely ATP levels, oxidative stress and
metabolism. Given the importance of mitochondrial acetylation and Sirt3, we
hypothesized the existence of a mitochondrial-localized acetyltransferase that 1) localizes
to the mitochondria; 2) has an acetyltransferase domain; and 3) counters known effects of
Sirt3. We found that the protein GCN5L1 localizes to mitochondria, and its depletion or
overexpression attenuates and augments mitochondrial protein acetylation, respectively.
Sirt3 increases mitochondrial respiration and ATP production. Acute GCN5L1
knockdown also increases mitochondrial respiration and ATP production suggesting
unopposed Sirt3 activity. GCN5L1 promotes the acetylation of the electron transport
chain proteins NDUFA9 and ATP5α (known Sirt3 targets). In addition, Sirt3 knockdown
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leads to mitochondrial hyperacetylation, which is countered by concurrent GCN5L1
depletion. We propose that GCN5L1 is an essential component of a mitochondrial
acetyltransferase complex.
As acetylation levels affect the housekeeping program known as autophagy, we
interrogated GCN5L1’s role in this program. GCN5L1 knockdown causes autophagic
proteins to accumulate on mitochondria, which can be reversed with concurrent Sirt3
depletion. This knockdown selectively promotes the autophagic clearance of
mitochondria (mitophagy) without altering global autophagy. Chronic GCN5L1 depletion
leads to the diminution of mitochondrial proteins/mass that is dependent on the
autophagy proteins ATG5 and p62 but independent of the E3-ligase Parkin. This program
is elevated in GCN5L1 knockout MEFs, which is reversed with reconstitution of
GCN5L1. GCN5L1 depleted mitochondria generate lower ROS levels and are resistant to
MPTP opening. Both mitophagy and mitochondrial biogenesis (i.e. mitochondrial
turnover) are simultaneously elevated with GCN5L1 knockdown. Therefore, GCN5L1
functions as a critical component of the mitochondrial acetyltransferase machinery and
regulates mitochondrial acetylation-dependent mitophagy/mitochondrial biogenesis.
GCN5L1 may play a role in numerous pathologies with known mitochondrial defects
such as neuro-degeneration, obesity and aging.
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Chapter 1 Introduction
Acetylation as a post-translational modification
The cell uses numerous mechanisms to control cellular functions. Aside from
regulating bulk protein expression levels by alterations at the gene, mRNA and ribosomal
stages of production, cells can fine tune protein function through the use of posttranslational modifications (PTM). PTMs can alter amongst other things enzymatic
function and activity, protein localization, interactions with other proteins, threedimensional shape and stability. The best characterized PTM is the phosphorylation of
protein serine, threonine and tyrosine residues by protein kinases. However, recent
advances in proteomics, mass spectrometry and the generation of modification-specific
antibodies have highlighted the importance and broad scope of countless other PTMs
including, but not limited to, lipidation, ubiquitinylation, methylation, sumoylation and
glycosylation. Adding another layer of complexity to the control of proteins by PTMs, a
single protein can have numerous sites and types of modifications occurring
simultaneously. The tumor suppressor p53 is controlled through acetylation, methylation,
phosphorylation, neddylation, sumoylation and ubiquitinylation at > 50 different sites
showing how tightly p53 function is controlled by the cell through utilizing numerous
signaling pathways [1-3]. It should be noted that not all PTMs have a functional
significance on the target protein. These detected PTMs can occur in a non-specific
fashion, especially on long lasting proteins that are turned over slowly, effectively
making some PTMs merely ‘decorations’ that do not appear to alter the protein’s
function [4].
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The regulation of PTMs is controlled both enzymatically and through available
substrate. For example, phosphorylation is regulated by kinases phosphorylating and
phosphatases de-phosphorylating target proteins. Kinases utilize ATP as a substrate for
phosphorylation such that the ATP/ADP ratio, essentially substrate availability, also
dictates the level of protein phosphorylation. This effect is especially seen in the
mitochondrial TCA cycle. High ratios of ATP/ADP slow mitochondrial respiration due to
an abundance of ATP levels in a feedback dependent fashion as originally shown by
Chance and Williams [5]. This feedback inhibition effectively maintains the ratio of
ATP/ADP across a dynamic range, such as cardiac tissue under varying workloads [6].
High ratios of ATP/ADP inhibit mitochondrial proteins both allosterically and through
reversible phosphorylation. Within the TCA cycle this inhibition occurs at the levels of
pyruvate dehydrogenase (PDH), citrate synthase (CS) and isocitrate dehydrogenase
(IDH). High ATP levels inhibit these enzymes allosterically, but a second level of
inhibition occurs by the direct phosphorylation of PDH by pyruvate dehydrogenase
kinase (PDK) [7]. There is also evidence of direct inhibition of IDH by phoshorylation
[8]. Therefore, PTMs are tightly regulated by both enzyme levels but also by substrate
availability.
As mentioned previously, phosphorylation is the best characterized PTM to date.
However, advances in proteomics have revealed an extensive network of other PTMs.
The scope of the PTM acetylation has only begun to be appreciated, an extensiveness that
rivals that of phosphorylation. Acetylation of proteins was initially discovered in the
1960’s with the discovery of acetyl groups attached to histones [9, 10]. Acetylation of
histones is enzymatically mediated by histone acetyltransferases (HATs) and histone
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deacetylases (HDACs). Generally, HATs promote gene activation while HDACs mediate
gene silencing. Lysine is positively charged when deacetylated which would result in
tighter binding of negatively charged DNA to histones and gene silencing. Acetylation by
HATs neutralizes this positive charge and weakens the DNA-histone interaction [11].
Work on acetylation therefore focused on the role of acetylation in the regulation of gene
expression for the ensuing decades [12]. The expansion of acetylation as a PTM beyond
histones was recognized in 1997 with the discovery that p53 is acetylated as well [13].
Acetylation can occur on lysine residues or the amino terminus of proteins. Aminoterminus acetylation is thought to play a role in regulating protein stability and occurs cotranslationally [14]. Acetylation of the ε-amino group of lysine has been shown to be
much more dynamic. Interestingly, aside from being acetylated, the same lysine residue
of a protein can be ubiquitinylated, mono- bi- tri-methylated, sumoylated and neddylated
suggesting extensive cross-talk between numerous signaling cascades [15]. As an
example of such cross-talk, p53 acetylation has been shown to block the ubiquitinylation
of lysine residues therefore preventing p53 nuclear export and degradation by the
proteosome [16, 17]. However, acetylation can also promote protein degradation as
acetylation of the gluconeogenic enzyme, PEPCK, promotes it ubiquitinylation and
degradation whereas its deacetylation promotes PEPCK stability [18].
Similar to phosphorylation, protein acetylation is regulated by substrate
availability. Acetyltransferases utilize acetyl-CoA, derived from glucose/pyruvate or fatty
acids, as a substrate to acetylate protein targets. With regards to nuclear HATs, acetylCoA is generated in the mitochondria and converted to citrate by the TCA cycle. Citrate
is then shuttled into the cytosol where ATP-citrate lyase (ACL) cleaves citrate into
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oxaloacetate and acetyl-CoA. Cytosolic acetyl-CoA can be used for fatty acid synthesis
or move into the nucleus for HAT mediated histone acetylation. Increased histone
acetylation in response to growth factors and glucose availability is dependent on ACL
generated acetyl-CoA linking gene expression to substrate availability [19].
Concurrently, deacetylation by class III deacetylases (sirtuins-see below) is mediated by
the substrate nicotinamide adenine dinucleotide (NAD or NADH when reduced). As such
the NAD/NADH ratio regulates sirtuin activity and therefore deacetylation of protein
targets. Increasing the generation of NAD by overexpression of nicotinamide
phosphoribosyltransferase (NAMPT), the rate-limiting enzyme NAD biosynthesis, drives
sirtuin activity and protein deacetylation [20]. Overall acetylation status is highly
regulated by acetyl-CoA and NAD levels. Feeding and fasting could alter acetyl-CoA
levels (higher with feeding) and the NAD/NADH ratio (higher with fasting) therefore
linking acetylation to the nutrient status of the cell and implicating acetylation status as a
key regulator of cellular metabolism.
By 2006 the number of proteins shown to undergo lysine acetylation had grown to
~100. Using mass spectrometry, three seminal studies greatly expanded the number of
proteins known to undergo lysine acetylation. Kim et al. identified 195 protein targets
with 388 acetylated lysine sites. Interestingly, acetylation of numerous sites changed
when cells were fed or fasted. Also of note ~20% of all mitochondrial proteins (133
proteins) were acetylated. The high number of acetylated mitochondrial proteins further
expanded this PTM beyond histones and the nucleus [21]. Another proteomics study
identified ~1750 acetylated protein targets with >3600 acetylation sites [22]. Zhou et al.
showed >900 non-nuclear proteins are acetylated [23]. Taken together >2000 proteins are
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acetylated including structural proteins, kinases, transcription factors, ubiquitin ligases
and metabolic enzymes. Of note, many metabolic enzymes involved in most major
metabolic pathways such as gluconeogenesis, glycolysis, fatty acid and amino acid
metabolism, the urea cycle and glycogen metabolism are found to be acetylated. The
mitochondria is involved in most of these pathways suggesting that the 20% of acetylated
mitochondrial proteins greatly regulate metabolism [24].
To date, approximately 500 kinases and 700 ubiquitin E3 ligases have been
described. However, only 22 acetyltransferases and 18 deacetylases are known [24].
Acetyltransferases fall into three classes: GNAT (GCN5-related N-acetyltransferases),
p300/CBP and MYST, which are classified based on conserved motifs. Each
acetyltransferase has a highly conserved acetyl-CoA binding site [25]. Protein
deacetylases are classified into four classes based on sequence homology with class I, II
and IV being zinc dependent and act by deacetylating target proteins with the use of
water to generate acetate; while class III consists of the NAD dependent sirtuin
deacetylases that target acetylated proteins and generate nicotinamide and 1-O-acetylADP-ribose as products [12] (Figure 1). Class I shows homology to the yeast deacetylase
Rpd3 and includes histone deacetylase (HDAC) 1, 2, 3 and 8; Class II shows homology
to the yeast enzyme Hda1 and includes HDAC 4, 5, 6,7, 9 and 10; and Class IV consists
of HDAC 11. Class III, the sirtuins, consists of Sirt1-7 [15]. It should be noted that
numerous HDACs (namely HDAC 1, 2 and 3) and all acetyltransferases function as
multi-subunit proteins [26, 27]. The presence of acetylated proteins was discovered in
1964, but the first identification of a protein with acetyltransferase activity did not come
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Figure 1: Sirtuin (sirt) mediated deacetylation or ADP-ribosylation of target proteins.
Sirt1, 2, 3, 5 and 7 perform deacetylation of cellular proteins utilizing the substrate NAD
(nicotinamide adenine dinucleotide) and yields deacetylated protein targets, acetyl-ADPribose and nicotinamide. Sirt4 and 6 also use NAD as a substrate but add ADP-ribose to
target proteins with the generation of nicotinamide. Sirt5 is also proposed to perform
desuccinylation and demalonylation reactions in the mitochondria.
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until 1979 with the first acetyltransferase complex characterized in 1997 [27-29].
Therefore, given that greater than 2000 proteins are known to undergo acetylation and the
slow progress in identifying the known 22 acetyltransferases and 18 deacetylases, it is
likely that more enzymes are yet to be discovered that regulate this PTM.
Caloric restriction and longevity
In the 1930’s Clive McCay showed that caloric restriction (CR) increased lifespan
in rats by up to 40% [30, 31]. CR is defined as a reduction in daily caloric intake by 3060%. The benefits of CR have been extended to other organisms including yeast, worms,
flies, mice and non-human primates and improve quality of life, delay age-related
diseases and reduce mortality [32]. Different CR protocols have been used including a
reduction in glucose or amino acid availability, but in general, life span extension in
yeast, worms, flies and mice results in a mean and maximal lifespan extension of 20100% [33]. However, the ability to increase life span in non-human primates has yielded
conflicting results in two longitudinal studies. In a 20-year study, Colman et al. showed
that CR treated rhesus monkeys (CR by 30%) have a delay in age-related pathologies
such as diabetes, cancer, brain atrophy and cardiovascular disease. The incidence of
cardiovascular disease and cancer was reduced by 50% in the CR treated group while
total age-related disease was reduced approximately three times compared to control
animals. When only age-related deaths are considered, survival analysis showed a
statistically significant improvement in CR treated groups (p = 0.03). However, when all
deaths were included mortality rates were statistically insignificant (p = 0.16) [34]. In
contrast, another longitudinal study failed to show an increase is survival rates in CR
treated rhesus monkeys even when only age- related deaths were analyzed. Similar to the
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results found by Colman et al., cancer related pathology was reduced with CR, but
diabetes and cardiovascular disease only trended downwards. Possible reasons for the
discrepancy between the two studies include differences in dietary content and genetic
differences between the groups of rhesus monkeys used [35], but the overall differences
highlight the complexities of studying how CR may benefit longevity and age-related
pathologies.
Despite conflicting results on whether CR may extend lifespan, CR is believed to
alter the aging process by regulating cellular metabolism, gene expression and signaling
pathways to allow the cell to minimize inflammation, oxidative stress and mitochondrial
dysfunction, all of which increase with age. Oxidative stress (ROS) was originally
proposed to augment aging by Harmen in 1956 by promoting cellular senescence through
DNA damage [36]. CR is thought to reduce ROS levels and the accumulation of ROS
damaged macromolecules [37]. Levels of peroxidized lipids, carbonylated proteins and
damaged DNA are lower with CR treatment possibly due to increased activation of
housekeeping programs such as the proteosome and autophagy [38]. The mitochondria
are the major source of ROS, and CR improves mitochondrial function and attenuates
mitochondrial generated ROS [37, 39]. Antioxidant systems, such as SOD and catalase,
are also thought to be augmented with CR [37].
The molecular mechanisms of the benefits of CR are only beginning to be
understood. To date, the signaling pathways/proteins coordinating CR’s ability to extend
lifespan tend to be those that are activated or inhibited in response to nutrient availability
including the insulin/IGF-1 pathway, mTOR, AMP-kinase (AMPK) and sirtuins (see
below) with extensive cross-talk occurring between numerous signaling pathways leading
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to activation of beneficial stress responses; autophagy to removed defective organelles
and toxic protein aggregates; improved oxidative stress (ROS) handling; changes in
ribosome/protein synthesis; and effects on metabolic rate [33, 37] (Figure 2). In worms,
Daf-16 (a member of the Foxo transcription factor family) is phosphorylated in response
to activation of Daf-2, an insulin-like receptor, by insulin or IGF-1. This phosphorylation
event prevents Daf-16 from entering the nucleus and thus prevents activation of
protective anti-oxidant and stress pathways. Therefore mutations that inhibit Daf-2 or
activate Daf-16 have been shown to promote longevity [37, 40-42]. Linking nutrient
availability to IGF-1 signaling, glucose inhibits Daf-16 and shortens lifespan [43].
Two other nutrient sensing proteins linked to the benefits of CR are AMPK and
mTOR. AMPK is activated upon an increase in the AMP/ATP ratio, which would be
expected to be higher with CR, and acts as a major regulator of the cell’s starvation
response. AMPK increases glycolysis and glucose uptake by its action on GLUT4 and
phospho-fructo kinase 2. It also promotes fatty acid oxidation by activating CD36,
lipoprotein lipase and acetyl-CoA carboxylase (and preventing the formation of the CPT1
inhibitor malonly-CoA) [44]. AMPK also inhibits the anabolic processes of triglyceride,
ketone, glycogen and cholesterol synthesis. To promote appetite, ghrelin signaling
increases AMPK activity in the arcuate nucleus of the hypothalamus activating
NPY/AgRP neurons [45]. Insulin/IGF-1 signaling inhibits AMPK, and AMPK
overexpression increases lifespan [46]. mTOR is a serine/threonine kinase and exists in
one of two complexes containing Rictor or Raptor. mTOR is activated by high levels of
amino acids (i.e. a fed state) and promotes protein translation by activating or inhibiting
p70s6k and 4ebp1, respectively. CR is proposed to inhibit mTOR activity. mTOR
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Figure 2: Caloric restriction (CR) augments lifespan in various organisms and utilizes
several signaling pathways in a coordinated fashion. CR is believed to change metabolite
ratios such as AMP/ATP (adenosine mono/tri-phosphate) and NAD/NADH
(nicotinamide adenine dinucleotide), and increases in AMP and NAD levels activate the
nutrient sensing enzymes AMPK (AMP-activated kinase) and sirtuins. CR is also thought
to lower levels of amino acids and insulin signaling, which attenuates mTOR
(mammalian target of rapamycin) and IGF (insulin-like growth factor) signaling.
Through these signaling cascades CR can activate housekeeping programs, such as
autophagy, lower oxidative stress, attenuate growth and promote mitochondrial function,
which all play a role in ameliorating age-associated degeneration. Numerous drugs are
being investigated to activate/inhibit these pathways to pharmacologically mimic CR. (5aminoimidazole-4-carboxamide ribonucleotide, AICAR)
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depletion can extend lifespan in yeast [47] or flies [37, 48]. Further promoting mTOR as
a mediator of CR mediated longevity, rapamycin, an mTOR inhibitor, treatment extends
lifespan in aged mice by 14% for females and 9% for males [49]. AMPK and mTOR also
coordinate their activities together with AMPK inhibiting mTOR through activation of
TSC-1. In addition, CR is thought to activate autophagy, which is a key cellular
housekeeping process to recycle nutrients and to eliminate defective organelles such as
ROS generating mitochondria and toxic protein aggregates seen in numerous
neurodegenerative disorders (see below). Autophagy has been shown to be reduced with
aging [50]. AMPK and mTOR activate and inhibit autophagy induction, respectively, in
two ways. Low glucose stimulates AMPK to activate the autophagy protein,
ATG1/ULK1, through phosphorylation at Ser 317 and Ser 777. mTOR meanwhile
inhibits ATG1/ULK1 by phosphorylating Ser 317 when nutrients are plentiful. Secondly,
AMPK can inhibit mTOR directly to promote autophagy [51].
It is unlikely that many people would willingly maintain a CR diet. Therefore
attempts have been made to create drugs to mimic the benefits of CR, and many of these
drugs target AMPK and mTOR (Figure 2). The drug rapamycin was originally
discovered in 1975 [52]. It has been used as an immunosuppressant and cancer treatment,
especially for renal carcinomas. Its ability to extend lifespan is believed to be due to its
inhibition of mTOR, which is inhibited when amino acids are limited, therefore lowering
protein synthesis and activating cellular-component recycling through autophagy [53].
Rapamycin has been shown to reverse the aging phenotype in cells from HutchinsonGilford progeria cells, a disease that causes premature aging [54]. The diabetic drug
metformin was originally discovered in the 1920s and inhibits hepatic gluconeogenesis
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[53]. Metformin is thought to activate AMPK, possibly inhibit mTOR and can act as a
CR mimetic by increasing lifespan in mice [53, 55]. Another possible AMPK activator is
5-aminoimidazole-4-carboxyamide ribonucleoside (AICAR). Therefore the ability to
mimic CR pharmacologically may improve the aging process without actually having to
maintain a CR diet.
Nuclear and cytosolic sirtuins (Sirt1, 2, 6 and 7)
Along with AMPK, mTOR and IGF-1 signaling another target that CR modulates
is the family of deacetylases known as sirtuins. As mentioned, sirtuins are dependent on
the metabolite NAD and deacetylate target proteins generating nicotinamide and 1-Oacetyl-ADP-ribose as by-products (Figure 1). It has been proposed that when nutrients
are available the NAD/NADH ratio would drop inhibiting sirtuin mediated deacetylation
while NAD levels are elevated during fasting or CR thus activating sirtuins. However, the
simplicity of this model has been questioned and is more likely tissue specific [56].
Overall, the sirtuins are centrally positioned to regulate the cell’s response to CR and
therefore possibly longevity. Sirtuins were initially described in yeast as a silencing
factor (silencing information regulator), and the protein Sir2 was found to regulate life
span in yeast linking the PTM of acetylation to life span [57]. Furthermore, the benefits
of CR on lifespan extension are reported to be dependent on Sir2 [58, 59].
Overexpression of Sir2 in worms was also shown to increase lifespan [60]. However, this
link has been questioned due to lack of proper controls for genetic background between
strains, which when taken into account Sir2 overexpression did not alter lifespan, adding
controversy to an already controversial field [61]. Mammals express seven sirtuins (Sirt17) that are found in distinct cellular compartments including the nucleus (Sirt1, 6 and 7),
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cytosol (Sirt1, 2) and mitochondria (Sirt3, 4 and 5). Sirt1, 2 and 3 show the closest
homology to Sir2 and exhibit the most robust deacetylase activity. Sirt4 and 6 are thought
to mediate ADP-ribosylation, although Sirt6 also shows weak deacetylase activity [62].
Sirt3 is thought to be the major deacetylase in the mitochondria (see below) while Sirt5 is
thought to have desuccinylase and demalonylase activity [63, 64]. The link between
sirtuins and aging in mammals has also been inconclusive as Sirt1 overexpression in mice
does not extend lifespan but showed diminished DNA damage and aging markers along
with lower incidence of carcinomas [65] while Sirt6 overexpression increased lifespan in
male mice through attenuated IGF-1 signaling [66]. Although a direct link between
sirtuins and increased lifespan has been inconclusive, sirtuin activity does appear to
promote ‘healthy aging’ rather than a direct effect on lifespan extension.
Despite the inability of Sirt1 overexpression to extend lifespan, Sirt1 activity on
target proteins is thought to promote healthy aging through its effects on age-related
pathologies such as neurodegeneration, cancer, metabolic syndrome, diabetes and
cardiovascular disease [59], and the regulation of metabolism is one of the main
mechanisms whereby Sirt1 is protective against these aging co-morbidities (Figure 3).
One of the key elements of the fasting response is the induction of gluconeogenesis, betaoxidation and mitochondrial biogenesis. Sirt1 can deacetylate the transcription factor
Foxo1 promoting production of the gluconeogenic enzymes PEPCK and glucose-6phosphatase, and the disruption of Sirt1 mediated deacetylation decreased fasting blood
glucose levels in mice [67, 68]. Beta-oxidation and mitochondrial biogenesis induction
are mediated by Sirt1 activation of PPAR𝛼 (along with Foxo1 which increases
triglyceride lipase expression) and PGC1-α, respectively [69-71]. Sirt1 controls
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Figure 3: Sirt1 is a cytosolic and nuclear localized sirtuin that regulates numerous
cellular processes. Sirt1 deacetylates numerous transcription factors and cellular proteins
to coordinate cellular metabolism in response to caloric restriction (CR). Deacetylation of
other Sirt1 targets is thought to play a role in the pathogenesis of several age-related
diseases. Crosstalk between Sirt1 and AMPK (AMP-activated kinase) further coordinates
the response to CR. (uncoupling protein-2,UCP2; peroxisome proliferator-activated
receptor gamma coactivator 1-alpha, PGC-1α; sterol regulatory element-binding
proteins-1, SREBP-1; peroxisome proliferator-activated receptors, PPARα/γ; brain and
muscle aryl hydrocarbon receptor nuclear translocator (ARNT)-like, Bmal; nicotinamide
adenine dinucleotide, NAD; liver kinase B1, LKB1, nicotinamide
phosphoribosyltransferase, NAMPT; nuclear factor kappa-light-chain-enhancer of
activated B cells, NF-κB; endothelial nitric oxide synthase, eNOS; hypoxia-inducible
factor 1, alpha subunit, HIF-1α)
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cholesterol and lipid synthesis by negatively regulating the sterol regulatory elementbinding protein-1 (SREBP-1). Fasting attenuated while feeding augmented acetylation
levels of SREBP-1in a Sirt1/p300 dependent manner. Sirt1 deacetylation of SREBP-1
leads to its ubiquitinylation and degradation improving the lipid profile of high fat diet
mice [72]. Sirt1 also improves insulin secretion by inhibiting expression of uncoupling
protein 2 and inhibits adipocyte maturation by blocking PPARγ (which is also inhibited
by the Sirt1 target FoxO1) activity [71, 73, 74]. In fact, Sirt1 overexpression protects
against high fat diet induced insulin resistance [75]. In addition, Sirt1 has been shown to
deacetylate and activate eNOS. eNOS generates cardioprotective NO which vasodilates
blood vessels, inhibits atherosclerosis and attenuates inflammation [76]. Thus Sirt1
mediated control of glucose, lipid and mitochondrial homeostasis may have implications
in diabetes, metabolic syndrome and cardiovascular health.
Aging also increases the risk for cancer, inflammatory disease and
neurodegeneration. With regards to cancer, Sirt1 acts on HIF-1α repressing its proangiogenic activity. Tumors tend to be hypoxic, which activates HIF-1α. Hypoxia lowers
Sirt1 levels due to lower NAD levels, which can be reversed by increasing NAD levels.
Furthermore, increasing Sirt1 expression is able to suppress HIF-1α activation with
subsequent reductions in tumor growth [77]. Sirt1 also promotes DNA stability by
deacetylating the DNA repair protein KU70 [78]. However, the evidence is not linear as
numerous lines of evidence suggest that Sirt1 may also promote carcinogenesis as various
tumors show elevated Sirt1 levels [79], and Sirt1 inhibits the tumor suppressors p53 and
Rb thereby blocking apoptosis and stimulating the cell cycle, respectively [80-82].
Inflammation is also a marker for aging with 2-4 fold elevations in IL-6, C-reactive
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protein (CRP) and tumor necrosis factor (TNF)-α, occurring systemically [83]. Sirt1
blocks inflammation by inhibiting NF-κB [84] and activating Foxo3, which induces
expression of the antioxidant enzymes superoxide dismutase and catalase [85]. Sirt1
knockout in mouse macrophages similarly increases LPS induced TNF-α secretion with
increased JNK activity while Sirt1 activation diminishes tissue inflammation in obese rats
[86]. With regards to neurodegeneration, Sirt1 is vital to cognitive function as Sirt1
depletion in mice diminished spatial learning and memory (Sirt1 expression is high in the
hippocampus) with defective synaptic transmission and dendritic branching [87]. Sirt1
increases the expression of α-secretase by inducing the ADAM10 gene, which acts on βamyloid aggregates seen in Alzheimer’s disease. Interestingly, brain specific Sirt1
knockouts showed increased β-amyloid aggregation while Sirt1 overexpression lowered
aggregation [88]. Sirt1 can also deacetylate the tau protein seen in Alzheimer’s disease
promoting its clearance [89]. Sirt1 is also involved in Parkinson’s disease by blocking αsynuclein aggregation, which seems to be mediated by activation of autophagy through
deacetylation of numerous autophagy proteins (see below) and the chaperone protein
HSP70 through HSF-1 [90, 91]. Sirt1’s activation of PGC-1α may also play a role as
PGC-1α is thought to be a therapeutic target for Parkinson’s disease [92].
Interestingly, Sirt1 activity is linked to the other CR regulated enzymes mTOR
and AMPK. Sirt1 decreases mTOR activity, which as stated previously is also inhibited
by CR, in neurons promoting their survival in fed and nutrient deprived conditions [93].
Sirt1 activity is tightly coupled to AMPK and vice-versa. Sirt1 can deacetylate LKB1,
which is an upstream activator of AMPK [94]. Meanwhile AMPK can activate Sirt1 by
increasing the de novo production of NAD by increased expression of NAMPT [95, 96].
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Of note, NAMPT overexpression, with subsequent increases in NAD levels, can inhibit
infarct size following ischemia in cardiomyocytes by inhibiting apoptosis and increasing
autophagy presumably through sirtuin activation [97]. This crosstalk between Sirt1 and
AMPK would occur with CR, fasting or exercise raising AMP levels to activate AMPK,
which would increase already elevated levels of NAD to activate Sirt1 thus creating a
positive feedback loop with AMPK through increased activation of LKB1 by Sirt1. Sirt1
and AMPK can then work in tandem to activate PGC1-α to promote gluconeogenesis, βoxidation and mitochondrial biogenesis [98-100]. Sirt1 and AMPK also work together to
regulate circadian rhythms. The circadian rhythm allows a cell to proactively anticipate
metabolic changes over the course of a 24-hour daily cycle. Numerous genes are
expressed cyclically throughout the day (up to 15% of expressed genes) with a large
fraction being metabolic enzymes [101]. In fact, the importance of circadian rhythm to
obesity was highlighted when mice were fed a high fat diet either ad libitum or restricted
to only 8 hours a day. Both groups consumed the same amount of calories each day. Yet
the time restricted group showed significantly less weight gain and maintained insulin
sensitivity in part through increased diurnal rhythms of the circadian clock and AMPK
activity suggesting that “you are when (as opposed to what) you eat” [102]. Central to the
circadian rhythm are core transcription factors whose expression oscillates throughout the
day and includes Per1/2, Cry1/2, Bmal and Clock (which interestingly shows HAT
activity). Interestingly, NAMPT levels oscillate along with NAD in the liver thereby
modulating Sirt1 function [103]. NAMPT expression is inhibited by Per2/Clock/Bmal
complex in part by acetylation of Bmal by Clock, which is countered by Sirt1 thus
allowing Sirt1 to promote its own activity by increasing expression of NAMPT.
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Therefore, Sirt1 directly regulates the circadian rhythm by its action on Bmal and Per2
[101, 103]. AMPK localization to the nucleus also oscillates, and AMPK can act on Cry1
(indirectly inhibiting Per2 and promoting NAMPT expression) promoting its degradation
[104]. The circadian rhythm coordinates daily activities, and its disruption can greatly
influence disease progression [105]. Therefore, it is not surprising that the crosstalk
between longevity proteins influences the circadian rhythm.
The abundant work on Sirt1 has shown that through deacetylation of numerous
targets in the cytosol and nucleus Sirt1 can regulate metabolism and cellular homeostasis
to greatly affect aging-related pathologies and is centrally located to play a part in the
cell’s response to CR. Also of note, the other cytosolic and nuclear localized sirtuins
(Sirt2, 6 and 7) are emerging as key regulators of cell function. Sirt2 is the only
exclusively localized cytosolic sirtuin and mirrors Sirt1 in various ways by regulating
metabolism, inflammation and carcinogenesis. For instance, it can deacetylate the Sirt1
targets FoxO1 and FoxO3 promoting their nuclear translocation and promoting lipolysis
and gluconeogenesis [106, 107]. CR increases Sirt2 in adipose tissue leading to FoxO1
deacetylation, which then inhibits PPARγ mediated adipocyte differentiation [106].
FoxO1 expression increases PEPCK expression, and Sirt2 can directly deacetylate
PEPCK promoting its stability and countering glucose/p300 mediated acetylation and
degradation by ubiquitinylation [18]. It also acts on FoxO3 to promote MnSOD
expression to attenuate oxidative stress [108]. Also like Sirt1, it can deacetylate NF-κB
on the p65 subunit therefore regulating inflammatory pathways [109]. With regards to
cancer, Sirt2 knockout mice show increased tumorigenesis. Males show increased
hepatocellular carcinoma while females had increased mammary tumors [110]. Sirt2’s
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tumor suppressor activity is thought to be mediated through regulation of genomic
stability during mitosis and delaying cell cycle progression by deacetylating tubulin [110112]. It is also thought to augment apoptosis through induction of the pro-apoptotic
proteins Bim (by FoxO3 activation) and BAD, via suppression of 14-3-3 ζ expression
and cytosolic sequestration of BAD [108] [113]. As a final tumor suppression
mechanism, Sirt2 expression is diminished by HIF-1α, which is inhibited by Sirt1 [114].
Interestingly, Sirt2 was recently shown to be vital to programmed necrosis through its
actions on the RIP1-RIP3 complex formation, which are key players in TNF-α-induced
programmed necrosis [115].
Sirt6 and Sirt7 along with Sirt1 localize to the nucleus. Rather than deacetylation,
Sirt6 performs NAD-dependent ADP-ribosylation. The best known targets of Sirt6 are
H3K9 and HK56 [100]. As mentioned, Sirt6 overexpression increased longevity in male
mice by 15% [66]. Overexpression of Sirt6 attenuated fat accumulation in mice fed a
high fat diet and improved insulin sensitivity by down regulating genes linked to lipid
storage [116]. Along with effects on fat accumulation, Sirt6 regulates glucose
homeostasis as Sirt6 knockouts die shortly after birth of hypoglycemia due to increased
Glut1 expression and glucose uptake into skeletal muscles. This effect is also in part due
to increased HIF-1α activity, glycolysis and diminished mitochondrial respiration
reminiscent of the cancer metabolic profile, the Warburg effect [117]. In fact, Sirt6
knockout cells are more glycolytic and show increased tumorigenesis with several
cancers showing lower levels of Sirt6 [118]. Sirt6 also promotes the repair of age and
oxidative stress-damaged DNA and attenuates senescence by promoting homologous
recombination and activating the ADP-polymerase PARP1 [119, 120]. As mentioned,
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IGF signaling is linked to diminished lifespan, and Sirt6 attenuates expression of IGF
signaling-related genes limiting cardiac hypertrophy [121]. Sirt6 also suppresses
hypertrophy through inhibition of NF-κB signaling [122]. Therefore, Sirt6 increases
lifespan by regulating glucose homeostasis, fat accumulation, lowering IGF signaling and
functioning as a tumor suppressor. Sirt7 is the least studied sirtuin and localizes to the
nucleolus deacetylating histone 3 K18 residues and attenuating tumorigenesis of cancer
xenographs in mice [123]. Sirt7 knockouts have diminished lifespan with increased
hypertrophy, inflammatory cardiomyopathy, fibrosis and increased p53 acetylation
leading to increased apoptosis [124]. In addition, Sirt7 increases RNA polymerase I
mediated transcription [125]. Therefore, like Sirt1, the other cytosolic/nuclear sirtuins
regulate metabolism, carcinogenesis and inflammation and may mediate many of the
benefits of CR.
Mitochondrial sirtuins (Sirt3, 4 and 5)
Three sirtuins (Sirt3, Sirt4 and Sirt5) localize to the mitochondria and greatly
regulate mitochondrial function (Figure 4) [126]. Along with Sirt1 and Sirt2, Sirt3 shows
strong deacetylase activity and like Sirt1 has been extensively studied. As such, Sirt3 is
the major mitochondrial deacetylase while Sirt4 and Sirt5 appear to perform other PTMs
(see below) [63]. Mice express both a long and short isoforms of Sirt3 with the long
isoform containing a mitochondrial localization sequence [127, 128]. The long isoform is
translated in the cytosol as a 44-kDa protein that is transported into the mitochondrial
matrix and cleaved to form the final 28-kDa protein [129]. There is also evidence that
Sirt3 can localize to the nucleus [130], but this may be an artifact from Sirt3
overexpression. Interestingly, CR and fasting increase expression of Sirt3 in liver,
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Figure 4: Mitochondrial sirtuins regulate mitochondrial function. Sirt3, 4 and 5 localize to the
mitochondria with Sirt3 being the major deacetylase. Sirt4 and 5 perform ADP-ribosylation and
desuccinylation/malonylation, respectively. Sirt3 deacetylates numerous targets to regulate lipid,
glucose and amino acid metabolism, oxidative stress and ATP (adenosine triphosphate)
generation. (voltage dependent anion channel, VDAC; peroxisome proliferator-activated receptor
gamma coactivator 1-alpha, PGC-1α; nicotinamide adenine dinucleotide phosphate, NADP;
hypoxia-inducible factor 1, alpha subunit, HIF-1α; AMP-activated kinase, AMPK; manganese
superoxide dismutase, MnSOD; reactive oxygen species, ROS; glutamate dehydrogenase, GDH;
isocitrate dehydrogenase, IDH; alpha ketoglutarate, α-KG; Ornithine transcarbamylase, OTC;
carbamoyl phosphate synthetase 1, CPS1; cyclophilin D, CyP-D; Adenine nucleotide
translocator, ANT; 3-hydroxy-3-methylglutaryl-CoA synthase-2, HMG-CoA synthase2;
Glutathione disulfide, GSSG; glutathione, GSH)
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skeletal muscle, brown adipose tissue, heart and kidney while chronic high fat diet and
diabetes lowers expression [131-134]. Sirt3 is also induced at the same time as
mitochondrial biogenesis with PGC1-α and ERRα activating the Sirt3 promoter [135,
136]. Sirt3 knockout animals are phenotypically normal but show hyperacetylation of
mitochondrial proteins [137]. Despite being phenotypically normal, Sirt3 knockout
animals have a >50% reduction in basal ATP levels in heart, liver and kidney tissues
[138]. Reductions in ATP levels are caused in part by the hyperacetylation of complex I
(NDUFA9) in Sirt3 knockout mitochondria, but this defect can be blocked in Sirt3
knockout MEFs by restoring Sirt3 expression [138]. Sirt3 has also been found to
deacetylate other components of the electron transport chain namely Complex I
(NDUFA11, NDUFS8) [138, 139]; Complex II (SDHA, SDHB) [139]; Complex III (56kDa core I subunit ) [131]; and Complex V (ATP5A1, ATP5B1, ATP5F1) [100, 139].
Therefore, it appears that Sirt3 greatly affects mitochondrial function and oxidative
phosphorylation through regulation of acetylation.
Mitochondria serve as central hubs for metabolism of lipids, glucose and proteins.
Non-alcohol fatty liver disease (NAFLD), diabetes and metabolic syndrome can lead to
lipotoxicity [136], and there is abundant evidence of a role for Sirt3 in regulating lipid
metabolism. Following fasting, livers from Sirt3 knockout animals have elevated
triglycerides and β-oxidation intermediates suggesting a defect in lipid metabolism [133].
High fat diet (HFD) also increases mitochondrial protein acetylation (including
complexes III and IV) and lowers Sirt3 expression while Sirt3 knockout animals on HFD
show accelerated development of metabolic syndrome (obesity, insulin resistance,
hyperlipidemia and hepatic steatosis) and reduced mitochondrial function [140-142].
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Susceptibility to lipotoxicity is enhanced in primary hepatocytes with Sirt3 depletion,
which can be reversed with N-acetylcysteine or Sirt3 reconstitution [141]. These effects
on lipid metabolism are mediated in part on Sirt3 activity including the deacetylation and
activation of long-chain acyl-CoA dehydrogenase (LCAD) while Sirt3 knockouts have
hyperacetylated LCAD [132, 133]. As mentioned, fatty acid metabolism is promoted by
AMPK and PGC1-α. There appears to be crosstalk between Sirt3, AMPK and PGC1-α as
overexpression of Sirt3 increases PGC1-α levels [143, 144] and increases AMPK
activation with diminished lipid accumulation [145]. These effects are reversed by Sirt3
depletion suggesting crosstalk between these two lipid metabolizing enzymes. Sirt3 has
also been suggested to deacetylate the upstream AMPK activator LKB1 [146]. Given the
crosstalk between Sirt1, AMPK and PGC1-α, it is possible that Sirt1 and Sirt3 also
coordinate effects on metabolism. Fatty acids can also be metabolized into ketone bodies
during fasting/CR to feed the heart and brain. Sirt3 promotes ketogenesis by
deacetylating and activating the rate limiting enzyme 3-hydroxy-3-methylglutaryl-coA
synthase 2 with Sirt3 knockouts showing diminished ketone body levels following fasting
[147]. Sirt3 can increase fatty acid production using acetate as a substrate by increasing
acetyl-CoA levels. It does this by deacetylating acetyl-CoA synthetase-2 (AceCS2),
which converts acetate into acetyl-CoA and can then be used for fatty acid synthesis.
AceCS2 is mitochondrial, and of note, Sirt1 activates the cytosolic AceCS1 [148].
Interestingly, this same system of regulation is found in the bacteria Salmonella enteric
with the bacterial sirtuin homolog CobB activating and an identified acetyltransferase Pat
inhibiting acetyl-CoA synthetase [149, 150]. It should be noted that no mitochondrial
eukaryotic acetyltransferase to counter Sirt3 activity on AceCS2 has been identified.
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Overall, Sirt3 greatly regulates lipid metabolism through its actions on numerous protein
targets.
In addition to lipid metabolism, Sirt3 affects protein metabolism. Sirt3 positively
regulates the enzyme glutamate dehydrogenase (GDH) leading to improved insulin
secretion, which counters the activity of Sirt4 on GDH (see below) [151]. GDH converts
glutamate into α-ketoglutarate with subsequent generation of ammonia. This ammonia is
converted into urea for subsequent elimination by the urea cycle. Sirt3 deacetylates the
urea cycle enzyme ornithine transcarbamylase (OTC), and Sirt3 knockout during CR
leads to elevated orotic acid levels, which is a signature of the metabolic disorder OTC
deficiency [132]. Therefore by activating GDH and OTC Sirt3 is able to regulate amino
acid catabolism.
Sirt3 can also influence glucose metabolism through its effects on hexokinase II
activity and cyclophilin D. Cyclophilin D is thought to be a component of the
mitochondrial permeability transition pore (MPTP). Sirt3 has been shown to deacetylate
cyclophilin D inhibiting its peptidyl-prolyl cis-trans isomerase activity causing it to
dissociate from adenine nucleotide translocator (ANT) which then promotes the release
of hexokinase II from VDAC and the outer mitochondrial membrane (OMM).
Mitochondrial localized hexokinase II promotes glycolysis, but its release form the OMM
shifts cell metabolism to oxidative phosphorylation, which is inhibited in cancer (i.e. the
Warburg effect) [152]. Therefore in combination with deacetylation of electron transport
chain proteins, crosstalk with AMPK and PGC1-α and cyclophilin D inhibition, Sirt3
promotes oxidative phosphorylation with a shift away from glycolysis and glucose
metabolism.
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Sirt3 has also been described as a tumor suppressor. This tumor suppressor role is
in part due to its ability to regulate mitochondrial ROS generation. Oxidative stress is
thought to be a central mediator of carcinogenesis and aging with 90% of ROS being
mitochondrial derived. Mitochondria have inherent anti-oxidant scavenging systems to
handle ROS such the Mn superoxide dismutase (MnSOD) [136]. Sirt3 is able to
deacetylate and activate MnSOD during CR to attenuate ROS levels [153, 154]. In fact,
Sirt3 activation of MnSOD prevented oncogene-mediated immortalization of MEF cells,
further suggesting a tumor suppressor function for Sirt3 [155]. In addition to direct
deacetylation of MnSOD, there are suggestions that Sirt3 increases expression of
MnSOD by increasing FoxO3a activity [156, 157]. A recent report suggests that low
glucose levels causes FoxO3a to localize to the mitochondria where it interacts with Sirt3
and mitochondrial RNA polymerase leading to mitochondrial genome activation and
increased respiration [158]. Mitochondria also regulate ROS levels through glutathione
by generating NADPH by isocitrate dehydrogenase 2 (IDH2). IDH2 converts isocitrate
into α-ketoglutarate and generates NADPH, which can then be used to generate reduced
glutathione. IDH2 is acetylated in a nutrient dependent manner [21], and Sirt3 can
deacetylate IDH2 itself [151]. In fact, Sirt3 activation of IDH2 during CR, with
subsequent elevated NADPH and reduced glutathione, was shown to attenuate aging
related hearing loss and neuron loss in the cochlea [159]. Further supporting Sirt3 as a
tumor suppressor, Sirt3 knockout cells have increased ROS with genomic instability,
attenuated contact inhibition and increased carcinogenesis induction while Sirt3 knockout
mice have increased breast cancer and human breast cancers have lower Sirt3 levels
[160]. As mentioned, Sirt3 inhibits the Warburg effect by promoting oxidative
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phosphorylation through cyclophilin D/hexokinase II. Sirt3 knockout cells also show
elevated glycolytic and pentose phosphate metabolites, increased glucose uptake with
augmented lactate production, which are all markers of a shift to the Warburg effect and
carcinogenesis [161]. Another major mediator of the Warburg effect is HIF1α, which as
mentioned is inhibited by Sirt1. Sirt3 inhibits HIF1α activity indirectly by lowering ROS
levels though its actions on IDH2 and MnSOD as ROS can stabilize HIF1α [161]. Sirt3
levels correlate with HIF1α stability with subsequent tumor growth in xenograft models
[162]. Also of note, Sirt3 deacetylation of cyclophilin D inhibits ethanol mediated MPTP
opening but also promotes Bax/Bak mediated apoptosis suggesting another method Sirt3
acts as a tumor suppressor [163, 164]. Therefore, in addition to regulating mitochondrial
metabolism, Sirt3 also regulates ROS production and acts as a tumor suppressor.
Sirt3 also influences cardiovascular age-related pathophysiology. The reninangiotensin system (RAS) plays a major role in hypertension, cardiac hypertrophy and
renal health. RAS increases mitochondrial ROS production, attenuates mitochondrial
number and function, and RAS blockade mimics the effects of CR [165]. Interestingly,
similar to CR, knockout of the Ang II receptor (AT1R) increases lifespan in mice by 26%
and show attenuated cardiac fibrosis, hypertrophy, aortic damage, ROS levels with
increased mitochondrial density [166]. Linking RAS to sirtuins, AT1R depletion
increases Sirt3 and NAMPT (and NAD) levels while Ang II treatment lowers these levels
in control animals, which was blocked by candesartan [166]. Also of note, Sirt1
overexpression attenuates AT1R levels in vascular smooth muscle cells [167]. Sirt3
overexpression has been shown to attenuate physiological and chemical induction of
cardiac hypertrophy in part through AMPK activation [156, 168]. In summary, Sirt3 is
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able to regulate mitochondrial metabolism, ROS production and function leading to an
impact on age related pathologies, In fact, population genetics have identified SNPs in
the Sirt3 gene that correlate with lifespan [169, 170]. Therefore Sirt3 and mitochondrial
acetylation appear to play major roles in aging.
Despite the abundant work on the role of Sirt3 in regulating metabolism and
mitochondrial function, relatively little is known about the other mitochondrial localized
sirtuins: Sirt4 and Sirt5. As mentioned, Sirt4 mediates NAD-dependent ADPribosylation. The best characterized target of Sirt4 is glutamate dehydrogenase (GDH).
Again, GDH mediates glutamate metabolism into α-ketoglutarate, NADH and ammonia
(which is subsequently eliminated by the urea cycle). This metabolism of glutamate
increases ATP production as well as gluconeogenesis. Sirt4 mediated ADP-ribosylation
of GDH inhibits its enzymatic activity and lowers ATP production and gluconeogenesis
[171]. As mentioned, Sirt3 deacetylation of GDH increases its activity [151]. Therefore
in pancreatic β-cells, Sirt4 counters Sirt3 activity and inhibits insulin secretion by
diminishing ATP levels leading to inactivation of potassium ATP channels, which can be
reversed through CR [171, 172]. Also of note, high fat diet increases the expression of
Sirt4 [173]. Interestingly, shRNA mediated knockdown of Sirt4 in primary hepatocytes
and myotubes increased expression of Sirt1, AMPK and mitochondrial metabolic and βoxidation enzymes leading to increased fatty acid oxidation and cellular respiration [174],
which again appears to counter Sirt3’s augmentation of respiration and fatty acid
metabolism. However, it is not known how Sirt3 and Sirt4 are co-regulated given that
both use NAD as a substrate yielding opposite effects on cellular metabolism. It does
appear that nutritional status has inverse effects on expression levels of both enzymes.
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Overall, Sirt4 may negatively regulate mitochondrial metabolism and may be a target for
treatment of metabolic syndrome.
Sirt5 was originally described as another mitochondrially-localized deacetylase
that acts on the mitochondrial enzyme carbamoyl phosphate synthetase 1 (CPS1). CPS1
catalyzes the rate-limiting step of the urea cycle, which detoxifies ammonia generated
during amino acid metabolism that occurs during such conditions as CR and fasting. As
mentioned, Sirt3 also promotes the urea cycle through its deacetylation of OTC
suggesting these two sirtuins co-regulate the urea cycle and amino acid metabolism
[132]. This deacetylation of CPS1 increases its activity with Sirt5 KO mice showing
elevated blood ammonia levels during fasting [175]. Overexpression of Sirt5 led to
decreased CPS1 acetylation levels and increased urea production [176]. However, the
ability of Sirt5 to act as a deacetylase has been questioned as Sirt5 has been shown to act
as a lysine demalonylase and desuccinylase with Sirt5 desuccinylating CPS1 and Sirt5
knockout mice having elevated levels of succinylated CPS1 [177-179]. Presumably, this
PTM occurs using the high energy metabolic intermediates succinyl-CoA (generated
from the TCA cycle or metabolism of branched chain amino acids and long chain fatty
acids with propionyl-CoA as an intermediate) and malonyl-CoA (whose formation
greatly depends on AMPK regulation of acetyl-CoA carboxylase) similar to acetylation
using acetyl-CoA. Interestingly, levels of branched chain amino acids in the blood greatly
predict risk for diabetes suggesting that protein succinylation may be altered with
diabetes and nutrient status [180]. In addition to CPS1, malate dehydrogenase-2, IDH2,
citrate synthase, GDH and HMG-CoA synthase 2 are malonylated and succinylated [177179], which of note correlates to numerous Sirt3 targets. Therefore the same
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mitochondrial enzymes may be both acetylated, succinylated and/or malonylated by Sirt3
and Sirt5. Interestingly, Sirt5 levels increase with CR and this increased expression was
linked to improved cognitive ability in mice [181]. Sirt5 appears to regulate some
elements of the CR response, and its desuccinylase/demalonylase activity has opened the
door to new areas of mitochondrial protein regulation through PTMs. Overall, it is
abundantly clear that sirtuin activity within the mitochondria, through changes in
acetylation and other PTMs, greatly alters mitochondrial function and plays a major role
in aging and the CR response.
Resveratrol and other sirtuin activators
Despite the clear benefits of CR on numerous pathologies and potentially
increasing lifespan (in the very least promoting “healthy aging”), population wide CR is
not practical. Therefore, attempts to chemically activate the sirtuins are being
investigated, similar to attempts to medically alter the other aging pathways involving
mTOR (rapamycin) and AMPK (metformin). The first compound found that appeared to
activate the sirtuins was the naturally occurring polyphenol resveratrol found in red wine
[182]. Initial studies with resveratrol showed that it had anti-inflammatory and antioxidizing properties that attenuated mammary gland carcinogenesis in culture and skin
cancer in mice [183]. Resveratrol activated Sirt1 in-vitro and Sir2 in yeast with a
subsequent extension of lifespan by 70%, that was dependent on Sir2 expression,
mimicking the benefits for CR [184]. In mice on a high fat diet, resveratrol improved
insulin sensitivity, increased AMPK and PGC-1α activation and reduced IGF-1 signaling
[185, 186]. Metabolomics analysis of HepG2 cells treated with resveratrol confirmed a
shift from glucose utilization to β-oxidation suggesting Sirt1 and PGC-1α activation by

29	
  
	
  
	
  

resveratrol [187]. Also of note, overexpression of PGC-1α in skeletal muscle increases
lifespan in mice through diminished age-related insulin resistance, inflammation and
bone/muscle loss, which further highlights the importance of the resveratrol/Sirt1/ PGC1α axis to attenuate aging [188]. Another study found that mice treated with resveratrol
have attenuated signs of aging such as inflammation, cataracts formation, bone density
and aortic elasticity. However, resveratrol did not increase lifespan in these animals
unlike that of lower organisms [189]. Of note, mice fed low dose resveratrol in middle or
old age showed a transcriptional profile that greatly overlaps with mice on CR in heart,
skeletal muscle and brain and diverges from aged mice [190]. Interestingly, SRT1720, a
resveratrol mimetic that is 1000-fold more potent, activates Sirt1, improves insulin
sensitivity and enhances mitochondrial function in mice fed a high fat diet with
subsequent lifespan extension [191, 192].
The mechanism of action of resveratrol and SRT1720 has come into question as
to whether or not they are direct sirtuin activators or act on other targets to induce sirtuin
activity [193]. Resveratrol has been shown to activate AMPK, which as previously
mentioned acts upstream of Sirt1 by increasing NAD levels, independent of Sirt1 [194].
This activation of AMPK by resveratrol has also been shown to occur via inhibition of
phosphodiesterases (PDE4). PDE4 inhibition increases cAMP levels to augment calcium
levels activating AMPK by CamKK-β. Interestingly, direct inhibition of PDE4 by
rolipram mimicked the benefits of resveratrol in mice by preventing obesity, improving
glucose sensitivity and augmenting mitochondrial function [195]. Another study showed
that the benefits of resveratrol are lost in AMPK knockout animals fed high fat diet with
knockouts failing to show improved insulin sensitivity and mitochondrial function [196].
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Therefore resveratrol may in fact be an AMPK activator and an indirect sirtuin agonist.
Regardless of the mechanism, resveratrol has shown beneficial effects in
numerous human studies. The benefits of resveratrol in human diets was initially
postulated in the 1990’s when populations consuming a Mediterranean diets showed
lower rates of cardiovascular disease despite consuming high levels of saturated fats,
termed the ‘French Paradox’ [32, 197]. Four weeks of resveratrol treatment (2 x 5
mg/daily) improved insulin sensitivity/signaling and reduced oxidative stress in diabetic
patients [198]. Similar to the studies in obese mice, resveratrol treatment (150 mg/day) in
human obese patients for 30 days improved mitochondrial function, increased Sirt1 and
PGC-1α levels, activated AMPK, lowered intra-muscular/hepatic lipid content and
lowered circulating triglycerides and inflammation markers suggesting that resveratrol
can mimic CR in humans [199]. In patients with cardiovascular disease, treatment with
resveratrol (10 mg/day for 3 months) improved left ventricular function and vasodilation
(possibly due to Sirt1/eNOS activity), lowered LDL levels and attenuated platelet
aggregation [200]. Further studies will certainly look at the effects of resveratrol and
SRT1720 on other age-related diseases. Despite the uncertainty of its mechanism,
resveratrol and subsequent activation of Sirt1 appear to have beneficial effects on
numerous pathologies and may offer the benefits of CR without having to actually
undergo a CR diet.
Autophagy
Prior to the 1940s, protein turnover was thought to be essentially non-existent
with body proteins being static and dietary proteins used primarily for fuel. However,
Rudolf Schoenheimer, Harold Urey and David Rittenberg utilized the isotope tagged 15N-

31	
  
	
  
	
  

tyrosine fed to rats and found that only 50% of the 15N was excreted in the urine with the
rest deposited in body tissues. Also of note was that the 15N-tyrosine was found in
proteins, and the 15N itself was found on other amino acids besides tyrosine suggesting
tyrosine metabolism with subsequent generation of new amino acids, i.e. protein
turnover. Therefore, it was shown that proteins exist in a dynamic equilibrium rather than
a static and stable state [201, 202]. The discovery of the lysosome containing digestive
enzymes sequestered from the rest of the cell by Christian de Duve in the 1950s offered a
potential mechanism for controlled and regulated protein degradation [201, 203]. To date,
two major classes of protein degradation have been described: the lysosomal-independent
ubiquitin-proteosome system and the lysosomal-autophagy pathway.
The notion of a non-lysosomal protein degradation system came from the
observation that rabbit reticulocytes, which lack lysosomes, perform hemoglobin
degradation. A cell-free prep from these cells could degrade hemoglobin at neutral pH
and required ATP [204]. Further work showed that this system is composed of multiple
proteins rather than a single protease [205]. One of these proteins was found to be
ubiquitin/APF-1, which had been previously shown to covalently attach to lysine residues
on histones [206], and it was then proposed that ubiquitin covalently tags target proteins
for degradation by the other proteins found in the reticulocyte cell-free model [201]. The
mechanism of tagging target proteins involves the E1 (ubiquitin-activating) enzyme that
uses ATP to adenylate ubiquitin, which then gets transferred to the E2 (ubiquitinconjugating) enzyme. Finally an E3-ligase transfers the ubiquitin to target proteins from
E2. Numerous E3 ligases are expressed in humans and offer specificity for which
proteins are ubiquitinylated and degraded. Target proteins become poly-ubiquitinylated
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with chains of ubiquitin forming on target proteins linked together at either K48 or K63
of ubiquitin [201]. The ubiquitin tagged protein target is then degraded by the 26S
proteosome (19S and 20S sub-complexes) composed of numerous proteins with the 19S
sub-complex recognizing the target protein and the 20S sub-complex having proteolytic
activity [207, 208]. To date, numerous pathologies are linked to defects in the ubiquitinproteosome system highlighting the importance of protein turnover in cellular
homeostasis [201].
The ubiquitin-proteosome system is able to degrade individual proteins providing
individual proteins with their own half-lives. However, bulk degradation of cellular
constituents, protein aggregates and entire organelles, is mediated by the lysosomalautophagy system thus promoting homeostasis through quality control of cellular
components. Autophagy or ‘self-eating’ was proposed by Christian de Duve in the 1960’s
and is mediated by the engulfment of cellular components into a double-membraned
autophagosome with subsequent fusion with lysosomes for degradation of the
autophagosome’s contents and recycling of basic building blocks [209]. Three forms of
autophagy exist which include macroautophagy (termed autophagy), chaperone mediated
autophagy and microautophagy. Briefly, chaperone mediated autophagy occurs when
individual proteins with a specific peptide sequence are shuttled directly into the
lysosome via chaperone proteins and LAMP2a in the lysosome. Microautophagy is the
direct engulfment of cytosolic components by the lysosome [210]. Autophagy
(macroautophagy) can be broken into three general steps with each step mediated by
unique proteins (many of which are termed ATG proteins in yeast with several known
mammalian homologues) [50, 210, 211] (Figure 5a): 1) initiation/nucleation of the
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Figure 5: Autophagy is a tightly regulated housekeeping program. (A) Autophagy is
triggered in numerous ways including starvation, infection and exercise where the
autophagosomal membrane is donated through several possible sources such as the ER,
mitochondria or plasma membrane. Phagophore nucleation uses the ULK1 and
Beclin1/VPS34 protein complexes, and elongation of the phagophore uses the ubiquitinlike conjugation systems to generate LC3-II. The completed autophagosome with cellular
contents fuses with the lysosome forming the autolysosome with subsequent degradation
of the autophagosome’s cargo. Numerous drugs such as chloroquine, rapamycin and
3MA affect autophagy. (B) Acetylation regulates autophagy in that Sirt1 directly
deacetylates and activates ATG proteins, TIP60 acetylates ULK1 and HDAC6 acts on
microtubules to affect autophagosome movement and autolysosome formation.
(endoplasmic reticulum, ER; B-cell lymphoma 2, BCL2; mammalian target of
rapamycin, mTOR; AMP-activated kinase, AMPK; insulin-like growth factor, IGF;
peroxisome proliferator-activated receptor gamma coactivator 1-alpha, PGC-1α; Tatinteractive protein 60, TIP60; histone deacetylase 6, HDAC6; acetylated lysine, Ac;
Glycogen synthase kinase 3, GSK3; General control of amino acid synthesis protein,
GCN5; phosphatidylethanolamine, PE; Bcl-2 homology domain 3, BH3)
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phagophore; 2) elongation of the phagophore and closure to form the autophagosome; 3)
fusion of the autophagosome to the lysosome.
The membrane source of the phagophore used for initiation of autophagy is
debated with the ER [212], mitochondria (during starvation) [213] and/or the plasma
membrane being potential sources [214]. The class-III PI3 kinase VPS34 is also
important for phagophore nucleation and can be inhibited using 3-methyladenine (3MA)
or wortmannin. VPS34 interacts with numerous proteins for nucleation including Beclin1
(ATG6), which promotes VPS34 activity [215]. Interestingly, Beclin1 is normally bound
to the anti-apoptotic protein BCL-2 preventing its interaction with VPS34 [216]. Also of
note, BH3 containing proteins such as BNIP3/NIX (important for some forms of
mitochondrial autophagy or ‘mitophagy’ (see below)) can bind to BCL-2 freeing Beclin1
promoting autophagy [217]. Another important complex for phagophore formation is the
FIP200/ULK1 (ATG1) complex, and as mentioned, ULK1 is activated and inhibited by
the longevity proteins AMPK and mTOR respectively [51].
Elongation of the phagophore requires two ubiquitin-like conjugation systems.
The first one involves ATG5-ATG12 conjugation where ATG12 is first activated by
ATG7 (E1-like) and then transferred to ATG10 (E2-like) and finally ATG12 is
covalently linked to ATG5. The ATG5-ATG12 conjugate is then linked with ATG16L
and a tetramer of the ATG5-ATG12:ATG16L conjugate forms an 800 kDa complex. The
second ubiquitin-like system results in phosphatidylethanolamine (PE) lipidation of LC3
(ATG8). LC3 is cleaved by ATG4 yielding LC3-I, which is then processed by ATG7
(E1-like), ATG3 (E2-like) and covalently linked to PE by ATG5-ATG12:ATG16L (E3like) forming LC3-II. LC3-II is a component of the phagophore membrane and thus is
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used as a marker for autophagosome assembly [210].
Finally, fusion of the autophagosome with the lysosome occurs after the
autophagosome is moved along microtubules by dynein motor proteins to areas enriched
with lysosomes [218]. Lysosomal fusion with the autophagosome utilizes numerous
proteins including ESCRT, SNAREs, UVRAG and Rab7 [210]. Lysosomal acidification
by H+-ATPases is also essential for the completion of the autophagic process. Inhibition
of lysosomal acidification by either chloroquine or bafilomycin leads to an accumulation
of autophagosomes containing extensive cellular debris. Therefore, these drugs can be
used to assess the rate of cellular autophagic flux with increased autophagosome buildup
following chloroquine or bafilomycin treatment indicating augmented autophagic flux
throughout the cell.
There are numerous mechanisms to induce autophagy, which is also tightly
regulated. The classic mechanism for autophagy induction is starvation allowing for
degradation of cellular components for use as metabolites to promote survival until
nutrients become available again. During starvation, IGF-1 signaling and ATP/amino
acid levels would be attenuated leading to downregulation of the AKT/mTOR pathway
and augmentation of AMPK thus promoting ULK1 activation and phagophore nucleation
[50]. Therefore, the mTOR inhibiting drug rapamycin is thought to promote longevity
through autophagy activation as autophagy induction diminishes with age [49, 219].
Recently, the transcription factor TFEB has been shown to be the master regulator for the
expression of most proteins involved in the autophagy-lysosome pathway [220, 221].
Interestingly, mTOR can localize to the lysosomal membrane during nutrient abundant
conditions where it phosphorylates TFEB promoting its binding to 14-3-3 proteins and

36	
  
	
  
	
  

cytoplasmic localization. However, upon starvation mTOR dissociates from the lysosome
and TFEB localizes to the nucleus promoting autophagy [222, 223]. Also of note, it was
recently shown that PGC-1α, which as mentioned is activated by Sirt1/AMPK, acts
upstream of TFEB to promote autophagy and rescues Huntington’s disease proteotoxicity
[224]. Therefore, mTOR regulates autophagy through nutrient-sensing and multiple
targets such as ULK1 and TFEB. Sirt1 also activates FoxO3, which has been shown to
activate autophagy in part by increasing BNIP3 expression [225]. Starvation also
activates JNK1 signaling to phosphorylate BCL-2 freeing Beclin1 for autophagy
induction [50]. Similarly, starvation increases expression of BNIP3, which promotes the
release of Beclin1 from BCL-2, and loss of BNIP3 leads to accumulation of abnormal
mitochondria suggesting defects in autophagy [226]. Starvation also induces ROS
formation, which is thought to induce autophagy through increased activity of ATG4,
AMPK and Beclin1 [210, 227]. Overall, starvation induced autophagy is the most
extensively studied mechanism of autophagy induction and is mediated through
numerous protein targets/mechanisms.
Besides starvation, other mechanisms for autophagy induction include exercise
and infection. Exercise induces autophagy to allow cells to adapt to changing nutritional
and energy demands through protein catabolism. Mice deficient in autophagy induction
have defective exercise endurance, altered exercise induced glucose metabolism and are
not protected from high fat diet insulin resistance by exercise. Therefore, autophagy is
essential for the benefits of exercise [228]. The ability to fight off certain pathogens such
as salmonella (see below) and tuberculosis also requires autophagy, which has been
found to play essential roles in innate and adaptive immunity. Autophagy can directly
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eliminate intracellular pathogens, plays a role in antigen presentation by positively
regulating MHC-II function and plays a role in immune cell development [210, 229,
230].
Given the numerous mechanisms of autophagy induction, it is not surprising that
alterations in autophagic induction play a role in numerous pathologies. Aging is thought
to occur in part due to an attenuation of housekeeping autophagic functions leading to
accumulation of cellular debris [231]. In fact, promoting autophagy by overexpressing
ATG8 in neuronal cells increases lifespan and reduces oxidative stress in Drosophilia
while ATG8 mutations attenuates lifespan [232] suggesting autophagy directly regulates
aging. Rapamycin also induces autophagy, increases lifespan in mice and can promote
stem cell viability [49, 233]. Autophagy is also thought to be one of the mechanisms by
which CR mediates its longevity benefits [50]. Aging greatly affects immunity, the
accumulation of protein aggregates in the nervous and cardiovascular systems, cancer
progression and the incidence of type-II diabetes. Crohn’s disease is an autoimmune
disease that is thought to occur in part due to an immune response to commensal bacteria
in the gut with defective autophagic clearance of intracellular bacteria and mutations in
the autophagy protein ATG16L [234, 235]. Autophagy can also inhibit inflammasome
activation, which plays a major role in autoimmune disease, by promoting mitochondrial
homeostasis [236]. In addition, autophagy defects play a major role in neurodegenerative
disorders such as Alzheimer’s, Parkinson’s, and Huntington’s disease with decreased
clearance of the protein aggregates that contribute to these age-related disorders. In
Alzheimer’s disease reduced Beclin1 expression in the brain leads to accumulation of
beta-amyloid plaques [237]. Early onset Parkinson’s disease is linked to mutations in the
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E3-ligase Parkin, which plays a role in mitochondrial autophagy (see below). Ischemic
heart disease is thought to activate autophagy as a protective measure and rapamycin
treatment before ischemia decreases infarct size [238, 239]. Autophagy is also believed to
inhibit hypertrophic cardiomyopathy [240]. The role of autophagy in cancer is much
more complex than its role in cardiovascular and neurodegenerative disease. It is believed
that autophagy can act as a tumor suppressor by removing damaged carcinogenic cellular
components prior to the onset of cancer, but it can also provide nutrients and promote
tumor cell growth in nutrient deprived tumors with poor vascularity [210]. The
autophagic protein best characterized as a tumor suppressor is Beclin1. Numerous human
cancers show monoallelic deletion of Beclin1, and mice with heterozygous deletion of
Beclin1 show increased tumorigenesis and decreased autophagy [241]. Also
overexpression of Beclin1 attenuates cancer cell proliferation in cell culture [242].
Knockout of another autophagy protein, ATG4, leads to increased incidence of
fibrosarcomas following exposure to carcinogens suggesting autophagy helps prevent
cancer [243]. It is believed that a major mechanism for autophagy tumor suppression is
through maintaining mitochondrial homeostasis and limiting DNA damaging ROS
production [244]. An oncogenic role for autophagy is seen in colorectal cells that have
increased rates of autophagy when placed under starved conditions. However, inhibition
of autophagy with 3MA or ATG7 knockdown leads to apoptosis [245]. At the clinical
level, the autophagy inhibiting drug chloroquine has shown promise as an effective
therapy for cancer [246]. Therefore, it appears that autophagy can prevent cancer onset
through basic cellular housekeeping, but it also promotes tumor growth once the tumor
has become established. Finally, with regards to diabetes, beta-cells from diabetics have
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increased numbers of autophagosomes and autophagic inhibition leads to death of betacells with impaired insulin secretion [247, 248]. Overall, autophagy appears to play a
central role in aging and age-related pathologies [210].
Given the clear roles of autophagy and sirtuins (acetylation) in age-related
disorders, there is emerging evidence that the two are intricately linked (Figure 5b). A
direct role for Sirt1 in autophagy regulation can be seen in Sirt1 knockout mouse
embryonic fibroblasts (MEFs) that fail to fully activate autophagy upon starvation and
accumulate damaged organelles while Sirt1 overexpression can increase autophagic flux
by directly deacetylating ATG5, 7 and 8 [249]. Interestingly, the acetyltransferase p300
acetylates ATG5, 7, 8 and 12 to inhibit autophagy with overexpression of p300 inhibiting
starvation-induced autophagy [250]. Therefore, acetylation can directly induce or inhibit
autophagy. As noted, Sirt1 deacetylates PGC-1α and LKB1, leading to TFEB and AMPK
activation, respectively, which could also indirectly promote autophagy. Counterintuitively, Sirt6 can lead to PGC-1α hyperacetylation by activating the acetyltransferase
GCN5 and may therefore inhibit autophagy, suggesting crosstalk between Sirt1 and Sirt6
as well [70, 99, 251-253]. Another mechanism for indirect autophagy activation by Sirt1
could be FoxO3 mediated increases in BNIP3 expression [225]. Sirt1’s regulation of
autophagy might contribute to Sirt1 knockout lethality directly after birth since
autophagy induction is essential in the period after birth and pre-weaning [50].
Further linking the PTM of acetylation to autophagy, upon starvation or
withdrawal of growth factors, the kinase GSK3 phosphorylates the acetyltransferase
TIP60. Phosphorylated TIP60 is more active and can then acetylate ULK1 promoting
autophagy [254]. Interestingly, TIP60 knockouts are embryonic lethal and die at a time
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point of development that is heavily reliant on autophagy [255, 256]. Also the ubiquitin
binding histone deacetylase, HDAC6, is essential for lysosome-autophagosome fusion
and shuttles autophagic targets on microtubules for delivery to autophagosomes in part
due to its ability to regulate tubulin acetylation [257, 258]. During mitochondrial
autophagy, also known as mitophagy (see below), damaged mitochondria become
ubiquitinylated and HDAC6 is essential for clearance by inducing their aggregation near
lysosomes [259]. Linking acetylation status, HDAC6 and neurodegenerative disorders is
the observation that the acetylation status of mutant Huntington protein affects its
autophagic clearance and that HDAC6 activity regulates tau protein aggregation in
Alzheimer’s disease [260, 261]. Therefore acetylation status of various target proteins by
TIP60 and HDAC6, along with Sirt1, appears to regulate autophagy.
Global acetylation patterns in the cytosol and nucleus also appear to affect
autophagy induction. Spermidine, an acetyltransferase inhibitor, and resveratrol, a sirtuin
activator, both promote autophagy induction through changes in acetylation status [262].
Spermidine treatment extends lifespan in yeast, flies and worms and attenuates oxidative
stress in aged mice in part due to decreased acetylation of histones and increased
autophagy induction [263]. Autophagy induction by resveratrol, but not spermidine,
depends on Sirt1 expression suggesting each drug alters the acetylation status of unique
targets. However, both drugs converge to inhibit mTOR activation and hence autophagy
induction [262, 264]. Spermidine and resveratrol alter the acetylation status of 375
proteins with 170 (and 27 being mitochondrial) of these proteins being a part of the
autophagy protein network [262, 264, 265]. Therefore the acetylation status of cytosolic,
nuclear and mitochondrial proteins can trigger autophagy.
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Mitophagy
Autophagy was initially described as being the non-selective bulk degradation of
cellular components. However, recent evidence suggests that selective autophagy occurs
for specific organelles: mitophagy (mitochondria); pexophagy (peroxisomes); ribophagy
(ribosomes); and xenophagy (intracellular bacteria). Given the central role of
mitochondria in aging, metabolism and cellular homeostasis, it has been proposed that
mitophagy degrades functionally impaired mitochondria to prevent numerous
pathologies. Mitochondria are the major source of ROS, and the accumulation of
dysfunctional mitochondria appears to increase oxidative stress. Increased ROS damages
nuclear/mitochondrial DNA, lipids, proteins and mitochondria themselves further
promoting oxidative stress in a vicious cycle. Dysfunctional mitochondria also attenuate
ATP production promoting necrosis and cytochrome c release leading to apoptosis [266].
Mitochondria are thought to “dilute” the effects of dysfunctional mitochondria
through the dynamic processes of fusion/fission. In this way, healthy mitochondria fuse
with dysfunctional mitochondria blunting their deleterious effects on the cell [267].
Fission/fusion utilizes specific proteins, and this machinery consists of unique GTPases
that fission or fuse the mitochondrial double membrane. Fission is mediated by various
proteins, such as Drp1, while fusion occurs through activation of MFN1/2 for the outer
membrane and Opa1 for the inner membrane [268]. Interestingly, mutations in MFN1/2
and Opa1 lead to the neurological diseases Charcot Marie Tooth 2a and Optic Atrophy
Type 1, respectively, highlighting the importance of functional mitochondrial dynamics.
The process of fission/fusion is functionally regulated by nutritional status with starvation
or rapamycin treatment promoting mitochondrial fusion in part through inhibition of
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fission by Drp1 phosphorylation. This inhibition of fission during short-term starvation
promotes global autophagy and lipid/protein metabolism but prevents mitophagy since
mitochondria are essential for lipid and protein catabolism [269, 270]. Interestingly,
during starvation-mediated autophagy cellular-component degradation occurs in an
orderly fashion with cytosolic proteins degraded first within minutes, ribosomes after
several hours and mitochondria after nearly a day [271]. It is hypothesized that if
starvation is prolonged or if mitochondria are too dysfunctional then these mitochondria
are degraded through mitophagy [267]. It has also been shown that mitophagy is
dependent on the fission apparatus as Drp1 knockout cells fail to undergo mitophagy
[272]. Therefore, it is proposed that fusion during acute starvation protects mitochondria
from degradation in part because large elongated mitochondria cannot be engulfed by the
autophagosome and mitochondria themselves can donate membrane for the
autophagosome during acute starvation [213]. However, after prolonged starvation or
extensive mitochondrial damage, fission is induced to generate mitochondrial fragments
that are degraded through mitophagy [267, 273]. The overall importance of mitophagy is
highlighted by the fact that autophagy mutants in ATG7, ULK1, ATG11 or ATG32
accumulate deformed mitochondria, have increased ROS levels, have damaged
mitochondrial DNA, show impaired respiration and have increased senescence, a key
marker of aging [272, 274-276]. It is also proposed that mitochondrial turnover through
mitophagy and PGC-1α-mediated biogenesis decreases with age, further emphasizing the
importance of mitophagy in cellular homeostasis [277].
In recent years, extensive work has gone into discovering the mechanisms by
which mitochondria are selectively degraded though mitophagy (Figure 6a). The best
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Figure 6: Mitophagy is induced through numerous mechanisms and closely resembles
xenophagy. (A) Depolarized mitochondria stabilize Pink1 levels, which activates the E3ligase Parkin. Parkin ubiquitinylates mitochondrial membrane proteins blocking fusion
and targeting mitochondria to autophagosomes by p62 and LC3-II. Hypoxia and cellular
differentiation induces mitophagy using NIX and BNIP3, which directly bind to LC3-II.
Dimerization is thought to free Beclin1 from BCL-2. Hypoxia also blocks FUNDC1
phoshorylation leading to FUNDC1 binding to LC3-II. The endogenous mitochondrial
E3-ligase RNF185 ubiquitinylates BNIP3 targeting mitochondria to autophagosomes. (B)
Xenophagy degrades intracellular bacteria through ubiquitinylation, adaptor proteins and
LC3-II binding. (B-cell lymphoma 2, BCl2; BCL2/adenovirus E1B 19 kDa proteininteracting protein 1/3, BNIP1/3; ring finger protein 185, RNF185; nucleoporin 62, p62;
PTEN-induced putative kinase 1, Pink1; voltage dependent anion channel, VDAC;
mitofusin, MFN; Presenilins-associated rhomboid-like protein, PARL)	
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characterized mechanism is that of Pink1/Parkin-induced mitophagy. Pink1 is a
serine/threonine kinase and Parkin is an E3 ubiquitin ligase. Both of these enzymes are
linked to autosomal-recessive early-onset Parkinson’s disease and mitophagy, suggesting
mitochondrial quality control plays a role in dopaminergic neurons [278]. Pink1 and
Parkin knockouts in Drosophilia show mitochondrial defects [279, 280]. Mitophagy was
initially described to occur following mitochondrial depolarization with subsequent
delivery to acidic vesicles [281]. Parkin translocates to depolarized mitochondria treated
with the mitochondrial uncoupling drug carbonyl cyanide m-chlorophenyl hydrazone
(CCCP) and requires functional Pink1 thus linking Parkin, Pink1 and depolarized
mitochondria to mitophagy [282, 283]. Normally, Pink1 is translocated into the inner
membrane of the mitochondria where mitochondrial proteases, such as MPP and Parl,
mediate its degradation, but upon mitochondrial depolarization, Pink1 is stabilized on the
outer mitochondrial membrane and recruits Parkin [284, 285]. Pink1 then phosphorylates
and activates Parkin leading to the ubiquitinylation of outer mitochondrial membrane
proteins such as VDAC and MFN1/2 [286-288]. Ubiquitinylated outer membrane
proteins are then thought to recruit the adaptor protein p62, which targets mitochondria to
the autophagosome through interaction with LC3-II in the autophagosome membrane
[288]. However, other studies conclude that p62 merely promotes mitochondrial perinuclear clustering and is dispensable for mitophagy [289-291]. Interestingly, the
ubiquitinylation of MFN1/2 appears to promote its degradation through p97 and the
proteasome, which increases mitochondrial fission, segregation of depolarized
mitochondria and mitophagy, while Drp1 knockdown stops Parkin mediated mitophagy
[292-294]. HDAC6, which regulates microtubule acetylation, autolysosome formation
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and movement of autophagic substrates along microtubules, is essential for Parkin
mediated mitophagy through peri-nuclear localization of defective mitochondria [259].
The link between mitochondrial dysfunction and Parkinson’s disease is vast as
mitochondrial toxins, such as MPTP and rotenone exposure, and mitochondrial protein
mutations in complex I are linked the disease [278]. With the addition of Parkin and
Pink1 mediated mitophagy, Parkinson’s disease is further tied to defects in mitochondrial
homeostasis. It also appears that Parkin mediated mitophagy extends beyond Parkinson’s
disease as ischemic preconditioning in the heart induces Parkin and p62 co-localization to
the mitochondria, and Parkin knockout hearts lose the cardioprotective effects of preconditioning [295].
On the opposite arm of mitophagy is mitochondrial biogenesis. Cells
overexpressing Pink1 or Parkin and exposed to CCCP completely eliminate mitochondria
through mitophagy within 24-96 hours [282, 283, 296]. Therefore, it is believed that after
mitophagy induction subsequent mitochondrial biogenesis replaces degraded
mitochondria. This mitochondrial turnover is hypothesized to preferentially remove
damaged mitochondria first with subsequent biogenesis yielding an overall healthier
mitochondrial population with improved respiration, ATP production, attenuated ROS
production and resistance to MPTP opening [297]. Fasting and CR induce mitophagy and
expression of the master regulator of mitochondrial biogenesis, PGC-1α, with improved
mitochondrial efficiency [296, 298, 299]. Furthermore, the zinc-finger protein Paris,
which accumulates in neurons from Parkinson’s disease patient neurons, inhibits the
expression of PGC-1α, and Parkin ubiquitinylates Paris for its degradation by the
proteosome thus increasing PGC-1α levels [300]. Therefore, it is hypothesized that
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Parkin can mediate both mitophagy and mitochondrial biogenesis through degradation of
Paris with subsequent PGC-1α activation yielding mitochondrial turnover. This turnover
is hypothesized to improve cellular/mitochondrial homeostasis and self-renewal thus
attenuating aging [277]. However, the occurrence of Parkin mediating both mitophagy
and mitochondrial biogenesis simultaneously in the same cell has yet to be shown.
Interestingly, the process of xenophagy, which is the autophagic degradation of
intracellular bacteria such as salmonella or listeria, appears to utilize a similar mechanism
to mitophagy by using ubiquitinylation and p62 (Figure 6b). The similarity between
mitophagy and xenophagy is interesting from an evolutionary standpoint as mitochondria
are believed to have bacterial origins, as stated by the endosymbiotic theory. Putting
these together, it is plausible that mitochondria and intracellular bacteria may be
degraded by the host-cell in similar ways [301]. In the case of salmonella, upon entering
the host-cell, salmonella membrane proteins are ubiquitinylated and the autophagy
adaptor proteins NDP52 and Optineurin target the bacteria to the autophagosome through
LC3-II binding [302, 303]. p62 is also found to localize to ubiquitin labeled bacteria
identical to Parkin mediated mitophagy [301, 304]. The E3 ligase(s) mediating the
process of xenophagy has not been described.
Other mechanisms for mitophagy have been proposed that do not utilize the
Pink1/Parkin pathway but also utilize LC3-II, p62 and ubiquitinylation (Figure 6a).
Mammalian cells can induce mitophagy independent of the adaptor protein p62 and
ubiquitinylation. Instead ‘mitophagy receptors’ such as NIX/BNIP3L and BNIP3
incorporate into the mitochondrial membrane, homo-dimerize and directly bind to LC3-II
in the autophagosomal membrane [305-307]. Homo-dimerization is also thought to block
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BCL-2/Beclin1 interaction to allow Beclin1 to trigger autophagosome nucleation [301].
NIX/BNIP3L-mediated mitophagy is essential for elimination of mitochondria in red
blood cells while BNIP3 expression increases and may induce mitophagy during
prolonged nutrient withdrawal or hypoxia [217, 226, 305, 307, 308]. As mentioned, Sirt1
deacetylates FoxO3 to promote BNIP3 expression, which may further tie CR to
mitophagy [225]. Hypoxia mediates mitophagy through another mechanism involving the
protein FUNDC1. Hypoxia is thought to inhibit Src kinase phosphorylation of FUNDC1,
which promotes direct binding of FUNDC1 to LC3-II in the autophagosome highlighting
another ubiquitinylation/p62 independent mitophagy mechanism [309]. Interestingly,
yeast contain a mitophagy receptor, ATG32, that directly targets mitochondria to the
autophagosome, but no homologue to ATG32 has been found in mammalian cells [310,
311] . Further complicating things, yet another mitophagy mechanism has been described
where a mitochondrial localized ubiquitin E3 ligase, RNF185, ubiquitinylates another
outer membrane protein BNIP1, which leads to p62 localization to mitochondria and
autophagosome targeting [312]. Therefore mitophagy can be induced through numerous
mechanisms utilizing unique proteins. In general, mitophagy uses adaptor proteins, which
includes p62, and ubiquitin labeling or mitophagy receptors. like NIX or BNIP3. which
directly target mitochondria to the autophagosome through LC3-II binding. It appears
that mitophagy is evolutionarily conserved, promotes the regulated elimination of
damaged/aged mitochondria, is induced through numerous mechanisms, such as hypoxia
and CR, and may play a central role in several aging related pathologies.
Summary and Hypothesis
For over 75 years, caloric restriction (CR) has been known to increase lifespan in
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a wide range of organisms. Only recently have the molecular mechanisms, which lead to
improved cellular homeostasis, for this augmented lifespan been unraveled. One such
mechanism involves CR-mediated activation of lysine deacetylase enzymes, known as
sirtuins, with many of the benefits of CR being dependent on sirtuin levels. As such,
acetylation has emerged as a major post-translational modification (PTM) rivaling
phosphorylation. However, the number of known deacetylase and acetyltransferase
enzymes is surprisingly small suggesting there are yet undiscovered enzymes regulating
this PTM. Over 20% of mitochondrial proteins are acetylated which is thought to greatly
regulate mitochondria function. Sirt3 is the major mitochondrial deacetylase and is
activated by CR. It is unknown if mitochondria contain an intrinsic acetyltransferase
enzyme complex to counter Sirt3 activity. It is also unknown if changes in expression of
such an acetyltransferase would alter mitochondrial turnover and function, countering the
effects of Sirt3. The following studies sought to (i) identify the initial components of the
mitochondrial acetyltransferase program, (ii) to determine how changes in acetylation
alter mitochondrial function, (iii) determine if mitochondrial protein acetylation can
induce mitochondrial autophagy or ‘mitophagy’ considering that cytosolic acetylation
status regulates global autophagy and (iv) begin to determine the needed components for
acetylation-mediated mitophagy and its effects on mitochondrial homeostasis.

General hypothesis: Global mitochondrial protein acetylation status is regulated
enzymatically by an intrinsic mitochondrial acetyltransferase (MAT) complex, which
alters mitochondrial function and turnover through changes in acetylation levels and
mitophagy.
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Specific Aim 1: To determine if mitochondrial protein acetylation is regulated
enzymatically.
Hypothesis: Mitochondria contain intrinsic MAT enzymes that utilize acetyl-CoA to
regulate global mitochondrial acetylation status.

Specific Aim 2: To evaluate if a MAT affects mitochondrial function.
Hypothesis: A MAT enzyme counters the known acetylation, oxidative phosphorylation
and respiratory effects mediated by the major mitochondrial deacetylase, Sirt3.

Specific Aim 3: To determine if changes in mitochondrial acetylation can induce
mitochondrial autophagy or ‘mitophagy.’
Hypothesis: Global mitochondrial protein deacetylation induces mitophagy and is
triggered by the loss of MAT proteins.

Specific Aim 4: Acetylation-mediated mitophagy is regulated by the core autophagy
machinery and alters mitochondrial homeostasis.
Hypothesis: Mitophagy induction, through the loss of MAT function, is dependent on
known autophagy proteins and improves mitochondrial health due to increased
mitochondrial turnover.
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Figure 7: General hypothesis that mitochondrial protein acetylation is controlled
enzymatically countering affects mediated by the deacetylase Sirt3. Also, given that Sirt1
deacetylates numerous autophagy proteins to trigger global autophagy, we hypothesize
mitochondrial acetylation status regulates ‘mitophagy,’ increases mitochondrial turnover
and improves overall cellular homeostasis.
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SIRT3 modulates respiration via the deacetylation of lysine residues in electron
transport chain proteins. Whether mitochondrial protein acetylation is controlled
by a counter-regulatory program has remained elusive. Here we identify an
essential component of this previously undefined mitochondrial acetyltransferase
system. We show that GCN5L1/Bloc1s1 counters the acetylation and respiratory
effects of SIRT3. GCN5L1 is mitochondrial-enriched and displays significant
homology to a prokaryotic acetyltransferase. Genetic knockdown of GCN5L1 blunts
mitochondrial protein acetylation, and its reconstitution in intact mitochondria
restores protein acetylation. GCN5L1 interacts with and promotes acetylation of
SIRT3 respiratory chain targets and reverses global SIRT3 effects on mitochondrial
protein acetylation, respiration and bioenergetics. These data identify GCN5L1 as a
critical, prokaryote-derived component of the mitochondrial acetyltransferase
program.
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INTRODUCTION
The mitochondrial sirtuin deacetylase SIRT3 plays an important role in regulating
oxidative metabolism [1-3] and redox stress [4-6]. Consequently, the regulation of SIRT3
activity is emerging as an important factor in the mitochondrial contribution towards
disease susceptibility (reviewed [7]). To understand this system more fully, it is necessary
to identify proteins that counteract SIRT3 activity. As such, the discovery of a
mitochondrial lysine acetyltransferase has been actively pursued [3].
Given the evolutionary history of mitochondria, one avenue of research has
focused on bacteria. In Salmonella enterica, the acetyltransferase Pat has been shown to
counteract CobB, a sirtuin homologue, in the regulation of acetyl-CoA synthetase [8].
However, eukaryotic orthologs to Pat have not been identified in either the mitochondrial
or nuclear genome [9]. An alternate scenario in eukaryotes could be that mitochondrial
proteins are acetylated in the cytosol prior to mitochondrial import. However, as fasting
and feeding result in a dynamic flux in these post-translational modifications [2, 10], it
would be most likely that these modifications occur within mitochondria. Additionally,
ATP synthase Fo subunit 8, a mitochondrial-encoded protein, is acetylated under nutrient
flux conditions, further supporting the existence of an in situ mechanism [10].
In this report, we identify GCN5L1, a protein with significant homology to the
nuclear acetyltransferase GCN5 (general control of amino-acid synthesis 5) [11], as a
mammalian regulatory protein in the control of mitochondrial protein acetylation and
respiration. We show that GCN5L1: includes prokaryote-conserved acetyltransferase
substrate and acetyl-CoA binding regions; is localized within mitochondria; modulates
mitochondrial electron transport chain (ETC) protein acetylation; alters mitochondrial
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oxygen consumption; and counters SIRT3 effects on mitochondrial protein acetylation,
respiration and ATP levels.

MATERIALS AND METHODS
Phylogenetic and Structural Analysis
BLAST searches for acetyltransferases related to GCN5L1 identified several prokaryotic
proteins, the closest being the xenobiotic streptogramin acetyltransferase from
Burkholderia thailandensis (ZP_02389502), which we designated BtXAT. The sequences
for acetyltransferases (all human, except BtXAT) described were obtained from Genbank
and analyzed using the phylogenetic tool PhyML (www.phlogeny.fr.) The XAT-repeat
region of GCN5L1 was identified by interrogation of the GCN5L1 protein sequence,
looking for a hexapeptide repeat motif matching X-[STAV]-X-[LIV]-[GAED]-X (NCBI
cd03349). Data from this region was also used to map the substrate- and acetyl-CoAbinding regions of BtXAT. Predictions of GCN5L1 protein biochemical properties were
performed using a Kyte-Doolittle hydrophobicity plot.
Cell Culture and Transfection
HepG2 cells were grown in DMEM supplemented with 10% FBS. Plasmids were
transfected using Fugene HD (Roche). For in vivo acetylation studies cells were starved
for 4 h in HBSS and the re-fed with DMEM for 1.5 h prior to harvesting. Electroporation
was used to transfect non-targeting control, GCN5L1 and SIRT3 siRNA (Dharmacon).
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Construction of plasmids
The cDNA for GCN5L1 (Open Biosystems) was cloned into p3XFLAG-CMV-14
(Sigma) to create GCN5L1-FLAG. The cDNAs for NDUFA9 and ATP5a (Open
Biosystems) were cloned into pCMV3TAG-4A (Stratagene).
Polyclonal Antibody Production
A synthetic peptide corresponding to 16 amino acids of human and mouse GCN5L1,
along with a conjugating cysteine at the C-terminus (MLSRLLKEHQAKQNER-C), was
produced and injected into NZW rabbits (Covance). Serum was affinity purified against
the immunizing peptide, and the antibody validated for recognition of human and mouse
GCN5L1.
GCN5L1 Localization, Immunoblot Analysis and Co-Immunoprecipitation
Confocal microscopy was used to localize GCN5L1-FLAG and dsRed-mito (Clontech) in
fixed hepatocytes, by indirect immunolabeling of FLAG using Alexa 488 (Invitrogen).
Immunogold labeling and electron microscopy was used to localize endogenous GCN5L1
and the ETC protein ATP5a. Sub-mitochondrial localization was performed by osmotic
pressure subfractionation and proteinase K protection assays. Antibodies used for
westerns include: monoclonal acetyl-lysine (Ac-K), OPA1, GAPDH, VDAC (Cell
Signaling); polyclonal Ac-K, ATP5a, NDUFA9, GDH (Abcam); FLAG (Sigma). In coimmunoprecipitation experiments between GCN5L1-FLAG and NDUFA9-Myc or
ATP5a-Myc, cells were co-transfected with plasmids for 24 h. Lysates were harvested
and incubated with FLAG- or Myc-conjugated beads (Sigma and Cell Signaling,
respectively). Beads were washed and analyzed by western blot. Endogenous co90	
  
	
  
	
  

immunoprecipitation experiments followed a similar protocol, however lysates were
incubated with the relevant antibodies overnight, and interacting proteins were captured
using protein A/G beads (Santa Cruz). Western blots were quantified using image
analysis software, and those shown are representative of at least three independent
experiments.
Animal husbandry
The use of mice in this study was approved by the NHLBI Animal Care and Use
committee, and animals were maintained according to their guidelines.
Metabolic Measurements
Oxygen consumption measurements were performed on the XF24 analyzer (Seahorse
Bioscience). Control- and GCN5L1-transfected siRNA cells were transferred to 24-well
plates overnight and incubated in sucrose respiration media for 1 h prior to analysis. To
measure the response to the mitochondrial respiration substrates glutamate and malate,
cells were permeabilized with digitonin (10 µg per 106 cells, 5 min) and incubated in
sucrose respiration media. 10 mM glutamate/5 mM malate were added after baseline
measurements had been taken. ATP levels in intact cells were measured (n = 5) using the
EnzyLight assay kit (Bioassay Systems).
In Vitro Acetylation Analysis and In Vitro Immunoprecipitation
An in vitro acetylation assay was adapted from a published protocol [12]. HepG2 cells
were transfected with control or GCN5L1-FLAG plasmids for 24 h; or control and
GCN5L1 siRNA for 72 h; at which time mitochondria were isolated. Samples were
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resuspended in reaction buffer (50 mM Tris-HCl pH 8.0, 50 mM NaCl, 4 mM MgCl2, 5
mM nicotinamide, pH 7.4), sonicated, then incubated for 1.5 h at 37 oC, in the absence or
presence of 2.5 mM acetyl-CoA. Mitochondrial proteins were used for global acetylation
analysis (reaction stopped by boiling with SDS sample buffer, followed by SDS-PAGE
and immunoblot analysis with a monoclonal acetyl-lysine antibody), or
immunoprecipitation from non-denatured samples. For the reconstitution of GCN5L1 in
mitochondria, HepG2 cells were depleted of GCN5L1 using siRNA as described, after
which intact mitochondria were isolated by sucrose gradient centrifugation. 50 µg of pure
mitochondria per sample were resuspended in acetyl-CoA assay buffer (100 mM TrisHCl pH 8.0, 50 mM NaCl, 4 mM MgCl2, 5 mM nicotinamide, pH 7.4) on ice and
sonicated. Samples were incubated at either 25 oC or 95 oC for 5 mins, followed by the
addition of 0.5 µg GST-GCN5L1 (Abnova) in PBS or PBS alone (control). After
incubation for 1.5 h at 30 oC, the reaction was stopped by boiling in SDS sample buffer.
The histone assay followed this protocol, save for the addition of 2.5 µg of recombinant
human histone H3 (New England Biolabs) to the mitochondrial samples where indicated.
Following the 1.5 h incubation, acetylated H3 was recovered by immunoprecipitation
from non-denatured samples with a polyclonal Ac-K antibody. For in vitro
immunoprecipitation, lysates from the in vitro acetylation analysis were incubated
overnight with a polyclonal Ac-K antibody. Immunoprecipitated proteins were purified
using protein G beads, washed and analyzed by western blot.

Statistical analysis
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Where required, data were tested for normality using the Kolmogorov-Smirnov test,
followed by a one-tailed Student’s t-test or a Mann-Whitney U-test using SigmaPlot 11
(Systat Software). A P value of < 0.05 was regarded as significant.

RESULTS
GCN5L1 is identified as a putative mitochondrial counter-regulator of SIRT3
To identify mitochondrial lysine acetyltransferases, we screened the human
mitochondrial proteome database MitoCarta [13] for proteins harboring acetyltransferase
regions, and used yeast GCN5 as ‘bait’ in BLAST searches. Fluorescent-tagged candidate
proteins were expressed to evaluate mitochondrial localization, and oxygen consumption
was measured following siRNA knockdown to identify candidates that counter the
known respiratory effects of SIRT3 depletion [1, 14]. The strategy employed is illustrated
in Figure S1A. Four candidate proteins identified included GCN5L1 (synonym
BLOC1S1), NAT8b, NAT9 and NAT11. Expression of YFP-tagged constructs and
dsRed-mito showed that two proteins, namely GCN5L1 and NAT9, co-localized with the
mitochondrial marker (Figure S1B). As the knockdown of SIRT3 blunts mitochondrial
respiration [1, 15], we reasoned that the genetic depletion of a counter-regulatory
component should show the inverse phenotype. siRNA was employed to knockdown
GCN5L1 and NAT9; however, only the loss of GCN5L1 resulted in increased oxygen
consumption in HepG2 cells (Figure S1C). Subsequent studies focused on the role of
GCN5L1 in mitochondrial protein acetylation, and as a putative counter-regulatory
protein to SIRT3.
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Figure S1. Mitochondrial lysine acetyltransferase search methodology and
characterization. (A) In silico and in vivo methodology used to identify putative
mitochondrial acetyltransferases. (B) cDNA of four putative mitochondrial
acetyltransferases were cloned into YFP-N1 (Clontech) and expressed in HepG2 cells
with dsRed-mito to identify possible mitochondrial localization. (C) Oxygen
consumption of two potential mitochondrial acetyltransferases. (D) Immuno-gold
labeling of ATP5a (mitochondrial control) and GCN5L1 in fixed mouse liver tissue. (E)
Kyte-Doolittle hydropathy plot (window size = 9) shows non-hydrophobocity of
GCN5L1, with a predicted hydrophilic surface region at the N-terminus.
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GCN5L1 is mitochondrial enriched and more highly expressed in oxidative tissues
GCN5L1 is a previously uncharacterized protein, although its sequence homology
to GCN5, the nuclear acetyltransferase, has been described [11, 16]. We first confirmed
its mitochondrial localization, using confocal microscopy on HepG2 cells transfected
with FLAG-tagged GCN5L1 and dsRed-mito (Figure 1A); and by immuno-gold labeled
electron microscopy, which showed that the endogenous protein has similar localization
to the alpha subunit of ATP synthase (ATP5a) in mouse liver mitochondria (Figure 1B
and S1D). Kyte-Doolittle hydropathy modeling of the GCN5L1 protein suggests that it is
a non-transmembrane globular protein (Figure S1E) [17], suggesting its location within
mitochondria to be in either the intermembrane space or matrix soluble fractions.
Osmotic pressure subfractionation and proteinase K assays of isolated mouse
mitochondria both support that GCN5L1 resides in the soluble matrix and intermembrane
space fractions (Figures 1C and 1D). Its mitochondrial enrichment was further supported
by the higher levels of GCN5L1 in slow- versus fast-twitch skeletal muscle (Figure 1E).
GCN5L1 possesses prokaryotic features and its knockdown disrupts mitochondrial
protein acetylation
Phylogenetic mapping places GCN5L1 in a clade containing a histone
acetyltransferase (HAT1), a bacterial xenobiotic acetyltransferase (BtXAT), and the
nuclear lysine acetyltransferase GCN5 (Figure 2A). As such, we compared the GCN5L1
amino acid sequence with BtXAT and yeast GCN5. This comparison revealed a 53%
similarity to the acetyl-CoA- and substrate-binding motifs of BtXAT. In contrast,
homology to yeast GCN5 was limited to the non-catalytic N-terminal region of the
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Figure 1. GCN5L1 localizes to mitochondria. (A) Indirect immunofluorescence confocal
microscopy of HepG2 cells co-expressing GCN5L1-FLAG and dsRed-mito. Scale bar =
5 µm. (B) Immuno-gold labeling of endogenous GCN5L1 in fixed mouse liver tissue.
Scale bar = 5 nm. (C) Sub-mitochondrial localization of GCN5L1 by osmotic pressure
analysis of isolated mouse mitochondria. Abbreviations: IMS – inter-membrane space,
HM – heavy mitochondrial membranes. (D) Proteinase K protection assay to establish
GCN5L1 sub-mitochondrial localization. (E) Expression of GCN5L1 in soleus (slowtwitch) and gastrocnemius (fast-twitch) skeletal muscle.
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Figure 2. GCN5L1 levels modulate the degree of mitochondrial protein acetylation.
(A) Phylogenetic mapping of GCN5L1 against human and bacterial acetyltransferases
identifies homology to HAT1 and BtXAT. (B) Alignment of GCN5L1 against yeast
GCN5 and BtXAT acetyltransferases. (C) Lysine acetylation (Ac-K) status of
endogenous mitochondrial and cytoplasmic proteins following GCN5L1 depletion; bar
shows region of Ponceau stain. The accompanying histogram shows relative protein
acetylation in the mitochondrial and cytosolic fractions comparing scrambled to GCN5L1
knockdown (KD) (D) Acetylation status of total mitochondrial proteins in control or
GCN5L1-depleted HepG2 cells following in vitro acetylation assay with the
accompanying histogram showing relative protein acetylation. (E) Acetylation status of
mitochondrial proteins expressing control or GCN5L1 constructs, following an in vitro
acetylation assay with the accompanying histogram showing relative protein acetylation.
Arrows indicate endogenous GCN5L1. Data are expressed a mean ± s.e.m. (n≥3). n.s. –
not significant, **p<0.01, compared to scrambled siRNA treated controls.
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protein (Figure 2B). The deduced GCN5L1 protein sequence, and especially the
prokaryotic-like XAT repeat region, is highly conserved in metazoans (not shown),
suggesting a functional role of this region.
To begin exploring the functional role of GCN5L1, we determined whether siRNA
knockdown of this protein would modulate protein acetylation. Although GCN5L1 is
predominantly mitochondrial, cytosolic expression was also observed. GCN5L1 levels
were depleted in both subcellular compartments by siRNA; however, only the
mitochondrial fraction showed a significant reduction in protein acetylation in HepG2
cells, supporting its functional role in mitochondria (Figure 2C). The acetylation function
of GCN5L1 was further supported by a ≈ 60% attenuation of mitochondrial protein
acetylation, in an in vitro acetylation assay, using GCN5L1-depleted cells (Figure 2D).
Furthermore, the overexpression of GCN5L1 in HepG2 cells increased mitochondrial
protein acetylation to a similar degree in the presence of acetyl-CoA (Figure 2E).
Histone H3 is acetylated by GCN5L1-enriched mitochondrial extracts
To further characterize this effect, in vitro assays were performed in assess
whether recombinant GCN5L1 can acetylate purified histones, a classic acetylation
substrate. In contrast to the in vivo studies, GCN5L1 promoted only weak histone
acetylation when co-incubated in vitro (data not shown). To investigate whether this
discrepancy may be due to the requirement of additional mitochondrial factors in the
functioning of GCN5L1, we assessed mitochondrial protein acetylation in response to the
addition of recombinant GCN5L1 to mitochondrial extracts purified from GCN5L1depleted cells. Here, the reconstitution of GCN5L1 restored protein acetylation; although
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Figure 3. Intact mitochondrial contents are required for GCN5L1 mediated protein
acetylation. (A) Effect of the reconstitution of GCN5L1 to native and boiled
mitochondrial fractions on protein acetylation (Ac-K). The accompanying histogram
shows relative protein acetylation in the native or boiled (denatured) mitochondrial
fractions with or without the restoration of GCN5L1. (B) The extent of recombinant
histone H3 acetylation in mitochondrial extracts in the presence or absence of GCN5L1.
The relative acetylation of histone H3 in the presence or absence of GCN5L1 is shown in
the accompanying histogram. Data are expressed a mean ± s.e.m. (n≥3). n.s. – not
significant, *p<0.05 and **p<0.01, compared to scrambled siRNA treated controls.
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this effect was limited to native, and not denatured mitochondrial extract samples (Figure
3A). It is interesting to note in Figure 3A that the denaturing of mitochondria appears to
facilitate ‘auto-acetylation,” as the boiled samples show enhanced protein acetylation in
the presence and absence of GCN5L1. To further explore the requirement of additional
mitochondrial cofactors in the acetylation function of GCN5L1, recombinant histone H3
was added to native GCN5L1-depleted mitochondrial extracts in parallel with the
reintroduction, or not, of GCN5L1. The subsequent immunoprecipitation of acetylated
lysine proteins, followed by immunoblot analysis with an antibody recognizing histone
H3, shows increased H3 acetylation in the presence of GCN5L1 (Figure 3B). These data
show that GCN5L1 positively regulates mitochondrial protein acetylation. However, its
activity appears to require additional factors that reside in mitochondria.
GCN5L1 Promotes Electron Transport Chain Protein Acetylation
As the predominant mitochondrial protein lysine deacetylase, SIRT3, activates
ETC proteins [1, 18], we investigated whether known SIRT3 ETC targets interact with,
and are modulated by, GCN5L1. Co-expression of GCN5L1 with Myc-tagged complex I
protein NDUFA9, or complex V protein ATP5a, followed by reciprocal
immunoprecipitation, shows that there is a physical interaction between both NDUFA9
and ATP5a with GCN5L1 (Figures S2A and S2B). To confirm these interactions occur
between the endogenous proteins in vivo, untransfected HepG2 cell extracts were used
for immunoprecipitation studies. Here the antibody directed against GCN5L1 was
employed for immunoprecipitation, and antibodies directed against NDUFA9 and ATP5a
were used in immunoblot analysis (Figure 4A). These data confirm the protein-protein
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Figure S2. GCN5L1 interacts with mitochondrial electron transport chain proteins.
Reciprocal co-immunoprecipitation experiments between GCN5L1-FLAG and Myctagged ETC proteins, (A) NDUFA9 and (B) ATP5a. n ≥ 3 for all experiments.
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Figure 4. GCN5L1 modulates the acetylation of mitochondrial electron transport chain
proteins. (A) In vivo interaction of GCN5L1 with the ETC proteins NDUFA9 and
ATP5a. The arrow shows the specific band for NDUFA9 relative to the non-specific band
seen in the IgG immunoprecipitation control. (B) In vitro immunoprecipitation
acetylation assay of endogenous NDUFA9 and ATP5a with accompanying histogram
showing the relative levels of the respective protein acetylation (Ac-K) levels in control
or GCN5L1-depleted HepG2 cells. (C) In vitro immunoprecipitation acetylation assay
using an acetylated-lysine antibody to assay endogenous NDUFA9 acetylation with the
accompanying histogram showing relative acetylation in HepG2 cells expressing control
or GCN5L1 plasmids. (D) In vitro immunoprecipitation acetylation assay using an
acetylated-lysine antibody to assay endogenous ATP5a acetylation with the
accompanying histogram showing relative acetylation in HepG2 cells expressing control
or GCN5L1 plasmids . n ≥ 3 for all experiments. *p<0.05, compared to respective
controls. Results are mean ± s.e.m.
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interaction between GCN5L1 and the ETC proteins. To functionally characterize whether
these ETC proteins are targets of GCN5L1 mediated acetylation, we then undertook in
vitro acetylation procedures using total mitochondrial protein in cells displaying either
knockdown or overexpression of GCN5L1. Using mitochondria from control and
GCN5L1-depleted cells, followed by immunoprecipitation with an acetylated lysine
antibody and immunoblot analysis, showed that acetylation of endogenous NDUFA9 and
ATP5a is diminished following GCN5L1 knockdown (Figure 4B). In parallel,
immunoprecipitation with an antibody against acetylated lysine demonstrates that
endogenous NDUFA9 and ATP5a exhibit increased acetylation in cells overexpressing
GCN5L1 relative to control samples (Figure 4C and 4D).
Mitochondrial Respiration is Attenuated Following GCN5L1 Knockdown
As GCN5L1 targets ETC proteins, we then evaluated the effect of GCN5L1
knockdown on mitochondrial respiration. Following knockdown of GCN5L1 compared
to scrambled control siRNA in HepG2 cells (Figure 5A), oxygen consumption was
assessed using the Seahorse apparatus. Basal cellular oxygen consumption was increased
by GCN5L1 knockdown, as was the maximal oxygen consumption following
mitochondrial uncoupling (Figure 5B). The depletion of GCN5L1 in HepG2 cells
resulted in a 36% increase in oxygen consumption (Figure 5C). To confirm that this
oxygen was consumed in the mitochondria, the HepG2 cells were permeabilized with
digitonin and oxygen consumption was determined in the presence of glutamate and
malate as specific mitochondrial respiratory substrates. Here, oxygen consumption was
increased by 32% in GCN5L1 knockdown cells (Figure 5D). In parallel with these
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Figure 5. GCN5L1 knockdown increases mitochondrial respiration. (A) Steady-state
GCN5L1 levels in HepG2 cells following control or GCN5L1 knockdown (KD). (B)
Representative tracing of basal oxygen consumption and maximal oxygen consumption
induced by the uncoupler dinitrophenol (2-DNP) comparing control and GCN5L1 KD
HepG2 cells. (C) The absolute differences in basal oxygen consumption comparing
control and GCN5L1 KD HepG2 cells, taken as a mean of the first three data points. (D)
Relative differences in oxygen consumption in control and GCN5L1 KD cells following
digitonin administration and the use of glutamate and malate as mitochondrial respiration
substrates. (E) Differences in cellular ATP levels in control and GCN5L1 KD HepG2
cells. n ≥ 3 for all experiments. *p<0.05 and **p<0.01, compared to respective controls.
Results are mean ± s.e.m.
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changes in oxygen consumption, the depletion of GCN5L1 results in significantly higher
cellular ATP levels (Figure 5E).
GCN5L1 Functionally Opposes SIRT3 Effects
The above results show that the acetylation and bioenergetic phenotype of
GCN5L1 depletion is in direct contrast to that observed following the loss of SIRT3. As
these findings suggest that GCN5L1 may counteract SIRT3 function, we explored the
response to the combined genetic manipulation of these proteins. We employed an in vivo
model where SIRT3 was knocked down in HepG2 cells, with or without the concurrent
knockdown of GCN5L1. Knockdown of SIRT3 alone increased mitochondrial protein
acetylation, which was significantly reversed by the concurrent knockdown of GCN5L1
(Figure 6A). Accordingly, the knockdown of SIRT3 diminished mitochondrial oxygen
consumption and cellular ATP levels [1, 14], and the concurrent knockdown of GCN5L1
reversed these metabolic phenotypes (Fig. 6B-C). The ability of GCN5L1 knockdown to
reverse SIRT3 acetylation and respiratory phenotypes was confirmed in SIRT3-/- MEF
cells (data not shown).
DISCUSSION
Identification of the mitochondrial acetyltransferase machinery has proven
elusive. This is in contrast to the nuclear compartment, where the acetyltransferases
GCN5, p300 and TIP60 have been found to function as counter-regulatory enzymes to
SIRT1 [19]. The identification GCN5L1 in this report reveals a novel mediator of
mitochondrial protein acetylation to counter sirtuin deacetylase function.
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Figure 6. GCN5L1 counteracts the effects of SIRT3. (A) Total mitochondrial protein
acetylation (Ac-K) in HepG2 cells transfected with control, SIRT3 or SIRT3+GCN5L1
siRNA with an accompanying histogram showing the relative differences in
mitochondrial protein acetylation under the three different conditions. Metabolic
measurements of (B) mean total oxygen consumption (n = 5) and (C) mean total cellular
ATP (n= 5) of HepG2 cells transfected with control, SIRT3 or SIRT3+GCN5L1 siRNA.
Western analyses of mitochondrial acetylation were performed at least five times, and
representative blots are shown. n.s. – not significant, *p<0.05 and **p<0.01, compared to
the defined controls. Results are mean ± s.e.m.
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The maintenance of sequence homology, from prokaryotes to nuclear-encoded
eukaryotic mitochondrial proteins, is consistent with the symbiotic hypothesis of
mitochondrial evolution [20]. This phylogenetic fidelity is also evident, for example, in
eukaryotic mitochondrial kinases [21], and in the iron/sulphur assembly regulatory
protein frataxin [22]. As with these examples, the conservation of the BtXAT protein
acetyl-CoA- and substrate-binding regions in GCN5L1 supports the strong evolutionary
pressure for retention of prokaryotic features in mitochondrial regulatory proteins.
The characterization of GCN5L1 in this study shows that its expression, in
isolation, is insufficient to significantly augment protein acetylation. However, the loss of
acetylation following GCN5L1 depletion, and the re-establishment of this activity after
its reconstitution, both demonstrate the requirement for GCN5L1 in mitochondrial
protein acetylation. The findings presented here suggest that GCN5L1 is one critical
component of the mitochondrial acetyltransferase machinery. This concept is compatible
with the function of yeast GCN5, where integration of this protein into a multi-subunit
complex is required for maximal acetyltransferase activity [23]. Together, these data have
compelled us to begin to investigate whether additional mitochondrial proteins form
multimeric complexes with GCN5L1 in order to orchestrate acetyltransferase activity.
The early characterization of the bioenergetic role of the mitochondrial deacetylase
SIRT3 was performed in genetic knockout or knockdown conditions in cell and murine
models. The initial studies showed that the absence of SIRT3 resulted in a marked
reduction in mitochondrial oxygen consumption and a decrease in cellular ATP levels [1,
14]. Subsequent studies in an in vivo context showed that the bioenergetic effects of
SIRT3 were most pronounced under fasted conditions, and that the activity of numerous
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enzymes in multiple mitochondrial metabolic pathways are modified by SIRT3-mediated
protein deacetylation. In this manuscript we employed a similar approach, and identified
that the absence of GCN5L1 inversely perturbs mitochondrial oxygen consumption and
cellular ATP levels. However, more comprehensive biochemical analysis of the effects of
mitochondrial protein acetylation will need to be performed as additional substrates of
GCN5L1 are delineated, particularly following the identification of the putative
functional partners of GCN5L1.
In summary, this study shows that GCN5L1 functions as an essential component of
the mitochondrial lysine acetyltransferase machinery, has phylogenetic linkage to
prokaryotic acetyltransferases, and modulates mitochondrial respiration via acetylation of
ETC proteins. GCN5L1 also counters the mitochondrial deacetylase function of SIRT3.
Further investigation of GCN5L1, its putative interacting proteins and substrates, and the
role of acetyl-CoA, should enhance our understanding of how acetylation modulates
mitochondrial function.
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SUMMARY

Mitophagy recycles redundant/dysfunctional mitochondria either selectively or as a
component of macroautophagy (autophagy). As nutrient-sensing nuclear/cytosolic
acetylation mediates autophagy, we investigated whether Sirt3/GCN5L1 regulated
mitochondrial acetylation modulates mitophagy. GCN5L1 siRNA diminished
mitochondrial protein acetylation and augmented mitochondrial enrichment of
autophagy mediators LC3-II, p62 and ubiquitinylation, independent of
macroautophagy. This program was disrupted by Sirt3 knockdown. Chronic
GCN5L1 depletion increased the mitophagy rate and reduced mitochondrial protein
content/mass. In parallel, GCN5L1 knockdown attenuated respiration with a
concomitant increase in glycolysis and activation of mitochondrial biogenesis.
Mitochondria also exhibited enhanced ‘stress-resistance’. The genetic disruption of
p62 and LC3-lipidation abolished, whereas the knockout of the mitochondrial E3ubiquitin ligase Parkin did not impede, GCN5L1-depletion mitophagy. Together
these data support that deacetylation of mitochondrial proteins initiate Sirt3-, Atg5and p62-dependent but Parkin-independent mitophagy. Furthermore, the
regulation of this nutrient-sensing mitochondrial protein acetylation program is
sufficient to modulate mitophagy with ameliorative effects on mitochondrial
homeostasis.
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INTRODUCTION

Cellular macroautophagy controls the regulated turnover of cellular content and
damaged organelles to both optimize cellular homeostasis and recycle intracellular
energy reserves when external supplies are limited. Interestingly, organelle autophagy
can function selectively or in concert with macroautophagy to remove and/or facilitate
the turnover of damaged organelles. This regulated program is operational in
mitochondria where mitophagy selectively removes mitochondria during erythrocyte
maturation and in response to mitochondrial depolarization (Youle and Narendra, 2011).
However, the role and contribution of mitophagy to ‘intracellular recycling’ under fasting
and/or starvation conditions in mammalia has not been clearly delineated. In yeast the
genetic disruption of the mitophagy program results in impaired clearance of
mitochondria during prolonged starvation in parallel with the disruption in mitochondrial
genomic fidelity (Kurihara et al., 2012).
In the context of nutrient limitation, cellular protein acetylation status plays an
important role in adaptation to starvation and/or in response to caloric restriction
(Hirschey et al., 2010; Someya et al., 2010). Moreover, the regulation of the acetylome
regulates autophagy, and the genetic manipulation of nuclear and cytosolic
acetyltransferase/deacetylase enzymes show that changes in acetylation status of
autophagy mediators alters macroautophagy induction (Hamai and Codogno, 2012; Lee
et al., 2008; Lee and Finkel, 2009; Yi et al., 2012). The nutrient-sensitive deacetylase
sirtuin enzymes link the cellular response to starvation, the regulation of the
acetylproteome and autophagy. Humans express seven sirtuin isoforms that localize to
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various cellular compartments. Of note, the nuclear and cytosolic localized Sirt1
mediated deacetylation of various autophagy proteins is necessary for starvation induced
macroautophagy (Lee et al., 2008).
Sirt3 is the major mediator of mitochondrial protein deacetylation (Lombard et al.,
2007) and regulates mitochondrial metabolism, redox status and mitochondrial mediated
cell death (Webster et al., 2012). Whether the intrinsic acetylation profile of
mitochondrial proteins regulates the mitophagy program is uncertain. The tools to
interrogate this program have been limited as overexpression of the mitochondrial
deacetylase Sirt3 results in its ectopic expression (Bao et al., 2010) with concomitant
deacetylation of mitochondrial, cytosolic and nuclear proteins (Lu et al., 2011; Shi et al.,
2005; Sundaresan et al., 2008). Recently, GCN5L1 was identified as an essential
component of the mitochondrial acetyltransferase program (Scott et al., 2012), and its
genetic depletion resulted in the restricted acetylation of mitochondrial proteins. In this
context, we interrogated mitochondrial protein acetylation biology to investigate whether
mitochondrial-restricted acetylation may function as a ‘molecular signature’ of starvation
or caloric restriction, to initiate mitophagy.
In this article we show that i) the absence of the mitochondrial deacetylase Sirt3
attenuates fasting induced mitophagy in-vivo; (ii) the genetic knockdown of GCN5L1 in
HepG2 and mouse embryonic fibroblasts (MEFs) restricts acetylation of mitochondrial
proteins and initiates the mitochondrial accumulation of autophagy mediators; iii)
GCN5L1 knockdown initiated selective mitophagy is dependent on the autophagy
mediators p62 and Atg5 but independent of Parkin, an E3-ligase shown to function in
mitochondrial depolarization induced mitophagy (Narendra et al., 2008); iv) the
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persistent activation of this mitophagy program results in mitochondrial dropout with
diminution of oxidative metabolism and the upregulation of the mitochondrial biogenesis
regulatory program; and v) the mitochondrial protein deacetylation program augments
mitochondrial stress-resistance.

RESULTS
Mitochondrial protein deacetylation promotes mitochondrial accumulation of
autophagy factors
To begin to explore whether fasting-induced mitophagy is dependent on
mitochondrial protein deacetylation, we measured the mitochondrial enrichment of
lipidated ATG8/LC3 (LC3-II), a canonical autophagy mediator recruited to mitochondria
(Liu et al., 2012), in response to fasting in wildtype and Sirt3 knockout mice. In wildtype
mice, fasting resulted in the accumulation of LC3-II to liver mitochondria in parallel with
increased Sirt3 and reduced GCN5L1 levels (Figure 1A). In contrast, the level of
mitochondrial-enriched LC3-II was not increased in mitochondrial deacetylation deficient
Sirt3 knockout mice liver in response to fasting (Figure 1B and S1A). To evaluate
whether the direct change in levels of mitochondrial acetylation regulatory enzymes
could modulate the recruitment of autophagy mediators to the mitochondria, we assessed
mitochondrial enrichment of LC3-II, p62 and concomitant mitochondrial protein
ubiquitinylation in response to siRNA mediated knockdown of either GCN5L1 or Sirt3.
Isolated mitochondria from GCN5L1-depleted HepG2 cells showed accumulation of
LC3-II, p62 and protein ubiquitinylation (Figure 1C). In contrast, and in parallel to the
lack of mitophagy induction in response to fasting in Sirt3 KO mice, Sirt3-depleted cell
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Figure 1. Depletion of GCN5L1 leads to accumulation of autophagy factors on mitochondria.
(A-B) Hepatic mitochondria from Sirt3+/+ and -/- mice were analyzed from fed and fasted
conditions. Western blotting was performed using antibodies against LC3, Sirt3 and GCN5L1
with VDAC as a loading control (n=4 animals per group). (C) Control and GCN5L1 siRNA
HepG2 cell mitochondria were used in western blot analysis with antibodies directed against p62,
LC3, Sirt3, GCN5L1 and ubiquitinylation with VDAC as a loading control. (D-E) Confocal
microscopy was performed on control or GCN5L1 siRNA treated HepG2 cells. Representative
images for co-localization of ds-Red labeled mitochondria with GFP-LC3 (D), GFP-ubiquitin or
p62 (E). Scale bar, 10 µm. (F-G) Representative western blot analysis of the effect of Sirt3
siRNA on GCN5L1 knockdown mediated mitochondrial accumulation of p62 and LC3-II in
HepG2 cells. Protein levels were determined relative to VDAC. Control samples were normalized
to 1 with Sirt3 and GCN5L1 siRNA treated samples determined relative to control values. Data
are expressed as the mean ± s.e.m. *p<0.05 vs. scrambled siRNA control, #p<0.05 vs. GCN5L1
siRNA levels. All experiments were repeated 3-8 times. AU, arbitrary units.
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Supplemental Figure 1. Sirt3 depletion fails to induce mitophagy while GCN5L1 knockdown
augments mitochondrial delivery to autophagolysosomes. (A) Quantification of LC3-II levels
normalized to VDAC in isolated hepatic mitochondria from fed and 48 hour fasted Sirt3 WT/KO
animals. Fed samples were normalized to 1 with protein levels from fasted animals presented
relative to controls (n=4 animals per condition). (B) Representative images for co-localization of
dsRed labeled mitochondria and GFP-LC3 in HepG2 cells treated with siRNA to Sirt3. Scale bar,
10 µm. (C) Confocal microscopy of mitochondrial incorporation into the autolysosome via
colocalization of dsRed-Mito and GFP-Lamp1 following siRNA to control or GCN5L1 in HepG2
cells. Scale bar, 10 µm. (D) Electron microscopy of HepG2 cells treated with siRNA to control or
GCN5L1. Arrows represent autophagic vacuoles and autolysosomes. To induce accumulation
and slow degradation of cellular material in autophagosomes, bafilomycin (10 nM) was added
(bottom images). Scale bar, 2 µm (top) and 1 µm (bottom). Data are expressed as the mean ±
s.e.m. with **p<0.01. All experiments were repeated 3-5 times. AU, arbitrary units.
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mitochondria showed similar levels of LC3-II, p62 and protein ubiquitinylation as the
scrambled control siRNA cells (Figure 1C). To confirm the mitochondrial accumulation
of these autophagy mediators, confocal microscopy was performed comparing scrambled
control to GCN5L1 siRNA in HepG2 cells. Co-localization was increased between GFPtagged LC3 and ds-red labeled mitochondria following the knockdown of GCN5L1
compared to scrambled control (Figure 1D), and this effect was not seen in Sirt3-depleted
HepG2 cells (Figure S1B). In parallel, p62 and ubiquitin showed similar enhanced
localization to mitochondria in response to the knockdown of GCN5L1 (Figure 1E). To
determine the extent of mitochondria accumulation in lysosomes, we compared the
localization of the GFP-Lamp1 and ds-red labeled mitochondria in scrambled control
compared to GCN5L1 knockdown HepG2 cells. Confocal microscopy showed greater
overlap of mitochondria with lysosomes following the genetic depletion of GCN5L1
compared to the scrambled control siRNA cells (Figure S1C). Electron micrographs
mirrored this biology as siRNA directed against GCN5L1 resulted in the induction of
autophagic vacuoles and autolysosomes compared to scrambled siRNA in HepG2 cells.
Mitochondrial accumulation within autophagosomes was enhanced following treatment
with bafilomycin, which prevents autophagic degradation, in GCN5L1-depleted cells
compared to controls (Figure S1D). We previously demonstrated Sirt3 knockdown leads
to augmented acetylation, which is blocked by the concurrent knockdown of Sirt3 and
GCN5LI (Scott et al., 2012). We exploited this to validate whether GCN5L1-knockdown
mediated mitophagy can be attenuated with simultaneous Sirt3 knockdown. We found
that the mitochondria enrichment of p62 and LC3-II was blunted following the
concurrent knockdown of GCN5L1 and Sirt3 (Figure 1F-G).
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Acute GCN5L1 depletion enhances mitochondrial function without perturbing
global autophagy or autophagosome-lysosomal flux
The acute induction of mitophagy has been proposed to function to maintain
mitochondrial quality control. Previously, we have shown that acute siRNA knockdown
of GCN5L1 enhances mitochondrial respiration and cellular ATP levels (Scott et al.,
2012). To further interrogate this phenotype, we evaluated the effect of mitophagy on
mitochondrial mass, protein content and on the mitochondrial capacity to generate
reactive oxygen species. We found that transient GCN5L1 knockdown resulted in a
modest reduction in the mitochondrial membrane potential without a change in the
mitochondrial mass (Figures 2A and 2B). Also there was no change in levels of
mitochondrial proteins including NDUFA9 and VDAC following the acute knockdown
of GCN5L1 (Figure S2A). As this mitochondrial bioenergetic profile could be consistent
with stress-resilience, we assessed the response to the generation of reactive oxygen
species in response to rotenone administration (Zhou et al., 2011). siRNA knockdown of
GCN5L1 blunted mitochondrial superoxide production (Figure 2C).
As GCN5L1 has also been shown to associate with lysosomes (Dell'Angelica, 2004),
we assessed whether its knockdown altered global autophagy or if it induces ‘selective’
mitophagy, and whether this program modulates flux through the autophagosomelysosomal catabolic pathway. To explore this, we evaluated the global autophagy
signature in whole cell preparations following control or GCN5L1 siRNA.
Phosphorylation of p70s6k, a signaling intermediate in autophagy, p62 and the ratio of
LC3-I to LC3-II were not altered by the depletion of GCN5L1 in whole cell preparations
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Figure 2. Acute GCN5L1 depletion enhances mitochondrial function without perturbing
autophagy. (A) Relative mitochondrial membrane potential measured by cytometric analysis with
TMRM (100 nM) fluorescence in scrambled control versus GCN5L1 siRNA in HepG2 cells. (B)
Relative mitochondrial mass was measured by cytometric analysis using Mitotracker Green (100
nM) in scrambled control versus GCN5L1 siRNA treated HepG2 cells. (C) Measurement of
relative mitochondrial superoxide generation under basal conditions and in response to the
inhibition of complex I of the electron transfer chain by the administration of rotenone (15 µM
for 4 hrs) in control and GCNN5L1 siRNA HepG2 cells as measured by Mitosox (5 µM)
fluorescence. Control levels were normalized to 1, and levels from rotenone and GCN5L1
knockout samples are relative to normalized controls. (D) Representative immunoblots to
determine changes in whole cell autophagy in response to GCN5L1 siRNA by assessing
dephosphorylation of p70s6k, the depletion of whole cell p62 or the appearance of LC3-II in
HepG2 cells. (E) Assessment of the capacity for mitochondrial accumulation of autophagy
mediators (autophagic flux) p62, LC3 and ubiquitinylation in control and GCN5L1 siRNA treated
HepG2 cells in response to the inhibition of lysosomal function by chloroquine (60 µM). Data are
expressed as the mean ± s.e.m. with n ≥ 3 replicates for each flow cytometry study. *p<0.05 vs.
scrambled control studies and **p<0.01 vs. the respective control group; n.s., not significant. All
experiments were repeated 3-7 times. AU, arbitrary units.
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Supplemental Figure 2. Acute knockdown of GCN5L1 does not alter mitochondrial protein
content or autophagy induction. (A) Mitochondrial proteins VDAC and NDUFA9 levels in whole
cell lysates from HepG2 cells treated with control or GCN5L1 siRNA. (B) Representative
immunoblot assaying autophagy induction following rapamycin (1 µM for 24 hours) treatment in
HepG2 cells. Autophagy induction was determined by LC3-II and phospo-p70s6k levels in whole
cell lysates following GCN5L1 siRNA mediated knockdown. (C) Confocal microscopy of HepG2
cells treated with siRNA to control or GCN5L1 overexpressing dually-tagged RFP-GFP-LC3.
Red punctae depict formation of autolysosomes. Scale bar, 10 µm. All experiments were repeated
3 times.
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(Figure 2D). The levels of p62 and LC3-II directly contrast the levels found in isolated
mitochondria following GCN5L1 knockdown suggesting ‘selective’ mitophagy induction
as opposed to macroautophagy. Furthermore, we confirmed that autophagy induction is
intact following GCN5L1 siRNA, as evident by the similar augmentation of this program
in response to rapamycin in control and knockdown cells (Figure S2B). Increased levels
of autophagic markers could be due to increased induction or a block in autophagic flux
leading to protein accumulation. To confirm that autophagosome-lysosomal flux is not
impaired following GCN5L1 knockdown, mitochondria were isolated following
chloroquine administration. As previously shown, baseline markers of mitophagy were
induced in the GCN5L1 knockdown cells compared to controls, and the disruption of
lysosomal acidification with chloroquine increased mitophagy markers in both control
and GCN5L1 knockdown mitochondria suggesting intact flux (Figure 2E). To further
assess whether autophagic flux is disrupted by GCN5L1 knockdown, dual RFP-GFP
labeled LC3 was transfected into control and GCN5L1 siRNA treated HepG2 cells. The
GFP fluorophore is more susceptible to lysosomal degradation such that RFP labeled
punctae would signify successful LC3 delivery to the autolysosome and intact autophagic
flux. Confocal microscopy confirmed red punctae formation in both control and GCN5L1
knockdown cells suggesting intact autophagic flux (Figure S2C).

Chronic GCN5L1 depletion diminishes mitochondrial mass and protein levels
As prolonged mitophagy reduces mitochondrial content (Kurihara et al., 2012),
we investigated whether the stable knockdown of GCN5L1 using lentiviral shRNA
infection replicates this phenotype. Stable depletion of GCN5L1 resulted in the robust
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attenuation of mitochondrial protein acetylation while the autophagy markers LC3-II, p62
and protein ubiquitinylation were enriched in the mitochondrial fraction of shRNA
infected HepG2 cells (Figure 3A). In contrast to transient GCN5L1-knockdown, the
stable knockdown of GCN5L1 resulted in a reduction in mitochondrial mass (Figure 3B).
Using whole cell extracts we additionally found that levels of mitochondrial proteins
residing in the matrix and in the inner and outer mitochondrial membranes are reduced by
≈ 20 - 50 % in the GCN5L1 shRNA knockdown cells compared to the scrambled shRNA
control cells (Figures 3C and 3D). To evaluate whether these reductions in proteins levels
are mediated in part via proteosomal or lysosomal degradation, we compared changes in
protein levels of GDH and VDAC in response to the proteosome and lysosomal inhibitors
MG132 and chloroquine, respectively. Interestingly, in both the control and GCN5L1
knockdown cells, chloroquine markedly increased steady state mitochondrial protein
levels above vehicle treated controls with no significant augmentation in protein levels in
the presence of the proteosomal inhibitor MG132, suggesting mitochondrial protein
degradation is mediated by autophagy rather than the proteosome following GCN5L1
depletion (Figures 3E and 3F).

GCN5L1 shRNA mitophagy is dependent on Atg5 and p62 but independent of
Parkin
As the mechanisms underpinning selective mitophagy are beginning to be
delineated, we investigated whether canonical autophagy mediators known to be enriched
on mitochondria undergoing mitophagy (Geisler et al., 2010; Liu et al., 2012; Mai et al.,
2012) are required in response to GCN5L1 knockdown. To interrogate this, we
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Figure 3. Chronic GCN5L1 depletion attenuates mitochondrial mass and protein levels via
autophagic degradation. (A) Representative immunoblots showing mitochondrial protein
acetylation and the accumulation of autophagy mediators p62, LC3 and ubiquitinylation in
isolated mitochondria following chronic lentiviral shRNA knockdown of GCN5L1 compared to
control vector infection in HepG2 cells. (B) Relative mitochondrial mass as measured by
cytometric analysis of Mitotracker Green (100 nM) fluorescence in scrambled control versus
GCN5L1 lentiviral shRNA infection in HepG2 cells. (C) Western blot analysis of whole cell
levels of mitochondrial proteins glutamate dehydrogenase (GDH), ATP5a, NDUFA9 (complex I),
VDAC and TOM20 following chronic lentiviral shRNA knockdown of GCN5L1 compared to
control vector infection in HepG2 cells. (D) Quantification of mitochondrial protein levels
relative to tubulin. Control shRNA samples were normalized to 1, and the GCN5L1 shRNA cell
mitochondrial protein levels are represented relative to the control values. (E) Representative
immunoblot showing the whole cell levels of mitochondrial proteins following chronic lentiviral
shRNA knockdown of GCN5L1 compared to control vector infection in HepG2 cells in response
to the proteosomal inhibitor MG132 (7.5 µM) and lysosome inhibitor chloroquine (60 µM). (F)
Quantification of mitochondrial protein levels relative to tubulin. The control shRNA untreated
samples were normalized to 1, and all other mitochondrial protein levels are represented relative
to these control values. Data are expressed as the mean ± s.e.m with n ≥ 3 replicates for each flow
cytometry study. *p<0.05 versus the shRNA control group and **p<0.01 versus the scrambled or
GCN5L1 control shRNA samples. All experiments were repeated 4-12 times. AU, arbitrary units.
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employed lentiviral shRNA particles directed against GCN5L1 to generate stable
knockdown of this mitochondrial acetyltransferase protein in wildtype MEF cells and in
MEF lines deficient in the canonical autophagy/mitophagy mediators: p62, Atg5 and
Parkin. As in the HepG2 cells, the stable depletion of GCN5L1 in wildtype MEF cells
resulted in a reduction in mitochondrial protein acetylation and the mitochondrial
accumulation of autophagy mediators (Figure S3A and S3B). Compared to wildtype
MEF cells, the basal mitochondrial levels of p62 were elevated in Atg5 KO MEFs,
although further accumulation of p62 was not evident following GCN5L1 knockdown in
these cells (Figure 4A). As Atg5 facilitates the lipidation of LC3-I to generate LC3-II, it
is not surprising the GCN5L1-depletion in Atg5 KO MEFs does not result in
mitochondrial accumulation of LC3-II (Figure 4A). In p62 KO MEFs, neither LC3
species associated with mitochondria. This pattern was not altered by GCN5L1
knockdown (Figure 4A). The chaperone p62 has been shown to link ubiquitinylated
proteins to LC3-II. It is therefore not surprising that the Atg5 KO MEFs, which have an
abundance of mitochondrial p62, show evidence of increased mitochondrial protein
ubiquitinylation (Figure 4B). Under these conditions, the additional knockdown of
GCN5L1 had no additional effect on mitochondrial protein ubiquitinylation. In stark
contrast, GCN5L1 knockdown increased mitochondrial protein ubiquitinylation in both
the control and p62 knockout MEF cells supporting that mitochondrial protein
ubiquitinylation is upstream of p62 in mitophagy (Figure 4B).
As impaired mitophagy results in the accumulation of mitochondrial content
(Kurihara et al., 2012), we compared the mitochondrial protein levels in whole cell
preparations in the wildtype, Atg5 and p62 knockout MEFs. We show that both the
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Supplemental Figure 3. GCN5L1 knockdown mediated mitophagy in MEF cells is dependent on
p62 but not Parkin. (A and B) Representative western blots of isolated mitochondria from
wildtype MEF cells following treatment with control or GCN5L1 lenti-viral shRNA. Blots probe
for acetyl-lysine, p62, LC3 and ubiquitinylation. (C and D) Whole cell lysates (C) and
mitochondrial mass levels, as determined by Mitotracker Green (100 nM) cytometric analysis,
from p62 knockout MEFs following control or GCN5L1 shRNA treatment. (E and F) Whole cell
lysates from Parkin +/+ (E) and -/- (F) MEFs to determine mitochondrial protein levels following
GCN5L1 shRNA knockdown. Representative blots are depicted. Data are expressed as the mean
± s.e.m. with n ≥ 3 replicates for each flow cytometry. **p<0.01. All experiments were repeated 35 times. AU, arbitrary units.
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Figure 4. GCN5L1 depletion initiated mitophagy is dependent on Atg5 and p62 but not Parkin.
(A-B) Representative mitochondrial protein immunoblots showing the extent of the accumulation
of autophagy mediators p62, LC3 and ubiquitinylation in isolated mitochondria from wildtype,
Atg5 and p62 knockout MEF cells following lentiviral shRNA knockdown of GCN5L1 compared
to the control vector infection. (C-D) Representative whole cell immunoblots showing levels of
mitochondrial proteins ATP5a and NDUFA9 in wildtype (C) and Atg5 knockout (D) MEF cells
following lentiviral shRNA knockdown of GCN5L1 compared to control vector infection. (E)
Relative mitochondrial mass as measured by cytometric analysis of Mitotracker Green (100 nM)
fluorescence in control versus GCN5L1 shRNA lentiviral infection in the wildtype and Atg5 KO
MEFs. (F) Representative immunoblots of isolated mitochondria showing autophagic protein
levels in Parkin knockout MEF cells following lentiviral shRNA knockdown of GCN5L1 or
control vector. (G) Relative mitochondrial mass as measured by cytometric analysis of
Mitotracker Green (100 nM) fluorescence in control versus GCN5L1 shRNA lenti-viral infection
in wildtype and Parkin KO MEFs. Data are expressed as the mean ± s.e.m with n≥3 replicates for
each flow cytometry study with **p<0.01. All experiments were repeated 3-7 times. AU, arbitrary
units.
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Atg5 and p62 KO MEFs accumulate ATP5a and NDUFA9 protein levels in response to
GCN5L1 knockdown compared to wildtype control MEFs (Figures 4C, 4D and S3C). In
parallel the Atg5 and p62 KO MEF’s also show increased mitochondrial protein mass
following GCN5L1 shRNA infection compared to the wildtype control MEFs (Figures
4E and S3D).
Numerous E3-ubiquitin ligases have been identified that localize to the mitochondria
(Narendra et al., 2008; Tang et al., 2011), and of these, Parkin has been the one most
definitively linked to selective mitophagy in response to mitochondrial depolarization. To
determine if Parkin is important in deacetylation-mediated mitophagy, we explored the
mitochondrial enrichment of p62 and LC3-II in Parkin KO MEFs following GCN5L1
knockdown. In contrast to the results found in Atg5 and p62 KO MEFs, the
mitochondrial accumulation of LC3-II and p62 was still evident in the absence of Parkin
(Figure 4F). Additionally, knockdown of GCN5L1 in Parkin KO MEFs led to increased
mitochondrial protein ubiquitinylation, suggesting an alternative E3 ligase involved in
this form of mitophagy (Figure 4F). Parkin KO MEFs also showed a reduction in
mitochondrial mass following GCN5L1 shRNA knockdown (Figure 4G). In parallel, the
absence of Parkin did not impair the GCN5L1 shRNA-mediated reduction in
mitochondrial protein levels (Figures S3E and S3F).

Chronic GCN5L1 knockdown increases mitophagic flux, reduces mitochondrial
bioenergetic function and activates mitochondrial biogenesis
Finally, we began to explore the mitochondrial consequences of chronic GCN5L1
knockdown-induced mitophagy. We first explored whether persistent deacetylation of
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mitochondrial proteins resulted in the continuous turnover of mitochondria via lysosomal
hydrolysis. To quantify the flux of mitochondria through the autophagic degradation
pathway, we used flow cytometry to measure the lysosomal acidic pH-dependent loss of
the mitochondrial enriched pH-sensitive fluorescent protein mKiema (Katayama et al.,
2011). Chronic depletion of GCN5L1 increased the percentage of cells undergoing
mitophagy compared to scrambled shRNA HepG2 cells as seen with a change in
fluorescence of the mKeima construct upon delivery to the acidic lysosome (Figures 5A
and 5B). Interestingly, the addition of bafilomycin, to impair lysosomal acidification, did
not alter the basal rate of mitophagy in the control shRNA HepG2 cells, although it did
blunt this process in the GCN5L1 knockdown cells (Figures 5B and S4A). To further
quantify autophagic flux, we employed flow-cytometry as a confirmatory assay to assess
whether the dissipation GFP signal in the RFP-GFP-LC3 construct is similarly
accelerated in GCN5L1 shRNA treated cells. We found that chronic GCN5L1
knockdown resulted in a significant reduction in GFP-LC3 signal compared to control
shRNA cells (Figures 5C, S4B and S4C). Similar to the acute knockdown of GCN5L1
using siRNA, the shRNA mediated depletion of GCN5L1 led to a reduction in
mitochondrial membrane potential (Figure S4D). As the dropout of mitochondria is likely
to result in less reliance of oxidative phosphorylation for energy production, we measured
basal and maximal rate of oxygen consumption and the rate of glycolysis in control and
GCN5L1 depleted cells. Consistent with the ‘loss’ of mitochondrial content the
GCN5L1-depleted cells showed a significantly lower rate of oxygen consumption and
reciprocal increase in glycolysis (Figures 5D, 5E, S4E and S4F). We expected that the
persistent knockdown of GCN5L1 may result in the progressive reduction in
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Figure 5. Chronic depletion of GCN5L1 augments mitophagic flux and alters mitochondrial
function. (A) Representative cytometric scatter plots showing the relative acidification of the
mitochondrial targeted Kiema (mKeima) protein in control and GCN5L1 shRNA infected HepG2
cells. (B) Quantification of mKeima acidification as a measure of mitophagy in control versus
GCN5L1 shRNA infected HepG2 cells. Lysosomal acidification was inhibition by bafilomycin
(10 nM). Untreated control values were normalized to 1 with treated samples expressed relative
to controls. (C) Quantification of autophagy induction by cytometry using RFP-GFP-LC3 as a
confirmatory measure of enhanced LC3 incorporation into lysosomes in response to the chronic
depletion of GCN5L1 in HepG2 cells. (D-E) Representative Seahorse analysis of basal and
maximal oxygen consumption using dinitrophenol (100 µM) and the rate of glycolysis in
response to chronic GCN5L1 depletion in HepG2 cells. (F) Transcript levels of genes encoding
mitochondrial biogenesis regulatory proteins and nuclear encoded electron transfer proteins in
response to chronic GCN5L1 depletion in HepG2 cells as measured by qPCR. Control values
were normalized to 1 with GCN5L1 shRNA values expressed relative to controls. (G)
Mitochondrial genomic copy number as measured by the relative content of the mitochondrial
genomic encoded cytochrome oxidase I to nuclear-encoded 18S. (H) Assessment of the relative
ionomycin (6.25, 12.5 and 25 nM) mediated mitochondrial permeability transition comparing
control to GCN5L1 depleted cells. The addition of cyclosporin A (2 µM for 30 min) is shown to
attenuate pore transition in the presence of 25 nM ionomycin. Data are expressed as the mean ±
s.e.m with n≥3 replicates for each flow cytometry, Seahorse or qPCR study.*p<0.05 and **p<0.01
vs. respective controls. All experiments were repeated 3-4 times.
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Supplemental Figure 4. Chronic depletion of GCN5L1 augments mitophagy, alters
mitochondrial respiration and induces mitochondrial biogenesis. (A) Representative FACs scatter
plots of shRNA control and GCN5L1 treated HepG2 cells overexpressing mKeima also treated
with and without bafilomycin (10 nM) to block lysosomal acidification. (B) Confocal microscopy
image of HepG2 cells depleted of GCN5L1 with lentiviral shRNA and overexpressing RFP-GFPLC3 to monitor autophagic flux. Scale bar – 10µm (C) Quantification of wildtype MEFs treated
with control or GCN5L1 shRNA and overexpressing RFP-GFP-LC3. Fluorescence levels of RFP
and GFP were determined by FACs. (D) Cytometric analysis with TMRM (100 nM) to assess
relative mitochondrial membrane potential in scrambled control versus GCN5L1 shRNA treated
MEF (top) and HepG2 (bottom) cells. (E and F) Seahorse analysis of wildtype MEF cells
depleted of GCN5L1 with lentiviral shRNA. Basal and maximal respiration (E) and extracellular acidification rate (ECAR) (F) were determined. Figures are representative samples. (G)
RT-PCR determination of PGC-1α transcript levels in wildtype MEFs treated with control or
GCN5L1 shRNA. All reactions were normalized using an 18S endogenous control. Control
samples were normalized to 1 with GCN5L1 samples expressed relative to controls. (H)
Mitochondrial copy number levels of wildtype MEFs depleted of GCN5L1 following lenti-viral
shRNA treatment. DNA copy number was normalized to nuclear encoded 18S. Data are
expressed as the mean ± s.e.m. with n≥3 replicates for each flow cytometry, Seahorse or qPCR
study. *p<0.05 and **p<0.01 vs. controls. All experiments were repeated 3-4 times.
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mitochondrial mass and oxidative metabolism with each subsequent passage of shRNA
knockdown cells. However, it appeared that despite the increased mitophagic flux a lower
steady-state mitochondrial content became established in the GCN5L1 knockdown cells
(data not shown). To explore whether this new steady-state level resulted from a
compensatory induction of the mitochondrial biogenesis program (McLeod et al., 2005),
we explored transcript levels of transcriptional mediators of biogenesis, i.e. PGC-1α and
NRF-1, and mitochondrial protein transcripts that would be induced by biogenesis. We
found that this regulatory program is indeed induced with a significant augmentation of
transcripts for the biogenesis regulatory program (Figures 5F and S4G) and for electron
transfer chain proteins ATP5a and NDUFS8 (Figure 5F). To confirm the induction of this
program, we measured the mitochondrial genomic content and show that following
chronic GCN5L1 knockdown, the relative mitochondrial genomic copy number was
increased (Figure 5G and S4H). A higher rate of mitophagic flux may be expected to
improve mitochondrial integrity (Kurihara et al., 2012). To explore this, we tested the
susceptibility of control versus GCN5L1 shRNA cells to ionomycin-induced
mitochondrial permeability transition. GCN5L1 depleted cells due showed greater
resilience to permeability transition and required a larger dose of ionomycin to result in
the same level of mitochondrial membrane permeability (Figure 5H).

DISCUSSION

Macroautophagy is an intricate program orchestrating cellular recycling and
renovation, and autophagy is increasingly recognized as a regulated program to maintain
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bioenergetic integrity during nutrient restricted conditions and as a cellular repair
program in response to a wide array of biological stressors. Protein acetylation is also
highly regulated under nutrient restricted conditions, and therefore it is not surprising that
the enzymatic modification of the nuclear and cytosolic ‘acetylomes’ are now linked to
the activation of canonical macroautophagy mediators (Lee et al., 2008; Lee and Finkel,
2009; Yi et al., 2012). At the same time, autophagy-specific degradation of cellular
structural components and organelle recycling to sustain bioenergetic viability occur in
an ordered manner, with the mitochondria being relatively spared during early autophagy
given its importance in energy maintenance (Kristensen et al., 2008). As the
mitochondrial acetylome is controlled by intrinsic molecular programs, we explored
whether the direct modulation of the mitochondrial acetylome is sufficient to initiate and
sustain the selective mitochondrial autophagy program. We show that the restricted
acetylation of mitochondrial proteins via the genetic depletion of GCN5L1 results in the
accumulation of canonical autophagy mediators on mitochondria, without the activation
of the macroautophagy program. Moreover this program is dependent on autophagy
mediators Atg5 and p62 and is independent of the known stress-induced mitophagy
mediator – Parkin. The activation of this selective mitophagy is additionally dependent
on the mitochondrial deacetylase Sirt3. Furthermore, we show that chronic mitochondrial
protein deacetylation induced mitophagy reduces cellular mitochondrial content and
cellular respiratory capacity with the concurrent induction of the reciprocal mitochondrial
biogenesis regulatory program. In parallel, these mitochondria exhibit enhanced
resilience to mitochondrial stressors.
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The concept that the modulation of whole cell acetylation can modulate autophagy
has been established using genetic and pharmacologic interventions (Eisenberg et al.,
2009; Lee et al., 2008; Lee and Finkel, 2009; Morselli et al., 2011; Yi et al., 2012).
Moreover, pharmacologic studies show a synergistic activation of autophagy by the dual
administration of a deacetylase activator and an acetylase inhibitor (Morselli et al., 2011).
In that study it was noted that numerous proteins residing in the inner and outer
mitochondrial membrane and mitochondrial matrix undergo deacetylation as a
component of the autophagy-associated modulation of the cellular acetylproteome
(Morselli et al., 2011). However, the mechanism(s) and or signaling emanating from
mitochondrial protein deacetylation that orchestrate the mitochondrial component of this
cellular homeostatic program remain elusive. It is interesting to note though, in an
unbiased siRNA library screen, that the depletion of the mitochondrial acetyltransferase
protein GCN5L1 (also known as Bloc1s1) was found to modulate Parkin-overexpression
mediated mitophagy (Orvedahl et al., 2011).
Mitochondrial localization to the autophagosome is thought to occur through two
general mechanisms. The first mechanism results from the direct binding of
mitochondrial localized ‘receptors,’ such as FUNDC1, NIX or BNIP3, to LC3-II on the
autophagosome (Hanna et al., 2012; Liu et al., 2012; Schweers et al., 2007). The second
proposed mechanism is that ubiquitinylation of various mitochondrial proteins by E3ubiquitin ligases attract the binding of the chaperone p62, which then functions as an
adaptor protein for LC3-II to target mitochondria to the autophagosome (15, 21). One
possible component of mitophagy initiation by mitochondrial protein deacetylation is that
this modification exposes lysine residues to facilitate ubiquitinylation (Glozak and Seto,
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2009), a post-translation modification evident following GCN5L1 knockdown. As
mentioned, numerous E3-ubiquitin ligases, in a stressor-specific manner, have been
identified to modify mitochondrial proteins as a component of mitophagy (Liu et al.,
2012; Narendra et al., 2008; Tang et al., 2011). The best characterized is Parkin, which,
in response to robust mitochondrial depolarization, is recruited to ubiquitinylate outer
mitochondrial membrane proteins (Narendra et al., 2008; Narendra et al., 2010; Suen et
al., 2010). Although, we do see evidence of modest mitochondrial depolarization
following GCN5L1 knockdown, it is probably insufficient to evoke Parkin-mediated
mitophagy, and we find that the mitophagy effects of GCN5L1 depletion remain evident
in Parkin null MEF cells. Which E3-ubiquitin ligase(s) is operational in response to the
modulation of the mitochondrial acetylome has not been identified to date and will
require further study.
Various pathological conditions are associated with concomitant perturbations in
mitochondrial function and alterations in the mitochondrial acetylome. Examples include
diseases associated with genetic defects in mitochondrial metabolic proteins (Wagner et
al., 2012) and in response to nutrient-overload conditions such as high fat feeding
(Kendrick et al., 2011). Whether, perturbations in the mitophagy program underpins or
contributes to the pathophysiology of these diseases is an interesting hypothesis
emanating from our findings, in that the modulation of the mitochondrial acetylome itself
is sufficient to initiate selective mitophagy.
The emerging concept of epistatic control of the acetylome has recently been
functionally delineated in skeletal muscle following the conditional knockout of Sirt1
(Philp et al., 2011). In that study, the expected attenuation of mitochondrial biogenesis in
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the absence of Sirt1 was not evident. Rather, the counter-regulatory acetyltransferase
GCN5 was concomitantly downregulated following the Sirt1 knockdown (Philp et al.,
2011) suggesting regulatory integration between acetyltransferases and deacetylases in
modulating the acetylome and cell function. With respect to autophagy, the same concept
was shown with the counter-regulatory effects of Sirt1 and p300 and by the
pharmacologic modulation of acetylation and deacetylation (Lee et al., 2008; Lee and
Finkel, 2009; Morselli et al., 2011). Our initial fasting study in Sirt3+/+ and -/- mice,
suggest that GCN5L1 and Sirt3 work in tandem to control mitophagy. Although
GCN5L1 is robustly downregulated in the Sirt3-/- mice in response to fasting, the
accumulation of LC3-II to the mitochondria was not evident compared to Sirt3+/+ mice.
The role of mitophagy in the broader context of starvation or fasting-induced
macroautophagy has also not been extensively explored. Data is emerging showing an
important role of the mitochondrial outer membrane in autophagosome membrane
biogenesis during amino acid deprivation (Hailey et al., 2010) and the recognition that
mitochondrial morphology itself may play a role in modulating mitochondrial turnover
during starvation (Gomes et al., 2011). The role of modulating the mitochondrial
acetylome in this program requires direct study. Additionally, how mitochondrial and
nuclear/cytosolic acetylomes integrates into broader macroautophagy pathways also
needs to be explored.
The mitochondrial turnover studies show that chronic knockdown of GCN5L1 almost
doubles the rate of mitophagy with a significant reduction in mitochondrial content and
bioenergetic function and capacity. In parallel, this increase in the rate of mitophagy is
sufficient to activate the mitochondrial biogenesis program and appears to improve
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mitochondrial ‘health’. Whether this increased mitochondrial turnover would impact
pathologies known to be linked with mitochondrial dysfunction requires further study.
Nevertheless, our findings expand the concept underpinning fine-tuning of the regulation
of mitochondrial homeostatic programs to sustain the optimal mitochondrial content and
functioning to most effectively maintain cellular homeostasis.
In conclusion, this study shows that the genetic modulation of the mitochondrial
acetylome via the knockdown of the mitochondrial acetyltransferase protein GCN5L1 is
sufficient to initiate selective mitophagy. We show that the acute induction of this
program has modest ameliorative effects on mitochondrial biology, and chronic GCN5L1
knockdown results in the reduction of mitochondrial content with a concomitant
activation of the mitochondrial biogenesis program. We find that this program is
dependent on Sirt3 activity and on the canonical autophagy mediators Atg5 and p62 but
is independent of Parkin (Figure 6). The manipulation of this program to enhance
mitophagy may be a novel approach to ameliorate diseases associated with mitochondrial
dysfunction and increased mitochondrial protein acetylation.
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Figure 6. Proposed model for mitochondrial acetylome initiated mitophagy.
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EXPERIMENTAL PROCEDURES

In-vivo mouse experiments
3-4 month old littermate wildtype and knockout offspring of C57BL/6 SIRT3+/- mice
were used for fasting experiments where mice were either fed ad-libitum or fasted for 48
hrs. Mice were euthanized and liver mitochondria isolated via differential centrifugation
(Lu et al., 2011). The Animal protocol was approved by the NHLBI Animal Care and
Use Committee.

Cell studies
HepG2 cells were obtained from ATCC. MEFs were generated from day 13.5
embryos (Parkin2 and Sirt3 +/+ and -/- mice) or obtained from other investigators (Atg5
and p62 knockout MEFs - see acknowledgements). HepG2 and MEF cells were
maintained in DMEM (Gibco) supplemented with 10% or 15% FBS, respectively. For
autophagy, lysosomal and proteosomal functional studies, chloroquine (60 µM),
rapamycin (1 µM), bafilomycin (10 nM) or MG132 (7.5 µM) was added to the culture
medium for 24 hrs.
To perform immunoblot analyses, whole cell total protein samples and isolated
mitochondria were obtained from cells using RIPA buffer (Pierce) or a Qiagen
mitochondrial isolation kit. Samples were sonicated and quantified prior to running 4%–
20% Tris-glycine gels (Invitrogen) and transferred onto nitrocellulose membranes
(Invitrogen). Antibodies used for immunoblotting were purchased from Sigma (tubulin
and LC3), Cell Signaling (ubiquitin, VDAC, acetyl-lysine (monoclonal), p70s6k,
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phospho-p70s6k, human Sirt3), Abcam (complex Vα, NDUFA9, GDH), Santa Cruz
(Tom20), Progen Biotechnik (p62), or custom made by Covance (mouse Sirt3 and
GCN5L1).
siRNA transfection was performed in HepG2 cells using scrambled or Smartpool
siRNA targeting Sirt3 and GCN5L1 (Dharmacon) via electroporation (Lonza).
Lentiviral shRNA were generated in HEK293T cells. For each plate, 2.6 µg of
scrambled or GCN5L1 shRNA plasmid plus 26 µL of Lentiviral Packaging Mix (Sigma)
were transfected into HEK293T cells with Fugene 6 transfection reagent (Roche). The
media was replaced 16 hrs after transfection. Media containing viral particles was
harvested twice and combined. To remove the cell debris, media containing viral particles
was centrifuged at 2,000 rpm for 10 min at 4ºC. Supernatants were transferred to a fresh
tube and subjected to centrifuge at 18,000 rpm for 3 hrs at 4 C. Supernatants were then
carefully removed. Pellets were resuspended in 500 µl of ice-cold PBS. Titer of viral
particles was determined with a Lenti-X p24 Rapid titer kit (Clontech) and used to infect
HepG2 and MEF cells in the presence of puromycin (2µg/mL).
Immunofluorescence studies were performed in HepG2 cells transfected with
scrambled or GCN5L1 siRNA (Dharmacon). On day three fluorescent-tagged plasmids
were transfected into HepG2 cells using FuGene HD (Roche) according to the
manufacturer’s instructions. Plasmids used were: dsRed-mito (Clontech), RFP-GFP-LC3
and GFP-Ubiquitin (Addgene), GFP-LC3 and RFP or GFP-Lamp1. Samples were viewed
on a Zeiss LSM510 confocal microscope. For p62 colocalization studies, siRNA
treatment proceeded for 48 hrs at which point dsRed-mito was transfected for 24 hrs.
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Indirect immunofluorescence was performed after cell fixation using the p62 antibody
(Progen Biotechnik) and Alexa Fluor 488 (Invitrogen).
Flow cytometry studies were performed to assess relative mitochondrial membrane
potential, mass, superoxide production, the extent of mitophagy and mitochondrial
permeability transition susceptibility. Mitochondrial membrane potential was measured
using 100 nM TMRM (Invitrogen). Mitochondrial mass was determined using
Mitotracker Green FM (Invitrogen). For mKeima or RFP-GFP-LC3 studies, stable
HepG2 GCN5L1 or scrambled controls shRNA cells were transfected with the RFP-GFPLC3 (or RFP-Lamp1/GFP-LC3 for compensation controls) or mKeima constructs using
Fugene HD for 24 hours. For data analysis, geometric means for GFP or RFP signals
were determined. For the mKeima studies, samples underwent cytometric analyses while
excited simultaneously with a 407nm/605 nm (ex/em) (for neutral staining cells, V605)
and at 532 nm/610 nm (ex/em) (for acidic staining cells, V610). The number of cells in
each population (acidic or neutral) was determined, and the ratio of acidic labeled vs.
total stained cells was compared between control and GCN5L1 shRNA infected cells.
Mitochondrial permeability transition was performed using the MitoProbe Transition
Pore Assay Kit (Molecular Probes). As a positive control cyclosporine A was used at 2
µM for 30 min. For oxidative stress studies, HepG2 cells were treated with siRNA for 3
days at which point cells were treated with DMEM + rotenone (15 µM) for 4 hours. To
detect mitochondrial superoxide generation, Mitosox (Invitrogen) was used at 5 µM for
30 min. Flow cytometry was performed on the FACSCaliber, LSR II Flow or
FACSCanto flow instruments (BD Bioscience).
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Electron microscopy was performed as previously described (Wu et al., 2009).
Briefly, following control or GCN5L1 siRNA in HepG2 cells, electron micrographs were
created with ultrathin sections of cells that were fixed in 2 glutaraldehyde/1%
paraformaldehyde and post-fixed with 1% OsO4. Samples were stained en bloc with 1%
uranyl acetate and embedded in Em-bed 812 (Electron Microscopy Sciences). Sections
were then imaged with a JEOL JEM1200EX transmission electron microscope with
AMT 6 megapixel digital camera.
Oxygen consumption rate (OCR) and extracellular acidification rate
(ECAR) were performed on the XF24 analyzer (Seahorse Bioscience) as previously
described (Scott et al., 2012). HepG2 cells were seeded in 24-well plates overnight
and incubated in unbuffered DMEM in a non-CO2 incubator for 1 h before
analysis. Oxygen consumption rate and extracellular acidification rate were automatically
calculated by the Seahorse XF-24 software. The maximal oxidative capacity was
calculated as the difference in oxygen consumption between dinitrophenol (100 µM)
administration and the basal oxygen consumption rate. The metabolic flux analysis was
repeated in triplicate and data normalized to protein content using a BCA assay (Thermo
Fisher Scientific).
RT-PCR was performed to assess mitochondrial biogenesis. RNA was isolated from
HepG2 and MEF cells using the RNeasy Mini Kit (Qiagen) following treatment with
scrambled or GCN5L1 shRNA. RNA was transcribed to cDNA using SuperScript III
First-Strand Synthesis Supermix (Invitrogen). RT-PCR was performed using primers
purchased from predesigned primers (QuantiTect primer assays - Qiagen). All reactions
were normalized using an 18S endogenous control. Mitochondrial copy number was
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performed as previously described (Pagel-Langenickel et al., 2008; Pagel-Langenickel et
al., 2007).

Statistics
Immunoblots were analyzed using ImageJ (NIH). Data are expressed as the mean
± s.e.m. for the indicated number of experiments. 2-tailed Student t-tests were performed
between groups and multiple comparison analysis was performed using ANOVA. p<
0.05 was considered statistically significant.

SUPPLEMENTAL INFORMATION
Supplemental information includes four figures.

ACKNOWLEDGEMENTS
We are grateful to the NHLBI Confocal, Light Microscopy, Flow cytometry and
Electron Microscopy Core Facilities for their assistance. We thank Toren Finkel for the
GFP-LC3 plasmid and for the Atg5 knockout MEFs, Jennifer Lippencott-Schwartz for
the GFP-LAMP1 plasmid and Atsushi Miyawaki for the mKiema construct. The Sirt3+/mice were kindly supplied by Dr. Fred Alt and the p62 knockout MEF’s by Richard
Youle. This work was supported by the Division of Intramural Research of the NHLBI
(HL006047-01). B.R.W., I.S., K.H., J.H.L., Z.L. and M.V.S. performed the experiments
and helped edit the manuscript. B.R.W. and M.N.S. designed the experiments and wrote
the manuscript. The authors declare that they have no competing interests.

146	
  
	
  
	
  

REFERENCES
Bao, J., Lu, Z., Joseph, J.J., Carabenciov, D., Dimond, C.C., Pang, L., Samsel, L.,
McCoy, J.P., Jr., Leclerc, J., Nguyen, P., et al. (2010). Characterization of the murine
SIRT3 mitochondrial localization sequence and comparison of mitochondrial enrichment
and deacetylase activity of long and short SIRT3 isoforms. J.Cell Biochem. 110, 238247.

Dell'Angelica, E.C. (2004). The building BLOC(k)s of lysosomes and related organelles.
Curr Opin Cell Biol 16, 458-464.

Eisenberg, T., Knauer, H., Schauer, A., Buttner, S., Ruckenstuhl, C., Carmona-Gutierrez,
D., Ring, J., Schroeder, S., Magnes, C., Antonacci, L., et al. (2009). Induction of
autophagy by spermidine promotes longevity. Nat Cell Biol 11, 1305-1314.
Geisler, S., Holmstrom, K.M., Skujat, D., Fiesel, F.C., Rothfuss, O.C., Kahle, P.J., and
Springer, W. (2010). PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and
p62/SQSTM1. Nat.Cell Biol. 12, 119-131.

Glozak, M.A., and Seto, E. (2009). Acetylation/deacetylation modulates the stability of
DNA replication licensing factor Cdt1. J Biol Chem 284, 11446-11453.

Gomes, L.C., Di Benedetto, G., and Scorrano, L. (2011). During autophagy mitochondria
elongate, are spared from degradation and sustain cell viability. Nat Cell Biol 13, 589598.

147	
  
	
  
	
  

Hailey, D.W., Rambold, A.S., Satpute-Krishnan, P., Mitra, K., Sougrat, R., Kim, P.K.,
and Lippincott-Schwartz, J. (2010). Mitochondria supply membranes for autophagosome
biogenesis during starvation. Cell 141, 656-667.

Hamai, A., and Codogno, P. (2012). New targets for acetylation in autophagy. Sci Signal
5, pe29.
Hanna, R.A., Quinsay, M.N., Orogo, A.M., Giang, K., Rikka, S., and Gustafsson, A.
(2012). Microtubule-associated protein 1 light chain 3 (LC3) interacts with Bnip3 protein
to selectively remove endoplasmic reticulum and mitochondria via autophagy. J Biol
Chem 287, 19094-19104.

Hirschey, M.D., Shimazu, T., Goetzman, E., Jing, E., Schwer, B., Lombard, D.B.,
Grueter, C.A., Harris, C., Biddinger, S., Ilkayeva, O.R., et al. (2010). SIRT3 regulates
mitochondrial fatty-acid oxidation by reversible enzyme deacetylation. Nature 464, 121125.

Katayama, H., Kogure, T., Mizushima, N., Yoshimori, T., and Miyawaki, A. (2011). A
sensitive and quantitative technique for detecting autophagic events based on lysosomal
delivery. Chem Biol 18, 1042-1052.

Kendrick, A.A., Choudhury, M., Rahman, S.M., McCurdy, C.E., Friederich, M., Van
Hove, J.L., Watson, P.A., Birdsey, N., Bao, J., Gius, D., et al. (2011). Fatty liver is

148	
  
	
  
	
  

associated with reduced SIRT3 activity and mitochondrial protein hyperacetylation.
Biochem J 433, 505-514.

Kristensen, A.R., Schandorff, S., Hoyer-Hansen, M., Nielsen, M.O., Jaattela, M.,
Dengjel, J., and Andersen, J.S. (2008). Ordered organelle degradation during starvationinduced autophagy. Mol Cell Proteomics 7, 2419-2428.

Kurihara, Y., Kanki, T., Aoki, Y., Hirota, Y., Saigusa, T., Uchiumi, T., and Kang, D.
(2012). Mitophagy plays an essential role in reducing mitochondrial production of
reactive oxygen species and mutation of mitochondrial DNA by maintaining
mitochondrial quantity and quality in yeast. J Biol Chem 287, 3265-3272.

Lee, I.H., Cao, L., Mostoslavsky, R., Lombard, D.B., Liu, J., Bruns, N.E., Tsokos, M.,
Alt, F.W., and Finkel, T. (2008). A role for the NAD-dependent deacetylase Sirt1 in the
regulation of autophagy. Proc.Natl.Acad.Sci.U.S.A 105, 3374-3379.

Lee, I.H., and Finkel, T. (2009). Regulation of autophagy by the p300 acetyltransferase.
J.Biol.Chem. 284, 6322-6328.

Liu, L., Feng, D., Chen, G., Chen, M., Zheng, Q., Song, P., Ma, Q., Zhu, C., Wang, R.,
Qi, W., et al. (2012). Mitochondrial outer-membrane protein FUNDC1 mediates hypoxiainduced mitophagy in mammalian cells. Nat Cell Biol 14, 177-185.

149	
  
	
  
	
  

Lombard, D.B., Alt, F.W., Cheng, H.L., Bunkenborg, J., Streeper, R.S., Mostoslavsky,
R., Kim, J., Yancopoulos, G., Valenzuela, D., Murphy, A., et al. (2007). Mammalian Sir2
homolog SIRT3 regulates global mitochondrial lysine acetylation. Mol.Cell Biol. 27,
8807-8814.

Lu, Z., Bourdi, M., Li, J.H., Aponte, A.M., Chen, Y., Lombard, D.B., Gucek, M., Pohl,
L.R., and Sack, M.N. (2011). SIRT3-dependent deacetylation exacerbates acetaminophen
hepatotoxicity. EMBO Rep 12, 840-846.

Mai, S., Muster, B., Bereiter-Hahn, J., and Jendrach, M. (2012). Autophagy proteins
LC3B, ATG5 and ATG12 participate in quality control after mitochondrial damage and
influence lifespan. Autophagy 8, 47-62.

McLeod, C.J., Pagel, I., and Sack, M.N. (2005). The mitochondrial biogenesis regulatory
program in cardiac adaptation to ischemia--a putative target for therapeutic intervention.
Trends Cardiovasc.Med. 15, 118-123.

Morselli, E., Marino, G., Bennetzen, M.V., Eisenberg, T., Megalou, E., Schroeder, S.,
Cabrera, S., Benit, P., Rustin, P., Criollo, A., et al. (2011). Spermidine and resveratrol
induce autophagy by distinct pathways converging on the acetylproteome. J Cell Biol
192, 615-629.

150	
  
	
  
	
  

Narendra, D., Tanaka, A., Suen, D.F., and Youle, R.J. (2008). Parkin is recruited
selectively to impaired mitochondria and promotes their autophagy. J.Cell Biol. 183, 795803.

Narendra, D.P., Jin, S.M., Tanaka, A., Suen, D.F., Gautier, C.A., Shen, J., Cookson,
M.R., and Youle, R.J. (2010). PINK1 is selectively stabilized on impaired mitochondria
to activate Parkin. PLoS.Biol. 8, e1000298.

Orvedahl, A., Sumpter, R., Jr., Xiao, G., Ng, A., Zou, Z., Tang, Y., Narimatsu, M.,
Gilpin, C., Sun, Q., Roth, M., et al. (2011). Image-based genome-wide siRNA screen
identifies selective autophagy factors. Nature 480, 113-117.

Pagel-Langenickel, I., Bao, J., Joseph, J.J., Schwartz, D.R., Mantell, B.S., Xu, X.,
Raghavachari, N., and Sack, M.N. (2008). PGC-1alpha integrates insulin signaling,
mitochondrial regulation, and bioenergetic function in skeletal muscle. J.Biol.Chem. 283,
22464-22472.

Pagel-Langenickel, I., Schwartz, D.R., Arena, R.A., Minerbi, D.C., Johnson, D.T.,
Waclawiw, M.A., Cannon, R.O., III, Balaban, R.S., Tripodi, D.J., and Sack, M.N. (2007).
A discordance in rosiglitazone mediated insulin sensitization and skeletal muscle
mitochondrial content/activity in Type 2 diabetes mellitus. Am.J.Physiol Heart
Circ.Physiol 293, H2659-H2666.

151	
  
	
  
	
  

Philp, A., Chen, A., Lan, D., Meyer, G.A., Murphy, A.N., Knapp, A.E., Olfert, I.M.,
McCurdy, C.E., Marcotte, G.R., Hogan, M.C., et al. (2011). Sirtuin 1 (SIRT1)
deacetylase activity is not required for mitochondrial biogenesis or peroxisome
proliferator-activated receptor-gamma coactivator-1alpha (PGC-1alpha) deacetylation
following endurance exercise. J Biol Chem 286, 30561-30570.

Schweers, R.L., Zhang, J., Randall, M.S., Loyd, M.R., Li, W., Dorsey, F.C., Kundu, M.,
Opferman, J.T., Cleveland, J.L., Miller, J.L., et al. (2007). NIX is required for
programmed mitochondrial clearance during reticulocyte maturation. Proc Natl Acad Sci
U S A 104, 19500-19505.

Scott, I., Webster, B.R., Li, J.H., and Sack, M.N. (2012). Identification of a molecular
component of the mitochondrial acetyl transferase program; a novel role for GCN5L1.
Biochem J 443, 627-634.

Shi, T., Wang, F., Stieren, E., and Tong, Q. (2005). SIRT3, a mitochondrial sirtuin
deacetylase, regulates mitochondrial function and thermogenesis in brown adipocytes.
J.Biol.Chem. 280, 13560-13567.

Someya, S., Yu, W., Hallows, W.C., Xu, J., Vann, J.M., Leeuwenburgh, C., Tanokura,
M., Denu, J.M., and Prolla, T.A. (2010). Sirt3 mediates reduction of oxidative damage
and prevention of age-related hearing loss under caloric restriction. Cell 143, 802-812.

152	
  
	
  
	
  

Suen, D.F., Narendra, D.P., Tanaka, A., Manfredi, G., and Youle, R.J. (2010). Parkin
overexpression selects against a deleterious mtDNA mutation in heteroplasmic cybrid
cells. Proc Natl Acad Sci U S A 107, 11835-11840.

Sundaresan, N.R., Samant, S.A., Pillai, V.B., Rajamohan, S.B., and Gupta, M.P. (2008).
SIRT3 is a stress-responsive deacetylase in cardiomyocytes that protects cells from
stress-mediated cell death by deacetylation of Ku70. Mol.Cell Biol. 28, 6384-6401.

Tang, F., Wang, B., Li, N., Wu, Y., Jia, J., Suo, T., Chen, Q., Liu, Y.J., and Tang, J.
(2011). RNF185, a novel mitochondrial ubiquitin E3 ligase, regulates autophagy through
interaction with BNIP1. PLoS One 6, e24367.

Wagner, G.R., Pride, P.M., Babbey, C.M., and Payne, R.M. (2012). Friedreich's ataxia
reveals a mechanism for coordinate regulation of oxidative metabolism via feedback
inhibition of the SIRT3 deacetylase. Hum Mol Genet 21, 2688-2697.

Webster, B.R., Lu, Z., Sack, M.N., and Scott, I. (2012). The role of sirtuins in modulating
redox stressors. Free Radic Biol Med 52, 281-290.

Wu, J.J., Quijano, C., Chen, E., Liu, H., Cao, L., Fergusson, M.M., Rovira, II, Gutkind,
S., Daniels, M.P.,

153	
  
	
  
	
  

Komatsu, M., et al. (2009). Mitochondrial dysfunction and oxidative stress mediate the
physiological impairment induced by the disruption of autophagy. Aging (Albany NY) 1,
425-437.

Yi, C., Ma, M., Ran, L., Zheng, J., Tong, J., Zhu, J., Ma, C., Sun, Y., Zhang, S., Feng,
W., et al. (2012). Function and molecular mechanism of acetylation in autophagy
regulation. Science 336, 474-477.
Youle, R.J., and Narendra, D.P. (2011). Mechanisms of mitophagy. Nat Rev Mol Cell
Biol 12, 9-14.
Zhou, R., Yazdi, A.S., Menu, P., and Tschopp, J. (2011). A role for mitochondria in
NLRP3 inflammasome activation. Nature 469, 221-225.

154	
  
	
  
	
  

Chapter 4 Discussion
Over the past few years lysine acetylation as a post-translational modification
(PTM) has moved well beyond its initial site of discovery and function, namely nuclear
histones as a mechanism for regulation of gene expression. Progress identifying nonhistone acetylated proteins was slow, and prior to 2006, only 100 proteins were known to
be acetylated. However, improvements in mass spectrometry have since identified > 2000
acetylated proteins [1-3]. This high number of protein targets rivals phosphorylation, the
best characterized PTM, which suggests that acetylation may greatly affect cellular
function. What has been perplexing in the field is the lack of enzymes to carry out this
PTM with only 22 acetyltransferases and 18 deacetylases having been identified
compared to hundreds of protein kinases [4].
Interest in protein acetylation intensified with the discovery of the NADdependent deacetylases known as sirtuins. Sirtuins were initially described in yeast and
mediate the lifespan extending effects of caloric restriction (CR) [5]. CR activates sirtuins
by increasing the NAD/NADH ratio. Humans express seven sirtuin isoforms, which are
localized to various cellular compartments and mediate protein deacetylation (Sirt1, 2, 3
and 7), ADP-ribosylation (Sirt4 and 6) and desuccinylation/demalonylation (Sirt5). Sirt1
is the best characterized sirtuin, localizes to the nucleus and cytosol and regulates
numerous cellular functions. Sirt1 regulates lipid and glucose metabolism, mitochondrial
biogenesis, oxidative stress, autophagy and plays a role in numerous age-related
pathologies. Other sirtuin enzymes have also been shown to greatly regulate cellular
functions and some have been directly linked to longevity, namely Sirt3 and 6 [6-8].
Sirtuins may therefore link CR to longevity and offer to be a therapeutic target, using
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such drugs as resveratrol, for ‘healthy aging’ as the population ages.
Interestingly, protein acetylation appears to greatly regulate mitochondrial
function as ~20% of mitochondrial proteins are acetylated [1, 4]. Also of note, three of
the seven sirtuins localize to the mitochondria (Sirt3, 4 and 5) with Sirt3 being the major
mitochondrial deacetylase [9]. Sirt3 regulates nearly every aspect of mitochondrial
function including oxidative stress, metabolism of lipids, glucose and proteins, apoptosis,
oxidative phosphorylation, ketogenesis and may serve as a tumor suppressor [10].
Mitochondrial protein acetylation is also dependent on nutrient status as a high fat diet
yields hyperacetylated mitochondria due to increased acetyl-CoA levels [11, 12]. Other
diseases have been shown to have increased mitochondrial acetylation levels as well [13].
Conversely, increasing the NAD/NADH ratio, through starvation or increases in NAD
synthesis, promotes mitochondrial protein deacetylation [14]. Therefore, given the central
importance of mitochondria to cellular metabolism, apoptosis, oxidative stress, and aging
interest in acetylation within the mitochondria has exploded in recent years.
The importance of protein acetylation within mitochondria can be attested to by
the large number of proteins undergoing this PTM and the presence of a mitochondrial
localized deacetylase, Sirt3. It should also be noted that in the nucleus and cytosol Sirt1
activity is opposed by the acetyltransferases p300, TIP60 and GCN5 [15]. It had been
hypothesized that mitochondria contain an acetyltransferase enzyme that utilizes acetylCoA as a substrate to counter Sirt3, but no such enzyme had been described [16]. Within
this context, we began investigating regulation of mitochondrial protein acetylation. The
studies presented in this manuscript are the first characterization of such an
acetyltransferase complex operating within mitochondria.
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Criteria for identifying a potential mitochondrial acetyltransferase include
proteins that 1) localize to the mitochondria; 2) have a potential acetyltransferase domain;
and 3) counter known effects mediated by Sirt3 as Sirt3 knockdown has been shown to
attenuate respiration [17]. As discussed in chapter 2, initial studies show that GCN5L1
and NAT9 fit the first two criteria, but only GCN5L1 knockdown augments
mitochondrial respiration as would be expected by unopposed Sirt3 activity.
Mitochondrial enrichment of GCN5L1 is further verified by confocal microscopy and
immuno-EM. Interestingly, osmotic pressure analysis shows that GCN5L1 localizes to
both the intermembrane space and the matrix, while Sirt3 is thought to localize only to
the matrix [18]. Acetyl-CoA is generated in the matrix in part by pyruvate dehydrogenase
so whether GCN5L1 mediates acetylation in the intermembrane space is not yet known.
Also given the bacterial origins of mitochondria, it is interesting to note that GCN5L1's
acetyl-CoA and substrate-binding sites have 53% homology with a prokaryotic
acetyltransferase suggesting an evolutionary link.
To functionally show that GCN5L1 regulates mitochondrial acetylation status, we
utilized multiple approaches namely knockdown or overexpression of GCN5L1 and show
attenuated (in-vivo and in-vitro) and augmented (in-vitro) protein acetylation,
respectively, and that GCN5L1 uses acetyl-CoA as a substrate. Known acetyltransferases
function within protein complexes consisting of multiple subunits [19-22]. It appears that
GCN5L1 also functions in combination with other subunits as GCN5L1 fails to increase
histone acetylation in-vitro when histone H3 and GCN5L1 are incubated together.
However, reconstitution of GCN5L1 with mitochondrial extracts depleted of endogenous
GCN5L1 promotes histone H3 acetylation suggesting the presence of mitochondrial
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factors that work in conjunction with GCN5L1. GCN5L1 working as an acetyltransferase
complex makes logical sense as it is only ~15 kDa in molecular weight. Future work will
need to identify the other mitochondrial proteins that work with GCN5L1. Returning to
the prokaryotic nature of GCN5L1, it is interesting that a unique XAT hexapeptide-repeat
region appears to be evolutionarily conserved amongst prokaryotic and eukaryotic
acetyltransferases and may play a role in acetyl-CoA or substrate binding. Also of note
and as mentioned in appendix 1, deletion of this XAT region blocks in-vitro
mitochondrial protein acetylation and stops GCN5L1 mediated effects on oxygen
consumption. The presence of such a domain may be a unique marker for
acetyltransferases and links GCN5L1 to known acetyltransferases such as p300 and
GCN5.
Further characterization of GCN5L1 activity was determined by exploring the
hypothesis that it opposes Sirt3 activity. As such, Sirt3 has been shown to positively
regulate ATP levels and mitochondrial respiration [17]. Therefore using the Sirt3
phenotype as a model, transient GCN5L1 depletion increases ATP levels and oxygen
consumption on par with unopposed Sirt3 activity. As chapter 2 shows, GCN5L1
mediates acetylation of complex I protein NDUFA9 and complex Vα, which are two
known Sirt3 targets [17]. Also as predicted, Sirt3 knockdown attenuates ATP levels,
oxygen consumption and increases protein acetylation, but the concurrent knockdown of
Sirt3 and GCN5L1 blocks these effects. Therefore GCN5L1 and Sirt3 appear to counter
each other’s effects similar to that of Sirt1 and other known acetyltransferases [15].
Given the clear ‘yin-yang’ effects of Sirt3 and GCN5L1 on each other, it will be
interesting to see if other known Sirt3 targets are counter regulated by GCN5L1. As
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mentioned in chapter 1, Sirt3 regulates ketone body production and β-oxidation through
deacetylation of HMG-CoA-2 and LCAD [23-25]. Therefore, it would be interesting to
see if GCN5L1 regulates lipid metabolism and ketogenesis in a manner opposite to Sirt3.
ROS generation is also attenuated by Sirt3 through deacetylation of both IDH and
MnSOD, and this attenuated ROS slows age-related hearing loss [26-28]. Interestingly, as
shown in chapter 3, siRNA knockdown of GCN5L1 attenuates mitochondrial ROS levels
at baseline and following stress with rotenone. This data was shown in the context that
increased mitophagy (see below) may improve mitochondrial health, but this may be in
combination with increased activation of MnSOD and IDH, which future work will have
to determine if these are targets of GCN5L1 as well. Following this same trend, chapter 3
also shows diminished MPTP opening with GCN5L1 depletion upon exposure to
ionomycin. Again this finding may be due to improved mitochondrial health due to
mitophagy or it may be due to decreased acetylation of cyclophilin D, which is a target of
Sirt3. Therefore, along with finding the functional acetyltransferase components that bind
to and work with GCN5L1, future work will have to determine the acetylation targets of
GCN5L1 to see if they correlate with known Sirt3 targets such as MnSOD, cyclophilin D,
HMG-CoA-2 and LCAD. It will be interesting to see if altering GCN5L1 activity can
counter mitochondrial hyperacetylation seen in numerous pathologies such as Freidrich’s
ataxia [13].
CR restriction elicits numerous cellular responses including changes in
metabolism, oxidative stress handling, mitochondrial function and housekeeping
programs. Key amongst these housekeeping programs induced by CR is the process
known as autophagy [29]. Autophagy allows for cellular recycling of damaged proteins
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and organelles and allows the cell to endure periods of nutrient limitations. Therefore,
autophagy is thought to be essential for CR mediated increases in lifespan [30]. The
nutrient sensing enzymes AMPK and Sirt1 have been shown to increase autophagy
through phosphorylation of ULK1/ATG1 and deacetylation of the canonical autophagy
mediators ATG5, 7 and 8, respectively. This is in concert with diminished activity of the
amino acid sensing enzyme mTOR. Direct induction of autophagy with the mTOR
inhibitor rapamycin increases lifespan in aged mice [31]. In addition, acetylation is a
major PTM of the autophagy proteome as seen by treatment with the acetyltransferase
inhibitor spermidine and sirtuin activator resveratrol with both drugs inducing autophagy
and extending lifespan in yeast, flies and worms [32, 33]. Both drugs altered the
acetylation status of 375 proteins and 170 (with 27 being mitochondrial) of those being
implicated in the autophagy proteome [32-34]. Therefore, it appears that CR, sirtuins,
acetylation and autophagy are linked. Given that cytosolic acetylation status can trigger
global autophagy and 27 mitochondrial proteins are both differentially acetylated and a
part of the autophagy proteome, we hypothesized that mitochondrial protein acetylation
status may alter mitochondrial autophagy or ‘mitophagy.’
Isolated liver mitochondria from fasted mice show attenuated GCN5L1 levels
with increased LC3-II levels suggesting increased mitophagy. Interestingly, in Sirt3 KO
animals LC3-II levels are not elevated with fasting. To mimic this effect in cell culture,
knockdown of GCN5L1 greatly triggers mitophagy with augmented p62, LC3-II and
ubiquitinylation being seen in isolated mitochondria and co-localized to mitochondria.
The dual knockdown of GCN5L1 and Sirt3 blocked this mitophagy induction. Electron
microscopy shows augmented autophagosome formation with GCN5L1 depletion while
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confocal microscopy suggests increased delivery of mitochondria to lysosomes. Overall,
this suggests that mitochondrial deacetylation triggers mitophagy and may be dependent
on nutritional status. In fact, two other studies have shown in unbiased screens that
GCN5L1 plays a role in autophagy and Parkin mediated mitophagy [35, 36].
Furthermore, it will be interesting to see if other tissues besides the liver show similar
mitophagy induction and decreased expression of GCN5L1 following fasting.
Preliminary evidence suggests that the brain does not have attenuated GCN5L1
expression in-vivo following 48 hours of fasting compared to the liver (Figure 1). It will
be interesting to see if tissues such as the heart or skeletal muscle show GCN5L1
depletion following fasting.
It is important to note that this mitochondrial phenotype differs between acute
versus chronic GCN5L1 depletion. siRNA mediated knockdown of GCN5L1 triggers
mitophagy, increases mitochondrial respiration (as described in chapter 2) and fails to
attenuate mitochondrial mass while chronic depletion of GC5L1 with lentiviral shRNA
triggers mitophagy leading to diminished mitochondrial respiration and mitochondrial
mass. We hypothesize that acute knockdown of GCN5L1 preferentially eliminates
damaged mitochondria and mimics a short term fasting condition possibly through Sirt3
deacetylation of electron transport chain proteins. As mentioned, ROS generation is also
attenuated with siRNA knockdown of GCN5L1, which could be a combination of Sirt3
deacetylation of MnSOD and IDH and increased mitophagy of damaged mitochondria. It
should also be noted that mitochondria are one of the last organelles to be eliminated
during fasting induced autophagy as mitochondria become hyper-fused during fasting and
fission is necessary for mitophagy [37-39]. Chronic GCN5L1 mimics long term fasting
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Figure 1: Fasting attenuates GCN5L1 protein levels in liver but not the brain. Isolated
liver and brain mitochondria from 48 hour fasted mice show selective attenuation of
GCN5L1 in liver samples while brain mitochondria retain GCN5L1 expression.
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with mitochondrial mass, protein content and respiration being attenuated. It will be
intriguing to evaluate whether mitochondrial fusion and fission correlate with the length
of GCN5L1 knockdown with longer periods of GCN5L1 depletion triggering
mitochondrial fission as a component of the mitophagy program.
Extensive work described in chapter 3 shows that GCN5L1 depletion leads to
selective mitophagy without global autophagy induction or disruption in autophagic flux.
Our data also show that mitochondrial protein degradation is mediated by the autophagy
pathway but not the proteosome. We also show that p62 and ATG5 are essential
components of this mitophagy program. However, the ubiquitin E3-ligase Parkin is nonessential. As mentioned, Parkin mediated mitophagy is the most extensively investigated
form of mitophagy. However, other E3 ligases such as Mulan, March5 and RNF185
regulate mitochondrial morphology and mitophagy [40-42]. Therefore, further work will
need to determine if a cytosolic or mitochondrial localized E3 ligase is involved in
GCN5L1-mediated mitophagy. Further work is also needed to determine how global
mitochondrial protein deacetylation signals for mitochondrial protein ubiquitinylation
with subsequent mitophagy. However, given the overall robustness of this form of
mitophagy with cells perpetually undergoing mitochondrial degradation (as opposed to
the artificial system of CCCP/Parkin mediated mitophagy), this system should prove to
be a useful tool in determining other proteins needed for mitophagy such as other
autophagy proteins like Beclin, HDAC6 and ULK1.
It is believed that aging leads to diminished autophagy and mitophagy leading to
the accumulation of dysfunctional mitochondria in part due to accumulation of lipofuscin
in lysosomes [43]. CR is able to induce mitochondrial biogenesis while also lowering
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mitochondrial membrane potential, respiration and ROS production, which is identical to
chronic GCN5L1 knockdown [44]. Therefore, CR induces both autophagy and
mitochondrial biogenesis and overall mitochondrial turnover in part through Sirt1
activation and deacetylation of both autophagy proteins (ATG5, 7 and 8) and the master
regulator of mitochondrial biogenesis, PGC-1α [45, 46]. However, it has not been shown
that mitophagy induction augments mitochondrial biogenesis leading to mitochondrial
turnover. Parkin-mediated mitophagy, following CCCP treatment, is hypothesized to
cause turnover since Parkin ubiquitinylates and increases degradation of the PGC-1α
inhibitor protein, Paris [47]. Yet, no study to date has shown that both arms of
mitochondrial turnover are simultaneously triggered by Parkin activity. The work
presented in this manuscript suggests that GCN5L1 knockdown induces both
mitochondrial mitophagy and biogenesis and thus turnover. GCN5L1 knockdown
increases mitophagy and also concurrently elevates PGC-1α and NRF-1 with increased
mtDNA copy numbers in HepG2 and MEFs. Recent work in the lab confirms
mitochondrial turnover in HepG2 cells depleted of GCN5L1 (Figure 2). The functional
consequences of such increased turnover are only hypothetical, but overall mitochondrial
health may be improved as seen with diminished MPTP opening upon ionomycin
treatment in these cells. It will be interesting to see if the increased mitochondrial
turnover shown in this model has applications to pathologies with known mitochondrial
defects such as diabetes, obesity and neurodegenerative disorders (Alzheimer’s, ALS and
Parkinson’s).
Highlighting GCN5L1’s importance, attempts by our lab and others have
confirmed that GCN5L1 knockout is embryonic lethal. However, we have been
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Figure 2: Stable isotope labeling by amino acids (SILAC) in HepG2 cells show that
GCN5L1 shRNA treatment leads to increased turnover of mitochondrial proteins
compared to control shRNA treated cells. Turnover is greater in GCN5L1 knockdown
cells in all mitochondrial compartments suggesting whole mitochondrial mitophagy with
subsequent mitochondrial biogenesis.
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able to generate GCN5L1 KO MEFs. Work with these cells has confirmed and
strengthened our previous findings ruling out any off targets that GCN5L1 siRNA or
shRNA might be silencing. As expected, compared to wildtype cells, isolated
mitochondria from GCN5L1 KO MEFs show increased levels of mitophagy markers
(p62, ubiquitin and LC3-II) (Figure 3A) and selectively attenuates mitochondrial but not
cytosolic acetylation levels (Figure 3B). Importantly, reconstitution of GCN5L1 into
these KO MEFs using a plasmid encoding Flag-tagged GCN5L1 attenuates the
accumulation of mitophagy markers on mitochondria while increasing mitochondrial
protein acetylation (Figure 3C-D). Furthermore, electron microscopy of these cells shows
increased levels of mitochondria in and being engulfed by autophagosomes (Figure 4).
As mentioned, nutritional status affects mitochondrial fission and fusion with
short term fasting causing mitochondrial fusion, which is thought to prevent mitophagy.
Longer fasting induces mitophagy, and it is proposed that mitochondrial fission is
essential for this process [36-38]. Therefore, we would hypothesize with either chronic
GCN5L1 depletion or in the GCN5L1 KO MEFs that mitochondrial fission would be
elevated promoting mitophagy. We further hypothesize that the mitochondrial fission
program is essential for GCN5L1 regulated mitophagy. Preliminary evidence in GCN5L1
knockout cells show increased fragmented mitochondria using electron (Figure 4) and
confocal microscopy (Figure 5). Future studies will have to determine the status of the
fission/fusion program in these cells as well as if GCN5L1 expression correlates with the
induction of either program.
Recently, the transcription factor Transcription Factor EB (TFEB) has been
shown to be the master regulator of autophagy with overexpression of TFEB resulting in
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Figure 3: GCN5L1 knockout MEFs show increased mitophagy, which is rescued by
reconstitution. (A) Isolated mitochondria from GCN5L1 KO MEFs show elevated p62,
LC3-II and protein ubiquitinylation. (B) Protein acetylation is selectively attenuated in
mitochondria from GC5NL1 KO MEFs with no change found in the cytosolic fraction.
(C and D) Reconstitution of Flag-GCN5L1 attenuates mitophagy induction and
hypoacetylation in GCN5L1 knockout cells.
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Figure 4: GCN5L1 knockout MEF electron microscopy (EM). EM from GCN5L1
knockout MEFs show augmented mitochondrial accumulation in double-membrane
autophagosome and autophagic features compared to wildtype cells. Also mitochondria
appear more fragmented with GCN5L1 knockdown.
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Figure 5: GCN5L1 knockout MEFs may have increased mitochondrial fission. dsREDmito labeled mitochondria from GCN5L1 knockout MEFs appear more fragmented than
wildtype cell mitochondria.
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the induction of numerous autophagy genes and lysosomal biogenesis. Furthermore,
starvation results in the translocation of TFEB from the cytosol to the nucleus with
subsequent autophagy induction, which is dependent on the inhibition of TFEB
phosphorylation by mTOR and ERK2, thus linking TFEB activity with nutrient status
[48, 49]. Interestingly, PGC-1α overexpression in a mouse model of Huntington’s
disease alleviates mutant htt protein aggregation, a hallmark of the disease. It was also
shown that PGC-1α acts upstream of TFEB, and TFEB overexpression alone diminished
htt protein aggregation [50]. Also of note is that TFEB has been shown to directly target
GCN5L1 expression [51]. As mentioned, GCN5L1 shRNA increases PGC-1α transcript
levels by ~2-fold. In GCN5L1 KO MEFs, PGC-1α transcript levels are elevated ~12-fold
compared to wildtype cells, and reconstitution of GCN5L1 into the KO MEFs attenuates
the PGC-1α transcript levels (Figure 6a). Also in GCN5L1 KO MEFs the expression of
TFEB is elevated compared to wildtype cells (Figure 6b). Furthermore, in GCN5L1 KO
MEFs GFP-TFEB shows greater nuclear localization compared to WT cells (Figure 6c
and 6d). Therefore, we hypothesize that GCN5L1 and nutritional status play a role in this
“PGC-1α/TFEB axis” (Figure 6e). With nutrient withdrawal, GCN5L1 expression is
attenuated (in the liver) along with mTOR and ERK2 activity. This leads to the activation
of PGC-1α and promotes TFEB nuclear translocation. PGC-1α then induces both
mitochondrial biogenesis along with TFEB expression therefore increasing GCN5L1 and
autophagy gene induction along with mitophagy, effectively creating a positive feedback
loop. Our preliminary results suggest that PGC-1α and TFEB activity are elevated with
GCN5L1 depletion. Future work will have to establish the importance of these
transcription factors in GCN5L1 mediated acetylation and mitophagy. It will also be
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Figure 6: GCN5L1 knockdown triggers the PGC-1α/TFEB axis. (A) GCN5L1 KO
MEFs show greatly elevated PGC-1α transcript levels, which can be reversed with
reconstitution of GCN5L1. (B) Concurrently, whole cell lysates show that TFEB
expression appears elevated with GCN5L1 knockdown. C) GFP-TFEB overexpression in
GCN5L1 KO MEFs shows greater nuclear translocation compared to WT cells (scale bar
= 10 µm). D) Quantification of GFP-TFEB nuclear translocation. E) Hypothesized PGC1α/TFEB axis to promote mitochondrial biogenesis and mitophagy.
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interesting to see if this pathway plays a role in pathologies such as Huntington’s disease.
Another potential area where GCN5L1 mediated mitochondrial turnover may play
a protective role is activation of the inflammasome. The inflammasome is a component of
the innate immune response that consists of a multi-protein complex which when formed
activates caspase-1 and subsequently inflammatory cytokines such as IL-1β and IL-18
[52]. Various pathogens such as bacteria and viruses can induce the inflammasome and
thus induce the innate immune system for pathogen clearance. However, excessive
inflammasome activation is thought to be a key component of numerous autoimmune
diseases [53]. Also of note, defective autophagy is thought to promote aberrant
inflammasome activation as ATG16L mutants have increased IL-1β and IL-18
production leading to symptoms that mimic Crohn’s disease, an autoimmune disorder of
the small intestine [54]. Defective autophagy is thought to induce augmented
inflammasome activation in part through an inability to clear out defective mitochondria
leading to increased ROS generation and release of mitochondrial DNA into the cytosol.
Mitochondrial DNA, which has prokaryotic features, and ROS are key activators of the
inflammasome [55, 56]. Therefore mitophagy may play a key role in inflammasome
activity. We have therefore hypothesized that mitochondrial deacetylation mediated
mitophagy would generate ‘healthier’ mitochondria leading to attenuated inflammasome
activation. Preliminary results in the lab show that in HepG2 cells with GCN5L1
knockdown, mitochondrial DNA release is diminished following treatment with the
stressors CCCP or palmitic acid. Work in J774A.1 cells, a mouse derived macrophage
cell line, shows that GCN5L1 depletion leads to lower IL-1β release. Furthermore, Sirt3
KO bone marrow or peritoneal macrophages have increased mitochondrial ROS, IL-1β
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and IL-6 levels. Therefore, mitochondrial acetylation status and mitophagy induction may
play a key role in various autoimmune disorders.
Finally, as mentioned in chapter 1, both mitophagy and xenophagy, the autophagy
mediated clearance of intracellular pathogens, utilize very similar mechanisms with outer
membrane protein ubiquitinylation and p62 binding occurring in both processes [57].
Highlighting this overlap, p62 overexpression decreases growth of the intracellular
pathogen Burkholderia cenocepacia in macrophages while p62 depletion increases its
proliferation with lower co-localization of Burkholderia cenocepacia and LC3-II [58].
Therefore, given that GCN5L1 depletion induces mitophagy and p62 activity, it will be
interesting to investigate if mitophagy induction also induces clearance of intracellular
pathogens concurrently.
Overall, this work has identified the first component of an acetyltransferase
program localized to the mitochondria that counters the well-established deacetylase
program mediated by Sirt3. GCN5L1 reverses Sirt3 mediated effects on mitochondrial
respiration and ATP production in part through antagonizing Sirt3 deacetylation of
components of the electron transport chain. Future work will identify the other
components of the GCN5L1 acetyltransferase complex and the ‘acetylome’ it targets. It
will be interesting to compare these targets with the known targets of Sirt3 to see if
GCN5L1 counters Sirt3 activity on mitochondrial function including ROS generation, βoxidation, ketone body production and the urea cycle. Furthermore, work presented in
this manuscript shows that mitochondrial acetylation status regulates mitophagy and
suggests that GCN5L1 functions as a ‘mitophagy suppressor.’ Work to date in the field of
mitophagy has only identified proteins essential for various forms of mitophagy when
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overexpressed such as Parkin, Nix, FUNDC1 and RNF185. GCN5L1 regulated
mitophagy is unique in that its expression prevents mitophagy induction. Therefore, by
acting as a ‘mitophagy suppressor,’ its depletion yields a condition where mitophagy is
perpetually elevated offering a system that can readily be used to further the
understanding of the mechanisms and consequences of mitophagy. Further work is
needed to identify how this form of mitophagy is occurring, which includes identifying
the E3-ligase that is ubiquitinylating mitochondrial proteins, how mitochondrial protein
deacetylation signals for mitophagy induction and what autophagy proteins are essential
for this process such as HDAC, Beclin and mitochondrial fission proteins. GCN5L1
mediated mitophagy also appears to induce mitochondrial biogenesis thus promoting
overall mitochondrial turnover. This is seen with both PGC-1α and TFEB induction
following GCN5L1 depletion, which induce mitochondrial biogenesis and autophagy,
respectively. The idea of mitochondrial turnover occurring has for the most part been
theoretical thus making our results even more significant. This is the first work, to our
knowledge, to show both arms of mitochondrial turnover (mitophagy and biogenesis)
functioning simultaneously. Therefore, it will be interesting to alter PGC-1α and/or
TFEB expression to see the effects on mitochondrial mass and function. Future work will
further investigate the importance of this PGC-1α/TFEB axis. This augmented
mitochondrial turnover appears to improve mitochondrial ‘health’ as seen by attenuated
ROS generation and MPTP opening. Therefore the functional consequences of this
improved mitochondrial health need to be explored in cell culture and in various
pathologies. Preliminary work suggests an attenuation of inflammasome activation,
which may be beneficial for autoimmune disorders, and GCN5L1 mitophagy may also
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affect xenophagy and therefore infections such as tuberculosis. Attempts to generate a
GCN5L1 knockout animal have proven elusive thus far but attempts are ongoing. If such
an animal is viable, then it would be hypothesized that overall mitochondrial health in
these animals would be improved and may be beneficial in the study of mouse models
with numerous pathologies where mitochondrial defects are known such as obesity,
diabetes, neurodegenerative disorders (Alzheimer’s, Parkinson’s, Freidrich’s Ataxia etc.),
heart disease and aging (Figure 7).
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Figure 7: Established mitochondrial functions of GCN5L1 and future research
directions. GCN5L1 counters Sirt3 mediated effects on oxidative phosphorylation,
respiration and ATP production by acetylating Sirt3 targets. GCN5L1 also functions as a
‘mitophagy suppressor’ promoting mitochondrial turnover and homeostasis. Future work
will identify GCN5L1 binding partners that together function as a mitochondrial
localized acetyltransferase complex with its own ‘acetylome,’ which can then be
compared to known Sirt3 targets. In addition, the mechanisms for mitophagy need to be
investigated such as finding the E3-ligase mediating mitophagy, roles for TFEB and
PGC-1α and defining which autophagy factors are essential for this process. Finally,
potential implications of GCN5L1 acetylation, mitophagy and turnover will explore
changes in oxidative stress, metabolism, fission/fusion and overall mitochondrial
homeostasis. A mouse model for GCN5L1 knockdown will allow for GCN5L1 function
to be explored in the context of various pathologies.
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Background: GCN5L1 has been identified as a critical component of the mitochondrial
acetyltransferase complex.
Results: The hexapeptide XAT-repeat region of GCN5L1 is highly conserved between
acetyltransferase enzymes and is necessary for the acetyltransferase function of GCN5L1.
Conclusion: The XAT-repeat region may be a common feature of mammalian
acetyltransferase enzymes.
Significance: Our understanding of biological role of this hexapeptide-repeat region
may identify a target sequence for the pharmacologic modulation of non-histone
acetyltransferases.
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SUMMARY
Acetyltransferase enzymes are commonly found in multi-protein complexes,
composed of catalytic and non-catalytic subunits, which function in regulatory,
adaptor and substrate binding roles. Recently, the first protein component of the
mitochondrial acetyltransferase machinery, GCN5L1, was identified, and its initial
characterization demonstrated that it countered the regulatory effects of the
mitochondrial deacetylase SIRT3. Investigation of GCN5L1 functional regions, and
its

‘exploitation’

to

identify

binding

partners,

should

enable

further

characterization of the mitochondrial acetyltransferase machinery. In this study we
investigate GCN5L1 and demonstrate that while two isoforms of this protein are
expressed, only the shorter isoform is enriched within mitochondria. We identify
several prokaryote conserved (xenobiotic acetyltransferase - XAT) hexapeptide
repeat motifs in GCN5L1, and demonstrate that motif is conserved across many
mammalian acetyltransferase proteins. Finally, we show that the genetic disruption
of this XAT region disrupts both the acetylation and mitochondrial respiratory
effects of GCN5L1, suggesting a novel functional role for this region in mammals.
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Lysine acetyltransferases catalyze acetylation of ε-amino groups on specific
protein lysine residues. Protein acetylation is emerging as a widespread and highly
regulated posttranslational modification (PTM) evident from bacteria to mammalia (1-3).
The functional effects of protein acetylation include the regulation of gene expression,
enzyme activity and protein stability. Within this field, histone acetyltransferase and
deacetylase enzymes, which regulate gene expression through changes in histone
acetylation status, have been widely characterized (4).
The study of sirtuins, a family of predominantly non-histone lysine deacetylases, has
expanded our understanding of the role played by protein acetylation status. In particular,
it is now recognized that lysine acetylation regulates functioning in numerous, nonnuclear cellular compartments (5). As the activation of sirtuins is nutrient- and redoxstate dependent, the role of this regulatory program in controlling mitochondrial function
has come to the fore (6). In mitochondria, the predominant sirtuin deacetylase is SIRT3,
and its role in controlling mitochondrial metabolism (7, 8), respiration (9, 10) and
responses to mitochondrial stressors (11-13) is well established. However, in contrast to
lysine acetyltransferases in the nucleus, characterization of the mitochondrial
acetyltransferase program has been elusive.
Lysine acetyltransferase enzymes commonly exist within multi-protein complexes,
where subunit integration is required for appropriate structure, function, and regulation
(14, 15). Therefore, to uncover the mitochondrial acetyltransferase machinery, a
prerequisite was to identify and characterize an ‘initial’ component of this putative
multiprotein complex. The mystery as to whether a mitochondrial acetyltransferase
program is operational has begun to be uncovered following the functional
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characterization of GCN5L1 (16). This mammalian gene was initially cloned 15 years
ago, and was found to have ~ 24% homology with the nuclear acetyltransferase GCN5
(17), in addition to being highly conserved between humans, flies and nematodes (18).
However, although it was present in a comprehensive mitochondrial proteome database
(19), the function of this protein in mitochondria has only recently begun to be
investigated. The initial genetic knockdown studies showed that GCN5L1 is an essential
component of the mitochondrial acetyltransferase machinery, and that its depletion
counters the acetylation and respiratory phenotype cause by the loss of SIRT3 (16).
Consistent with the multi-subunit characteristics of other acetyltransferase enzymes, the
in vitro acetyltransferase capacity of recombinant GCN5L1 was found to require
additional, but as-yet unidentified, mitochondrial components.
In this study we further explore the characteristics of GCN5L1 and find that: (i) it is
expressed in multiple tissues; (ii) while two isoforms of the proteins are expressed, only
one is found in mitochondria; and (iii) that the prokaryote-conserved xenobiotic
acetyltransferase

(XAT)

region

is

conserved

across

numerous

mammalian

acetyltransferase enzymes, and that this region is necessary for the acetylation and
respiratory effects of GCN5L1.

EXPERIMENTAL PROCEDURES

Cells, Plasmids and Transfection Reagents
Human liver HepG2 cells were maintained in DMEM/10%FBS/1xPen-Strep at 37oC/5%
CO2. Cells were transfected using Fugene (Roche) for 48 h, then used according to
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experimental need. The deletion constructs used in this study were created from
GCN5L1-FLAG (16) using standard PCR cloning techniques, and inserted into the same
p3XFLAG-CMV-14 vector (Sigma). Plasmids were sequenced prior to use to ensure
fidelity.

Cellular Fractionation and Western Blotting
Whole mouse liver tissue or HepG2 cells were lysed on ice in detergent-free sucrose
buffer using a Dounce homogenizer or 25-gauge needle, respectively. Following
disruption, cells were centrifuged at 4 oC according to the noted scheme (Fig. 2C) to
recover the mitochondrial and cytosolic fractions. For western blotting, proteins were
denatured by boiling in SDS sample buffer, and then separated by SDS PAGE. Proteins
were transferred to nitrocellulose membranes, followed by incubation with the following
antibodies: GCN5L1 (16); FLAG (Sigma); GAPDH, VDAC (Cell Signaling
Technology); polyclonal acetyl-lysine (Ac-K), ATP5a (Abcam). Each western blot
shown is representative of at least three independent experiments.

In Vitro Acetylation Assay
The in vitro acetylation assay was carried out according to Scott et al, (16). Briefly,
HepG2 cells were transfected with noted plasmids for 48 h, at which time mitochondria
were isolated. Samples were resuspended in reaction buffer (50 mM Tris-HCl pH 8.0, 50
mM NaCl, 4 mM MgCl2, 5 mM nicotinamide, pH 7.4), sonicated then incubated for 1.5 h
at 37 oC, in the absence or presence of 2.5 mM acetyl-CoA. Mitochondrial proteins were
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then used for global acetylation analysis (reaction stopped by boiling with SDS sample
buffer), followed by SDS-PAGE and immunoblot analysis with an Ac-K antibody.

Metabolic Measurements
Oxygen consumption measurements were performed on the XF24 analyzer (Seahorse
Bioscience). Cells transfected with the noted plasmids for 48 h were transferred to 24well plates overnight and incubated in sucrose respiration media for 1 h prior to analysis.
Data are representative of three independent experiments of n = 5 replicates per
condition.

Bioinformatics and Sequence Analysis
The XAT-repeat regions of GCN5L1 were identified by interrogation of the deduced
GCN5L1 protein sequence, looking for a hexapeptide repeat motif matching x-[STAV]x-[LIV]-[GAED]-x (NCBI cd00208). Human lysine acetyltransferases from the GCN5,
p300 and MYST families containing three or more tandem XAT repeats were found by
performing a MOTIF search (http://www.genome.jp/tools/motif/MOTIF2.html) against
the KEGG database for proteins bearing the following pattern: x-[STAV]-x-[LIV][GAED]-x(0,100)-x-[STAV]-x-[LIV]-[GAED]-x(0,100)-x-[STAV]-x-[LIV]-[GAED]-x.
The XAT regions from these proteins were analyzed using PhyML (www.phylogeny.fr)
and separated into phylogenetic clades using the automated function. In any protein
displaying multiple, discrete XAT regions, the one containing a conserved
acetyltransferase domain was used. Alignment of GCN5L1 with BtXAT from
Burkholderia thailandensis (ZP_02389502), or with GCN5L1 homologues (current
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NCBI accessions) from Mus musculus, Bos taurus, Xenopus laevis, Danio rerio,
Drosophila melanogaster and Arabidopsis thaliana were carried out using T-Coffee. The
secondary structure of the human HAT1 acetyltransferase domain was modeled using
PSIPRED from data contained in Dutnall et al (20).

Animal Husbandry
The use of mice in this study was approved by the NHLBI Animal Care and Use
Committee, and animals were treated according to their guidelines.

Statistical analysis
Where required, data were tested for normality using the Kolmogorov-Smirnov test,
followed by a one-tailed Student’s t-test using the Microsoft Excel statistics package. A P
value of < 0.05 was regarded as significant

RESULTS

The short form of GCN5L1 is enriched in mitochondria.
GCN5L1, also variously known as RT14, BLOS1 and BLOC1S1, was first cloned
as a cDNA from human fetal brain (18, 21). At the time of its initial description, two
distinct gene products were identified by Northern Blot analysis, however the authors
concluded that the shorter form was the correct transcript from this gene (18).
Interrogation of GenBank shows that the longer form has now been cloned in Homo
sapiens (accession number NM_001487), while the shorter form has been identified in
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both H. sapiens and Mus musculus (accession numbers BC130640 and BC034662,
respectively). The human sequence, identifying the two in-frame start codons, is shown
in Figure 1A. Using an antibody directed to a shared region of both isoforms, we
determined the relative protein expression of these transcripts, in concert with
ascertaining their tissue distribution. GCN5L1 appeared to be ubiquitously expressed as a
≈ 15 kDa protein in mouse, while a larger (≈ 18 kDa) form is evident at much lower
levels in a few tissues, such as liver and kidney (Fig. 1B). The molecular weights of these
peptides corresponds closely to those calculated from the deduced amino acid sequences
of both the short (125 aa; 14.3 kDa) and long (153 aa; 17.3 kDa) forms of GCN5L1
found in humans. To determine whether both isoforms are present in mitochondria, we
fractionated liver tissue into subcellular compartments using differential centrifugation.
While both isoforms were found in the whole-cell preparation, the longer isoform is not
evident in the mitochondrial-enriched fractions (Fig. 1C). This suggests that the shorter
isoform is the mitochondrially-active version, and we therefore investigated this further.
To determine whether the 15kDa mitochondrial enriched protein has a classical
mitochondrial localization sequence, FLAG-tagged deletion constructs were generated to
remove the amino-, carboxy- or both termini (as schematized in Fig. 1D). These various
constructs were transfected into human liver HepG2 cells, and cellular localization were
determined by subcellular fractionation, followed by immunoblot assay for FLAG
expression. Interestingly, GCN5L1 does not appear to harbor a classic mitochondrial
localization sequence, as deletion of either or both termini did not alter its mitochondrial
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Figure 1. The Short Isoform of GCN5L1 in Enriched in Mitochondria. A. Nucleotide and
deduced amino acid sequences of both GCN5L1 isoforms in human. The two in-frame
start codons, along with the stop codon, are marked by boxes. The epitope of the
GCN5L1 antibody is highlighted. B. Tissue distribution of the short (black triangle) and
long (open triangle) isoforms of GCN5L1 in mouse. C. Subcellular fractionation of
mouse liver tissue to identify localization of the short (black triangle) and long (open
triangle) isoforms of GCN5L1. D. Human GCN5L1-FLAG expression constructs used in
this study. E. Subcellular localization of human GCN5L1-FLAG constructs following
transient expression in human HepG2 liver cells.
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enrichment (Fig. 1E). This suggests that GCN5L1 enters the mitochondria through
another import process, perhaps via an internal, non-cleavable targeting sequence (22).

The xenobiotic acetyltransferase region of GCN5L1 is phylogenetically preserved.
As the initial description of GCN5L1 as a component of the mitochondrial
acetyltransferase machinery noted its similarity to prokaryotic proteins (16), we
compared the sequence of GCN5L1 to the Burkholderia thailandensis streptogramin
xenobiotic acetyltransferase (BtXAT; accession number ZP_02389502). BtXAT is a
member of the Left-handed parallel beta-Helix (LbetaH; cd00208) class of proteins
characterized by a tandem hexapeptide repeat motif (x-[STAV]-x-[LIV]-[GAED]-x).
Proteins in this class typically display acyltransferase activity, and are most commonly
found in microbes (23, 24). We found that the GCN5L1 XAT-containing region has 53%
sequence similarity to the BtXAT substrate- and acetyl-coA-binding domains, although
the similarity is mainly restricted to the former region (Fig. 2A). BtXAT has four XAT
hexapeptide repeat motifs that largely bracket its two binding domains, suggesting that
these regions are either involved directly in substrate binding, or aid the formation of the
correct tertiary structure required for this process.
GCN5L1 has three XAT hexapeptide repeat motifs, with two of these regions
separated by a single amino acid, and the third separated by 61 amino acids (Fig. 2B). We
determined whether this architecture, and the fidelity of these XAT repeat regions, is
conserved across species. We find that this hexapeptide repeat architecture and sequence
similarity is highly conserved in GCN5L1 orthologues from fruit flies to humans, with
100% sequence fidelity in the XAT repeat regions throughout members of the Chordata
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Figure 2. The Prokaryotic Xenobiotic Acetyltransferase (XAT) Architecture of GCN5L1
is Highly Conserved. A. Alignment of the streptogramin acetyltransferase from
Burkholderia thailandensis (BtXAT) and the short isoform of GCN5L1. The XATcontaining region of GCN5L1 (grey highlight), BtXAT substrate-binding (grey line),
BtXAT acetyl-CoA-binding (black line) and XAT repeats (open box) are marked. B.
Sequence alignment of GCN5L1 proteins from Homo sapiens, Mus musculus, Bos taurus,
Xenopus laevis, Danio rerio, Drosophila melanogaster and Arabidopsis thaliana. The
full XAT-containing regions of the proteins (open box) and each individual XAT repeat
(grey highlight) are marked.
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phylum (Fig. 2B). Interestingly, while maintaining much similarity to the animal
sequences throughout its length, the Arabidopsis thaliana deduced protein sequence is
devoid of XAT hexapeptide motifs (Fig. 2B).

Phylogenetic conservation of the XAT region across known acetyltransferases.
Given the well-characterized presence of XAT hexapeptide repeats in prokaryotic
acetyltransferases, and their presence in the sequence of GCN5L1, we then reasoned that
these features may be conserved within other mammalian lysine acetyltransferase
proteins. Using a MOTIF search, we looked for acetyltransferase proteins harboring
multiple tandem repeats of the XAT repeat signature in the KEGG human protein
database

(25).

Surprisingly,

several

members

from

the

three

major

lysine

acetyltransferase families – GCN5, p300 and MYST – were found to
contain multiple XAT regions in addition to GCN5L1 (Table 1). Of these proteins, 82%
contained at least one XAT repeat within their acetyltransferase domain. We then
investigated the position of these XAT repeats in HAT1, a GCN5 family
acetyltransferase whose yeast crystal structure has been reported previously (20). The
acetyltransferase domain of human HAT1 contains two XAT repeats, which bracket
motif A of its conserved GCN5 catalytic core (Fig. 3A). This motif, which contains the
conserved [QR]-x-x-G-x-G sequence necessary for acetyltransferase activity, is thought
to be the main area of acetyl-CoA contact (20). It would appear, therefore, that there is a
large degree of similarity between XAT repeat placement conserved between human and
prokaryotic acetyltransferases.
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Figure 3. The XAT Motif from Prokaryotic Acetyltransferases is Retained in Human
Lysine Acetyltransferases. A. The human HAT1 acetyltransferase core domain contains
two XAT repeats (grey highlight), which bracket the conserved motif A. The three motifs
of the HAT1 core domain are identified by boxes. B. Phylogenetic sorting of the XAT
repeat regions from human lysine acetyltransferases matches their overall placement into
GCN5, p300 and MYST family groupings.
197	
  
	
  
	
  

To see if there are connections between the XAT repeat regions and overall
homology within acetyltransferase families, we analyzed the phylogenetic relationships
of this sequence region in human proteins. We extracted the deduced amino acid
sequence of each protein between two bordering XAT repeats (Suppl. Fig. 1), and then
separated these peptides into clades using PhyML. Interestingly, there was 100%
concordance between the sequences of human XAT repeat regions and their known
acetyltransferase family (Fig. 3B).

The XAT region is required for the acetyltransferase functioning of GCN5L1.
The evolutionary conservation of the XAT architecture and sequence suggests an
important functional role of this region. To test this, we deleted the first two hexapeptide
repeats of GCN5L1 using overlap PCR, and designated this construct ΔXAT-FLAG (Fig.
4A). Overexpression of both GCN5L1-FLAG and ΔXAT-FLAG in HepG2 led to similar
mitochondrial enrichment of the FLAG constructs (Fig. 4B). We then compared the
capacity of control (empty FLAG vector), GCN5L1 and ΔXAT constructs to acetylate
mitochondrial proteins. In the presence of acetyl-CoA, mitochondria extracted from
HepG2 cells overexpressing GCN5L1 displayed a greatly-increased capacity to acetylate
mitochondrial proteins, relative to those expressing control or ΔXAT-FLAG plasmids
(Fig. 4C). To further explore the functional effects of the XAT region, we then measured
mitochondrial respiration in these HepG2 cells. We have previously shown that the
genetic knockdown of GCN5L1 increases mitochondrial respiration (16). Here we show
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Figure 4. The XAT Repeat Region of GCN5L1 is Required for Acetyltransferase
Activity in Mitochondria. A. GCN5L1 constructs used in this study. B. Subcellular
localization of human GCN5L1-FLAG constructs following transient expression in
human HepG2 liver cells. C. An in vitro acetylation assay of mitochondrial proteins from
cells expressing control, GCN5L1-FLAG and ΔXAT-FLAG constructs, in the presence
or absence of exogenous acetyl-CoA. D. Maximal uncoupled oxygen consumption in
HepG2 cells expressing control, GCN5L1-FLAG and ΔXAT-FLAG constructs,
following treatment of with 2-DNP.
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that the overexpression of GCN5L1 suppresses maximal uncoupled respiration (Fig. 4D)
compared to the control and ΔXAT-FLAG expression plasmids.

DISCUSSION

To enhance our understanding of mitochondrial acetyltransferase function, it is
necessary to characterize the proteins operational in this program (16). We recently
identified GCN5L1, a mitochondrial protein displaying homology to prokaryotic
acetyltransferases, as the first member of this regulatory program. In this study we
examined the function of GCN5L1 in light of its secondary structure, and show that its
prokaryotic-derived features are crucial to its acetyltransferase activity. We also show
that these same prokaryotic features are evident in other human lysine acetyltransferases,
hinting at a previously-unrecognized link between the corresponding enzymes in these
two phylogenetic groups.
Although the structure-function of prokaryotic BtXAT protein has not been
characterized, two closely related bacterial XAT proteins have been studied in terms of
tertiary structure (24, 26). In common with other XAT-type proteins Vat(D), a
virginiamycin acetyltransferase from the human pathogen Enterococcus faecium, exhibits
a homotrimeric structure, with active sites formed between the surfaces of two apposed
subunits. The imperfect tandem hexapeptide XAT repeats of Vat(D) create a series of βsheets and turns, which fold to form a triangular prism that is characteristic of LbetaH
proteins (26). These prisms form part of the acetyl-CoA- and substrate-binding surfaces
between two subunits of the trimer. As such, the hexapeptide repeat is crucial to the
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correct confirmation of XAT acetyltransferase proteins. Removal of two XAT repeats
from GCN5L1 blocked its acetyltransferase activity in vitro, with a subsequent loss of
function in regulating mitochondrial respiration in vivo (Fig. 4). It is therefore tempting to
speculate that this mutation may have altered the conformation of GCN5L1, preventing it
from binding either acetyl-CoA or its protein substrates.
While examining the conservation of XAT repeat architecture in GCN5L1, we were
interested to discover that these repeats are common in other human lysine
acetyltransferase proteins (Table 1). While these motifs are not restricted to
acetyltransferases per se, it was also interesting to note that there was a close correlation
between the position of human XAT repeats and the acetyltransferase core domain. This
is exemplified in the GCN5-family protein HAT1, where there are two XAT repeats
bordering the highly conserved motif A (Fig. 3A). This region has been shown to be the
acetyl-CoA-binding region of yeast HAT1 (Dutnall et al, 1998), and disruption in this
area can reduce the acetyltransferase activity of GCN5 family proteins by > 90% (27).
We therefore would speculate that the folding generated by the XAT repeat may aid in
the binding of acetyl-CoA, and that this feature has therefore evolved, or been retained, in
acetyltransferases in many phylogenetic groups. Further work on the importance of the
XAT repeat in acetyltransferase function is therefore warranted.
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Acetyltransferase
Family

Gene
Name
HAT1
ELP3
GCN5
PCAF

NCBI
Gene
ID
8520
55140
2648
8850

Protein
Length
(aa)
419
547
837
832

GCN5

NAT14
NAT15
NAT9
NAT8B
NAT6
NAT8L
NAT10

57106
79903
26151
51471
21412
339983
55226

206
242
207
227
286
302
953

p300

GCN5L1
p300

2647
2033

125
2414

MYST

CBP
MOZ

1387
7994

2404
2004

TIP60
MOF
MORF

10524
84148
23522

494
458
2073

XAT Repeat
Coordinates
15-273
240-380
158-248
55-249
350-489
69-173
61-93
95-196
15-177
118-269
29-255
138-384
506-611
36-114
432-473
1212-1400
2373-2413
1140-1398
683-771
1349-1555
1788-1884
373-406
288-372
894-913
1402-1462
1789-1919

XAT Repeat In
Acetyltransferase
Domain?
Yes
No
No
No
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes

Table 1. Human Lysine Acetyltransferase Proteins Containing XAT Repeat Regions. List
of human lysine acetyltransferase proteins identified by the MOTIF search, along with
the positions of their XAT repeat regions.
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The architecture of GCN5L1 is closely conserved in its orthologs throughout
eukaryotes, with particularly striking sequence homology in the XAT hexapeptide repeat
regions in vertebrate animals (Fig. 2B). Apart from its identification as a part of the
mitochondrial acetyltransferase machinery in humans, the only other functional
characterization of a GCN5L1 protein has been in the flowering plant Arabidopsis
thaliana (28). Here, it was shown that GCN5L1 interacted with proteins that mediated
endosomal-vacuolar transport, with the authors speculating that loss of GCN5L1 led to an
inhibition of protein degradation in the vacuole (28). While there have been suggestions
of a role for human GCN5L1 in protein degradation through analogous autophagic
pathways (29, 30), it is interesting to note that the Arabidopis GCN5L1 does not contain
any XAT repeats, and therefore may have evolved to perform a very different, nonrelated role in plants.
Our findings show that the XAT hexapeptide repeat region plays an important
function role in GCN5L1 in mitochondrial protein acetylation and that these repeat
regions are a common feature across mammalian acetyltransferase enzymes. The next
task is to evaluate whether this region functions in protein-protein interaction as a
component of the mitochondrial acetyltransferase machinery and/or whether it functions
to incorporate acetyl-CoA into this acetylation reaction.
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ABSTRACT
For much of the time since their discovery, the sirtuin family of deacetylase enzymes has
been associated with extensions in lifespan. This longevity promoting capacity in
numerous model systems has enabled the sirtuins to gain ‘celebrity status’ in the field of
aging research. However, the mechanisms underpinning these changes remain
incompletely defined. A general phenotype long associated with aging is the
dysregulation of biological systems, which partly occurs via the accumulation of damage
over time. One of the major sources of this damage is oxidative stress, which can harm
both biological structures, and the mechanisms with which they are repaired. It is now
becoming clear that the beneficial lifespan effects of sirtuins, along with many of their
other functions, are closely linked to their ability to regulate systems that control the
redox environment. Here we investigate the links between sirtuins and their
oxidative/redox environment, and review the control mechanisms which are regulated by
the activity of sirtuin deacetylase proteins.
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Introduction to sirtuin biology
The free radical hypothesis governing the pathophysiology of disease advocates that
excess oxidative stress, and/or the diminished capacity to control reactive species, plays a
role in disease initiation and progression [1-4]. In parallel, members of the NADdependent sirtuin deacetylase family are increasingly recognized as pivotal mediators in
the regulation of nuclear, cytosolic and mitochondrial quality control programs –
mechanisms which enhance cellular homeostasis and diminish degenerative disease
susceptibility. Taken together, these concepts suggest that the control of redox stress, and
the biological effects of sirtuin-dependent protein deacetylation, may be intertwined. To
date, the majority of studies have suggested caloric-dependent factors in the control of
sirtuin biology (recently reviewed [5, 6]). However, evidence is emerging that several
sirtuin isoforms are activated during redox stress and may modulate crucial responses,
including the adaptation to hypoxia and ameliorating reactive oxygen species-induced
pathologies.
As background, the Sir2 (silence information regulator 2) or sirtuin family of class III
deacetylases differ from class I and II histone deacetylases (HDACs) by their protein
sequences and in that they are NAD+- rather than Zn-dependent enzymes [7]. Seven
mammalian homologues of Sir2 have been identified, and are designated as SIRT1
through SIRT7 [8]. SIRT1, SIRT2 and SIRT3 are classified as subclass I enzymes, which
show closest homology to yeast Sir2, and exhibit the most robust deacetylase activity.
SIRT4 and SIRT5 are assigned to subclasses II and III, respectively; while SIRT6 and
SIRT7 are classified as subclass IV enzymes [8]. Sirtuins appear to also catalyze ADP210	
  
	
  

	
  

ribosyl transferase activity, although this biology has been less well studied [9]. There is
also recent work to suggest that Sirt5 functions as a ‘desuccinylase’ and/or a
‘demalonylase’ rather than a deacetylase, which may explain a lack of functional targets
for Sirt5 compared to Sirt3 [10]. The mammalian sirtuins are found in distinct subcellular
compartments, and emerging evidence shows that they regulate specific biological
functions, via the deacetylation of target proteins, within these restricted subcellular
locations. The biological effects of sirtuin-mediated lysine residue deacetylation include
the direct modulation of transcription, and substrate-specific diverse effects on cell
growth, aging, stress-tolerance and metabolism [11, 12]. This review will focus on how
redox signaling controls sirtuin abundance and activity and, conversely, how sirtuins
regulate the response to changes in redox potential and oxygen concentration through
substrate-specific deacetylation events.
Nuclear and Cytosolic Sirtuins
SIRT1 is the most widely characterized protein in the sirtuin family, and as such a
great deal of information has been amassed regarding its regulation over the last decade.
The potential role of SIRT1 in a number of vital physiological pathways has made it a
prime target for pharmacological intervention (see [13, 14]). One major area of SIRT1
research has been its role in caloric restriction (CR), which has long been known to
increase lifespan in a variety of organisms. CR was first shown to have an effect on
sirtuin activity in yeast and worms, where loss or gain of the SIRT1 homologue led to a
reduction or increase, respectively, in lifespan [15, 16]. These effects were mediated in a
large part by the availability of the sirtuin activator, NAD+, which was increased during
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CR and is required for the function of the sirtuin protein [17]. Later work demonstrated
that CR may affect sirtuin function through several NAD+- linked redox pathways in
yeast: CR may increase nicotinamide levels, a specific inhibitor of SIRTs [18]; or reduce
the levels of cellular NADH, which acts as a competitive inhibitor of sirtuin activity [19].
The extent to which NAD+ is involved in the overall control of SIRT function in
mammals is, however, less well established. Finally, CR has been shown to increase the
protein expression of a number of SIRTs, including SIRT1, SIRT3 and SIRT5 [20-22],
which may further enhance their overall deacetylase activity.
The ability of SIRT1 homologues to increase lifespan in various organisms led to
the search for novel pharmacological activators of sirtuins. One of the best characterized
is resveratrol, a weak polyphenolic antioxidant found in red wine. Resveratrol improves
the enzyme kinetics of SIRT1 by increasing its ability to bind and deacetylate substrates,
such as p53, in an NAD+-dependent manner [13]. Addition of resveratrol to yeast
activated the SIRT1 homologue, Sir2, leading to increased DNA stability and lengthening
lifespan by 70% [13]. Further work by the same group extended these findings to
metazoans, showing that resveratrol increased lifespan in fruit flies and worms by 2030% in a sirtuin-dependent manner [23]. More recent studies have identified a group of
small-molecule activators of SIRT1, which have a 1000-fold increase in potency
compared to resveratrol. Treatment of mice and rat diabetes-model animals with these
compounds, which include SRT1720, SRT1460 and SRT2183, led to an improvement in
overall metabolic function and a reduction in diabetic progression [14]. While the authors
related these results to an upregulation of mitochondrial function, based on the ability of
SIRT1 to deacetylate and activate PGC-1α (see below; [14]), there has been some
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controversy regarding whether these compounds are in fact direct activators of SIRT1,
and therefore what mechanism is behind this improvement [24]. While the role of SIRT1
in increasing lifespan in higher animals remains an open question [25], it would appear
from knockout and over-expression studies (see below) that SIRT1 may be involved in
ameliorating some of the phenotypes linked to aging diseases, such as diabetes, obesity
and cancer (reviewed in detail here:[26]).
SIRT2, SIRT6 and SIRT7 are the other sirtuins that reside in the nucleus and
cytosol [11]. SIRT2 is the only isoform predominantly localized in cytoplasm, although it
does transiently reside in the nucleus during phases of mitosis [27]. Multiple target
proteins that are deacetylated by SIRT2 have been characterized [12]. SIRT6 appears to
possess nuclear ADP-ribosyltransferase activity, and it functions as a classical histone
deacetylase [28, 29]. SIRT7 associates with the nucleolus, and only a limited number of
substrates for this deacetylase have been identified [11]. The biology relevant to redox
and hypoxic stress associated with these sirtuins will be discussed later in this review.
The role of redox signaling and oxygen in the regulation of SIRT1
In contrast to the emerging characterization of substrates responsive to SIRT1
deacetylation, our knowledge pertaining to the molecular control of SIRT1 itself, and
especially in response to redox stress and differing oxygen levels, is less well established.
The gene transcript encoding SIRT1 is induced in response to mild oxidative stress [30],
although the transcriptional regulatory program controlling this regulation has not been
delineated. Furthermore, in response to hypoxia the SIRT1 promoter is directly transactivated by HIF transcription factors [31]. Emerging data also shows that the SIRT1
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protein is modulated by numerous regulatory events in response to altered redox states.
At pathological levels, H2O2 and redox stress associated with environmental toxins
diminish SIRT1 protein levels, via increased proteosomal degradation [32]. The activity
of SIRT1 is additionally modulated by post-translational modifications that alter
deacetylase activity. For example, oxidative stress has been shown to promote the
desumoylation and inactivation of SIRT1, resulting in increased susceptibility to
apoptosis [33].

Redox Targets of SIRT1
A large number of sirtuin deacetylation substrates have now been identified in the
human proteome, and several of these are related to maintaining redox homeostasis
within the cell. One of the first major targets of SIRT1 to be identified was the tumor
suppressor p53. As a transcription factor, p53 is involved in activating a suite of pro- and
anti-oxidant genes, such as sestrins, mitochondrial manganese superoxide dismutase and
glutathione peroxidase 1 (reviewed in [34] ). SIRT1 binds and deacetylates p53 at
Lys382, which attenuates its transcriptional activity [35, 36]. The cellular localization of
p53 in response to reactive oxygen species (ROS) has been shown to be dependent on
SIRT1 deacetylation, and may help to regulate the switch from antioxidant protection to
apoptosis. Over-expression of SIRT1 attenuated the transcriptional activity of p53 in
response to exogenous hydrogen peroxide treatment, which prevented the induction of a
p53-mediated apoptosis program [37]. At lower ROS levels, the SIRT1-p53 interaction
appears to be responsible for regulating the induction of an antioxidant program. In wildtype mouse embryonic stem cells, the removal of culture medium antioxidants led to the
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translocation of p53 to mitochondria and subsequent apoptosis. However in SIRT1-/cells, this endogenous increase in ROS led to the nuclear translocation of p53, which the
authors speculated would result in the induction of an antioxidant response [38].
A second pathway that relies on sirtuins to activate an antioxidant response
involves the forkhead box O (FOXO) transcription factor family. Both SIRT1 and SIRT2
have been shown to deacetylate and activate FOXO3a in response to oxidative stress [39,
40]. This is significant, as FOXO3a is a transcriptional activator of the SOD2 gene which
encodes the mitochondrial-localized MnSOD antioxidant protein [41]. A second target of
SIRT1-FOXO3a is catalase, an important enzyme that protects against damage caused by
excess hydrogen peroxide. Again, the action of SIRT1 appears to be bi-directional, with
low levels of hydrogen peroxide leading to the upregulation of FOXO3a-induced
catalase, and higher levels leading to the switch to FOXO3a-mediated apoptosis [42]. In
the heart, pressure overload and related oxidative stress leads to an upregulation in
SIRT1, and mimicking this increase using transgenic over-expression of SIRT1 in mice
leads to the induction of protective mechanisms, such as increased catalase expression
[43]. However, high levels of SIRT1 led to increased oxidative stress, apoptosis and
cardiac hypertrophy. As such, these sirtuins appear to act as ROS sensors, with the ability
to induce protective mechanisms in response to low-level stresses, and signaling for
apoptosis when the stress becomes too great.
Given the requirement for NAD+ in sirtuin function, mechanisms which regulate
the intracellular NAD+:NADH ratio have a powerful role in SIRT1 regulation. One of the
most closely studied is the interaction between cellular NAD+ levels (particularly the
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NAD+ salvage pathway) and AMP-activated kinase (AMPK), a key energy homeostasis
enzyme. One of the first studies to link AMPK function and SIRT1 activity looked at
glucose metabolism during muscle development, and found that reduced levels of glucose
led to the activation of SIRT1[44]. Reducing the glucose available to myoblasts led to the
activation of AMPK and, consequently, the induction of NAD+ salvage pathway enzyme
Nampt, which increased intracellular NAD+ levels and activated SIRT1 [44]. These
results were further extended by studies demonstrating that AMPK, acting as a metabolic
fuel sensor, could stimulate transcriptional activity downstream of SIRT1 [45]. A
reduction in cellular energy stores leads to the phosphorylation and activation of AMPK,
which leads to an increase in available NAD+ within the cell. This stimulates SIRT1 to
activate several transcriptional activators, such as FOXO proteins and the peroxisome
proliferator-activator receptor-α coactivator 1α (PGC-1α), leading to an upregulation of
genes involved in catabolism and mitochondrial biogenesis [46]. The activation of
AMPK in this manner can also occur through SIRT1, using positive feedback
mechanisms. LBK1, an upstream kinase that phosphorylates and activates AMPK under
nutrient stress conditions, has been shown to be acetylated on multiple lysine residues.
Stimulation or over-expression of SIRT1 leads (either directly or indirectly) to the
deacetylation of LBK1, which promotes its translocation from the nucleus to the
cytoplasm, allowing it to phosphorylate AMPK [47], [48]. As such, there appears to
multiple levels of metabolic regulation occurring through the AMPK-SIRT1 axis, and
many of these steps require further elucidation.
As noted above, SIRT1 has the ability to interact with and deacetylate PGC-1α, a
major transcriptional coactivator involved in cellular metabolism and mitochondrial
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biogenesis. The functional role of this deacetylation, however, appears to depend greatly
upon the tissue type and metabolic conditions in which it takes place. It has been
demonstrated that in the liver, SIRT1 is activated in response to fasting, which leads to
the deacetylation of PGC-1α [49]. Acting through this pathway, PGC-1α deacetylation
can both inhibit glycolytic genes and induce the expression of those involved with
gluconeogenesis [49]. A contemporary study showed that in the adrenal PC12 cell line,
SIRT1 could directly interact with and deacetylate PGC-1α, and that this led to a
decrease in both PGC-1 α transcriptional activity and related mitochondrial oxidative
metabolism [50]. Conversely, induction of SIRT1 activity using resveratrol, and
subsequent PGC-1α deacetylation, led to an increase in mitochondrial function in
numerous oxidative tissue types (including muscle and brown adipose tissue), indicating
that deacetylation was responsible for an increase in PGC-1α transcriptional activity [51].
In skeletal muscle, fasting induced SIRT1 activity and PGC-1α deacetylation, which led
to an increase in mitochondrial fatty-acid oxidation [52]. More recent work has indicated
that SIRT1-dependent deacetylation of PGC-1α is required for the induction of
mitochondrial biogenesis and activity in response to adiponectin in muscles [53] and
Fibroblast Growth Factor 21 in adipocytes [54], and therefore is crucial to the function of
these anti-diabetic metabolic regulators. Loss of PGC-1α activity has been linked to a
down-regulation of mitochondrial anti-oxidant proteins, such as MnSOD, indicating that
SIRT1 may have a direct effect on cellular redox states through this pathway [55].
Following the discovery of resveratrol, and its effect on health and lifespan, there
were several avenues of research that opened up to elucidate the mechanisms involved.
One pathway that was of interest to the cardiovascular field was the effect of resveratrol
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on the endothelial nitric oxide synthase gene, eNOS, which when uncoupled leads to
ROS production and quenching of nitric oxide (NO). Previous work had shown that
resveratrol was an agonist of the estrogen receptor [56], and that estrogens led to the
upregulation of the eNOS gene involved in the synthesis of cardioprotective NO
(reviewed in [57]. Addition of resveratrol to endothelial HUVEC cells led to a time- and
concentration-dependent increase in eNOS expression and cellular NO levels [57],
indicating a direct effect on the NO pathway. Similar research showed that calorie
restriction, another known SIRT1 activator, was capable of enhancing eNOS expression
and increasing mitochondrial biogenesis through transcription factors such as PGC-1 α
[58]. To square the circle, further research demonstrated that SIRT1 interacted with and
deacetylated eNOS in vivo, leading to an upregulation of eNOS activity and intracellular
NO levels [59]. As such, it would appear that SIRT1 has an important cardioprotective
effect on vascular tone in an eNOS-dependent manner.
SIRT1 in hypoxia
As with other aspects of redox stress, non-mitochondrial sirtuins play a prominent
role in the response to hypoxia. The transcriptional response to hypoxia is regulated, in a
large part, by the Hypoxia Inducible Factor (HIF) family of proteins, the best
characterized of which are HIF1α and HIF2α (reviewed in [60]). HIF proteins are
constitutively expressed, however under normoxic conditions they are kept at low levels
by continual hydroxylation and proteosomal degradation. A change in the cellular
environment from normoxia to hypoxia attenuates this proteolysis, stabilizing the HIF
subunits and allowing them to transcriptionally upregulate key hypoxia-response genes.
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Both HIF1α and HIF2α have been shown to be targets of SIRT1 deacetylation, however
this interaction leads to very different outcomes for these two subunits. HIF2α forms a
complex with SIRT1 under hypoxic conditions, and is deacetylated at three lysine
residues (K385, K685, and K741) in the carboxy terminus [61]. This deacetylation
upregulates HIF2α transcriptional activity, and leads to an increase in the abundance of
HIF2α -dependent hypoxia-related proteins such as erythropoietin [61]. Recent work by
the same group has shown that SIRT1 protein levels are increased at the initiation of
hypoxia, and that this induction is regulated by HIF2α transcriptional activity [31].
In contrast to HIF2α, SIRT1 has been shown to act as a repressor of HIF1α
activity. Under normal conditions SIRT1 can bind to, and deacetylate, HIF1α. This
deacetylation prevents HIF1α from interacting with the transcriptional coactivator p300,
thereby blocking its transcriptional activity [62]. However, under hypoxic conditions, the
repression of HIF1 α by SIRT1 is lifted indirectly through changes in the metabolic
environment. The reduction in oxygen levels during hypoxia leads to a shift in the
NAD+:NADH ratio, and results in a decrease in the NAD+ available to stimulate SIRT1.
This NAD+-dependent loss of SIRT1 activity allows HIF1α to remain acetylated, thereby
facilitating its hypoxic transcriptional activity [62]. Interestingly, HIF1α activity has also
been shown to be regulated by SIRT6. HIF1α transcriptionally regulates a number of
genes involved in the shift to glycolysis under low oxygen conditions. These genes, along
with HIF1α itself, are upregulated in SIRT6-deficient cells, leading to an increase in
glucose uptake and glycolysis [63]. In wild-type cells, SIRT6 acts as a H3K9 histone
deacetylase, blocking the HIF1α -dependent transcription of multiple glycolytic genes,
and co-repressing HIF1α in a deacetylase-dependent manner [63]. As such, it would
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appear that while SIRT1 can regulate the activity of HIF subunits in general, SIRT6 may
act as a glucose metabolism-specific regulator of hypoxia-related genes.
The redox phenotype in SIRT1 knockout and transgenic mice
The composite of data discussed would suggest that SIRT1 should play an
adaptive role in protection against redox stressors. A major limit to testing this hypothesis
has been the production of SIRT1-/- mice, as this deletion leads to high levels of
embryonic lethality. Nevertheless, in vivo studies have been performed with either
heterozygous SIRT1+/- mice, tissue-specific knockout mice, or following over-expression
of SIRT1 using transgenic technology. Here mice have been studied in the context of
degenerative and redox stress diseases. Heterozygous SIRT1 knockout mice show
increased susceptibility to oxidative stress in the kidney [64] and the combined SIRT1+/p53+/- mice show greater tumor susceptibility compared to p53 haploinsufficiency alone
[65]. Tissue-specific deletion of SIRT1, including in the liver and brain, has been shown
to negatively alter fat metabolism and increase susceptibility to diet-induced obesity [66,
67]. Limited copy number over-expression of SIRT1 has been shown to protect against
redox stress in the brain, heart and kidneys, to ameliorate hepatic hepatosteatosis that
results from diet induced obesity, and to ameliorate colon cancer [43, 68-70]. SIRT1 is
also implicated, as necessary, to enable the innate adaptive reprogramming to resist
ischemia-reperfusion injury, as a component of the ischemic preconditioning program
[71].
Additional nuclear and cytosolic sirtuins and redox biology
Although the role of SIRT2has not been as well characterized as SIRT1 or SIRT3,
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it does play a regulatory role in modulating redox stress tolerance. SIRT2 is mainly
localized in the cytosol, however it can undergo translocation to the nucleus during
certain events, such as mitosis [72]. Indeed, other sirtuins such as SIRT3 have been
shown to translocate under different cellular conditions [73], although this may be the
result of using an over-expression vector with an incomplete murine SIRT3 [74]. Redox
stress has been shown to result in the upregulation of both SIRT2 transcript and protein
levels [40, 75]. Functional characterization of this process suggests that redox-stress
upregulation of SIRT2 is associated with increased cell death, in parallel with the
induction of the pro-apoptotic protein Bim [40], and that overexpression of SIRT2
similarly promotes neurodegeneration [76]. In contrast, basal levels of SIRT2 under lowstress conditions upregulate mitochondrial MnSOD via FOX3a deacetylation, with the
subsequent attenuation of reactive oxygen species levels [40]. Genetic knockdown of
SIRT2 is associated with upregulation of the cytosolic chaperone 14-3-3ζ, which in turn
sequesters the pro-apoptotic mitochondrial protein BAD in the cytosol and augments
tolerance against anoxia-reoxygenation induced cell death [75]. A ‘dose-dependent’
function of SIRT2 under redox stress conditions is further supported by data showing that
a SIRT2 inhibitor rescues α-synuclein-mediated toxicity in a cellular model of
Parkinson’s disease [77], and that SIRT2 knockdown is protective in neuronal and
cardiac cells [75, 77].
The role of SIRT6 in biological control under redox and hypoxic stress has not
been well characterized, although mice lacking SIRT6 are predisposed to accelerated
senescence. This includes the development of degenerative features, telomerase
shortening and a lifespan limited to approximately 4 weeks [78]. As noted above, SIRT6
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additionally modulates hypoxic signaling through corepression of HIF1α during the
control of glucose homeostasis [63]. SIRT7 is the least-well studied sirtuin, although the
genetic knockout of this gene does have a robust phenotype, with a 50% reduction in
lifespan and the development of degenerative features and an inflammatory
cardiomyopathy [79]. In the absence of SIRT7, p53 exhibits robust acetylation, which is
postulated to diminish resistance to genotoxic and oxidative stress [79]. The role of
SIRT7 in ameliorating oxidative stress is also evident in that it blunts cell proliferation
under oxidative stress conditions [80]. A summary of the role played by nonmitochondrial sirtuins in redox biology can be found in Figure 1.
Mitochondrial sirtuins
The role of redox signaling and oxygen in the regulation of SIRT3
Of the three family members found in the mitochondria, SIRT3 functions as the
major sirtuin deacetylase [81]. An initial controversy regarding the localization of the
murine SIRT3 [82] has now been resolved, with the identification and functional
characterization of its mitochondrial localization sequence [74, 83, 84]. The number of
SIRT3 substrates identified is increasing at a prodigious pace, and their role in numerous
biological programs is still being explored. Here we focus on those substrates that
modulate redox-stress directly, and discuss their role in redox-stress associated
pathology. SIRT4 and SIRT5 are also enriched in the mitochondria, although fewer
substrates of these two sirtuins have been described. As mentioned previously Sirt5 may
function to remove succinyl and/or malonyl, rather than acetyl, groups from
mitochondrial targets [10]. However, where they are relevant to the role of sirtuin biology
in redox stress, these data have been included. As numerous SIRT3 mitochondrial targets
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Figure 1 Of the non-mitochondrial sirtuins, SIRT1 is the most widely characterized
deacetylase. In common with the other sirtuins, SIRT1 is activated by NAD+; levels of
which can be increased following AMPK activation. Redox stress and hypoxia may,
directly or indirectly, increase SIRT1 levels or activate its deacetylase activity (broken
arrow). In terms of oxidative stress, one of the main roles of SIRT1 is to deacetylate and
activate transcription factors involved in upregulating antioxidant proteins, such as
MnSOD and catalase. In addition, SIRT2 has also been shown to activate the
transcription factor FOXO3a through deacetylation. The activity of SIRT1, along with
SIRT6, can inhibit HIF1α activity; however, SIRT1 has the opposite effect on HIF2α.
Finally, SIRT1 deacetylates and activates the eNOS, leading to an increase in
intracellular cardioprotective NO.
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play a role in the control of ROS generation and amelioration (see below), studies have
begun to explore whether ROS levels themselves regulate SIRT3. Both SIRT3 transcript
and protein levels are induced by the generation of mitochondrial ROS [85]. Whether
SIRT3 is modulated at the post-translational level, in response to redox signaling, has not
been explored. However, prolonged high fat feeding results in evidence of hepatic redox
stress, and an associated reduction in SIRT3 protein levels [86]. SIRT3 levels are also
induced in parallel with mitochondrial biogenesis, where the transcriptional co-activator
PGC-1α and transcription factor ERRα, respectively, transactivate the SIRT3 gene
promoter [87].
Redox Targets of SIRT3
Mitochondria are the major source of cellular oxidative stress, with ROS
formation occurring during normal function of the electron transport chain (ETC). Any
reduction in mitochondrial function, through processes such as metabolic disease
progression or aging, can augment oxidative stress [88]. Mitochondria have therefore
developed numerous biological programs to combat this innate oxidative stress and
maintain functional homeostasis. One such program utilizes reduced glutathione, via the
generation of NADPH by isocitrate dehydrogenase 2 (IDH2). IDH2 uses NADP+ as a
substrate in the TCA cycle, during the decarboxylation of isocitrate to aof isocitrate ,
which yields NADPH. This, in turn, is used for the regeneration of reduced glutathione to
confer antioxidant properties [89]. IDH2 was initially shown to be differentially
acetylated in a nutrient dependent manner in a proteomics screen by Kim et al. [90]. A
role for SIRT3 in this process was identified by Schlicker et al., who showed that in the
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presence of NAD+ purified SIRT3, but not SIRT5, deacetylated IDH2 and increased its
activity [91]. The sites of SIRT3 deacetylation (K211 and K212) found by Schlicker et
al. were different to those identified in the initial proteomics screen (K75 and K241), and
it is unclear how the latter two residues are regulated [90, 91]. Recently, this work has
been linked to age-related hearing loss (AHL). It was previously shown that CR
attenuates AHL by slowing neuronal loss in the cochlea, which correlated with increased
SIRT3 expression levels [89]. Further work demonstrated that CR prevented AHL in 12
month old mice and attenuated spiral ganglion neuronal loss. However, these benefits
were completely abolished in SIRT3 knockout animals, suggesting that the process was
SIRT3-dependent [89]. CR also ameliorated oxidative damage to DNA in various
organs, including the brain and liver, and promoted hair cell survival in the cochlea of
aged mice. To provide a mechanism for these SIRT3-dependent benefits, Someya et al.
showed that GSH/GSSG ratios were increased, and that NADPH levels were elevated in
liver, brain and the inner ear following CR. CR also decreased the acetylation levels of
IDH2, increasing its activity, in a SIRT3-dependent manner [89]. Confirming previous
results, they further demonstrated that SIRT3 directly deacetylates and augments the
activity of IDH2, and that overexpression of SIRT3 or IDH2 was sufficient to increase
NADPH levels and attenuate oxidative stress-mediated cell death [89]. Linking CR,
SIRT3 and IDH2 supports the concept that oxidative stress is a major component of
aging, and that nutrient status can regulate the cellular response to degenerative
pathologies.
Another major mitochondrial defense against oxidative stress is superoxide
dismutase (SOD). Humans express three forms of SOD, which converts superoxide
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anion (O2-) to hydrogen peroxide (H2O2), limiting ROS damage to nucleic acids, proteins
and lipids. SOD1 and SOD3 are localized in the cytosol and extracellular space, using
copper and zinc as prosthetic groups, respectively. SOD2 contains manganese (MnSOD)
and localizes to the mitochondria [92]. MnSOD, like IDH2, has been linked to agerelated disorders such as cancer and cardiovascular disease [93-95]. SIRT3 was first
shown to regulate SOD2 by modulating FOXO3a activity in the mitochondria, which led
to subsequent FOXO3a-mediated SOD2 expression [95, 96]. It is not clear if these results
were due to an over-expression artifact leading to the nuclear localization of SIRT3 [74].
Nevertheless, more recent evidence has directly tied SIRT3 to MnSOD function. Qiu et
al. showed that caloric restriction lowers oxidative stress in a SIRT3 dependent manner
[97]. SIRT3 overexpression in mouse embryonic fibroblasts (MEFs) lowered ROS levels
in an SOD2-dependent manner, suggesting that acetylation status regulates SOD2
activity. They further showed that SIRT3 interacts with SOD2, and that SIRT3-mediated
deacetylation of SOD2 increased its activity, which provided protection against oxidative
stress [97]. SOD2 was previously identified as an acetylated protein at K68 and K130
[90, 98]. However, there is some uncertainty regarding which acetylated lysine residue
regulates SOD2 activity. Qui et al. showed that mutating K68 and K130 did not alter
total acetylation levels of SOD2. However acetylation of K53 and K89, two lysine
residues near the active site of SOD2, regulated its activity [97]. While a second study by
Tao et al. confirmed that SIRT3 regulates SOD2 activity, and subsequent protection
against ionizing radiation (see below), this group identified K122 as the crucial lysine
[99]. Fasting wild-type mice for 36 hours promoted deacetylation of SOD2, which was
blocked in SIRT3 knockout animals. Hyperacetylation of SOD2 in SIRT3-deficient mice
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led to lower enzymatic activity and elevated ROS levels [99]. Further complicating the
post-translational regulation of SOD2, Chen et al. recently showed that acetylation of
K68 does indeed regulate SOD2 activity, and that SIRT3 deacetylates SOD2 at this site
[85]. The differences observed in the site-specific regulation of SOD2 by SIRT3 may
reflect cell type, species or stress conditions, or may reflect a higher-order regulation that
requires changes in several lysine residues. As Chen et al. state, it is interesting to note
that the lysine to arginine mutation (which mimics deacetylation) increased SOD2
activity for K53R, K89R and K122R mutants, while in the K68R mutant it does not [85].
Although the precise site(s) of regulation remains unclear, it is clear ROS levels are
tightly controlled by SIRT3 by increasing the activity of two major ROS regulating
enzymes, IDH2 and SOD2.
Indirect SIRT3 and SIRT5 targets for regulation of mitochondrial oxidative stress
MnSOD and IDH2 represent SIRT3 targets that directly regulate mitochondrial
ROS. However, other targets of SIRT3 and SIRT5 have indirect effects on oxidative
stress. As mentioned previously, the electron transport chain generates ROS, and SIRT3
has been shown to deacetylate complexes I, II, V and most recently III [86, 100, 101].
SIRT5 is also implicated in the deacetylation of cytochrome c, although this has not been
functionally characterized [91]. Secondly glutamate dehydrogenase (GDH), which can
regulate glutamate oxidative stress and generate NAPDH, is deacetylated by SIRT3 [81]
(and inhibited by SIRT4 mediated ADP-ribosylation) [102]. A final example of indirect
regulation of ROS levels by mitochondrial sirtuins occurs during fasting, when protein
catabolism is augmented to provide TCA cycle intermediates. Protein catabolism leads
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to the generation of ammonium, which can result in oxidative stress [103]. To prevent
damage, ammonium is converted to urea for subsequent elimination in the urea cycle.
SIRT3 and SIRT5 regulate the mitochondrial localized reactions of the urea cycle, with
SIRT5 acting on carbamoyl-phosphate synthase 1 (CPS-1), and SIRT3 deacetylating
ornithine transcarbamoylase (OTC) [20, 104]. Both deacetylation reactions promote urea
cycle function, leading to the elimination of the oxidative stress-promoting ammonium.
Biological roles of SIRT3 in redox-associated pathology
Oncogenesis
Numerous studies have highlighted a pivotal role for SIRT3 in cancer, even going
as far as referring to it as a tumor suppressor. However, the ability of SIRT3 to act as a
tumor suppressor is directly related to its role in regulating ROS levels. SIRT3 knockout
cells display a propensity towards carcinogenesis, with increased ROS, nuclear and
mitochondrial genomic instability and diminished contact inhibition [93]. Combining the
expression of oncogenes with deletion of SIRT3 further promotes a cancer phenotype,
which can be rescued by overexpression of SOD2. SIRT3 knockout mice also have a
higher incidence of breast cancer, while human breast cancer samples exhibit lower
levels of SIRT3 [93].
Cancer cells display a characteristic metabolic profile, and SIRT3 appears to play
a role in preventing the switch to this phenotype. In cancer cells, hexokinase II activity is
greatly upregulated, which promotes increased glycolysis and attenuates oxidative
phosphorylation – classic indicators of the Warburg effect (reviewed in [105]).
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Hexokinase II binds to VDAC in the outer mitochondrial membrane, and utilizes ATP to
generate glucose-6-phosphate (G6P). G6P is shuttled through glycolysis, generating
pyruvate and lactic acid; or through the pentose phosphate pathway to generate NADPH,
which is used to drive anabolic reactions. Some of the G6P is also used to generate citrate
in the mitochondria, which enters the cytosol to allow phospholipid and cholesterol
synthesis. SIRT3 knockout MEFs show elevated levels of glycolytic and pentose
phosphate pathway metabolites, increased glucose uptake and lactate production, and
lower levels of TCA cycle intermediates – all suggesting a metabolic profile similar to
cancer cells [106]. SIRT3 has been shown to deacetylate cyclophilin D (CypD), which
limits its interaction with the mitochondrial permeability transition pore (MPTP).
Importantly, this deacetylation also prevents hexokinase II from binding to VDAC and
the mPTP, limiting its ability to use ATP and augment glycolysis [107]. Shulga et al.
speculate that this would limit the transition to a Warburg phenotype, thereby attenuating
tumor growth [107]. Other studies have also found that SIRT3 drives oxidative
phosphorylation and augments ATP generation [74, 100].
Metabolic reprogramming of cancer cells relies on HIF-1α, and the loss of SIRT3
leads both to its stabilization, and increased levels of HIF-1α gene targets, including
hexokinase II [106]. As noted above, SIRT1 can deacetylate HIF-1α. Although SIRT3
does not directly interact with HIF-1α, HIF-1α is stabilized in SIRT3 knockouts via an
indirect mechanism. The increased ROS levels found in SIRT3 knockouts increase HIF1α stabilization promoting cancer cell metabolism [106]. Bell et al. also showed the
effect of SIRT3 on HIF-1α stability, along with the ability of SIRT3 to attenuate tumor
growth using xenograft models [108]. SIRT3 also appears to regulate p53 activity, by
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altering growth arrest and apoptosis in a complex manner involving a similar mechanism
to HIF-1α, namely elevated ROS levels affecting p53 activity [109-111]. Although the
majority of data shows that SIRT3 can act as a tumor suppressor, SIRT3 may promote
tumorigenesis in some forms of cancer. SIRT3 expression levels were elevated in oral
squamous cell carcinoma (OSCC); while inhibition and down regulation of SIRT3
slowed growth, promoted apoptosis and increased susceptibility to radiation and
chemotherapy [112]. These conflicting roles of SIRT3 as tumor suppressor or promoter
may be due to its role in regulating p53, with SIRT3 inhibiting the ability of p53 to arrest
growth [110]. Overall it appears that Sirt3 can regulate cellular energetics, and possibly
substrate selection such as lipids (see below), by increasing mitochondrial oxidative
phosphorylation through deacetylation of various electron transport chain targets
including complexes I, II and V (sources) and cyclophilin D attenuating ROS levels and
glycolytic metabolism.
Lipotoxicity
Obesity and over-nutrition can lead to diabetes, the metabolic syndrome and nonalcoholic fatty liver disease (NAFLD), along with an increase in circulating free fatty
acids, i.e. lipotoxicity. Lipotoxicity generates a pro-inflammatory state with increased
oxidative stress, promoting insulin resistance systemically and diminishing insulin
secretion by the pancreas (reviewed in [113]). Concurrent with this pro-inflammatory
state, mitochondrial function and biogenesis, through defects in PGC-1α, also diminish
with obesity and diabetes – further promoting ROS generation [3]. Interestingly,
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expression of SIRT3 leads to an upregulation of PGC-1α and consequently the
transcription of its biogenesis gene targets [87, 114, 115].
Nutritional status greatly alters mitochondrial protein acetylation levels, with
fasting and high fat diets leading to the hypo- and hyper-acetylation of mitochondrial
targets, respectively [90, 116]. Hirschey et al. showed that fasting increases SIRT3
expression and lowers acetylation levels in mouse livers. Although phenotypically
normal, SIRT3 knockout animals had higher levels of triglycerides and β-oxidation
intermediates, suggesting a defect in lipid processing. They showed that long chain acylCoA dehydrogenase (LCAD) is hyperacetylated at K42 in SIRT3 knockout mice, leading
to lower activity, and that SIRT3 deacetylates LCAD directly [117]. Hallows et al. also
found LCAD to be a SIRT3 target [20]. It has also been shown that SIRT3 prevents lipid
accumulation in HepG2 cells by acting alongside AMPK, which phosphorylates acetylCoA carboxylase (ACC) and inhibits lipid synthesis. SIRT3 appears to regulate AMPK
activity, however the mechanism of the cross-talk between these two nutrient sensing
proteins is currently unknown [118]. On the opposite end of the nutritional spectrum, six
weeks of high fat diet (HFD) led to hyperacetylation of numerous protein targets in
mouse livers involved in metabolic pathways [116]. Under these conditions, SIRT3
activity was diminished, while oxidative stress was elevated, further supporting a role of
SIRT3 in regulating oxidative stress [116]. SIRT3 knockout animals exposed to HFD
showed even higher levels of acetylation and diminished mitochondrial respiration [116].
The absence of SIRT3 similarly increased susceptibility to lipotoxicity in primary
hepatocytes, and this phenotype was ameliorated by either the reconstitution of SIRT3, or
via the administration of the antioxidant N-acetylcysteine [86]. It appears that SIRT3
231	
  
	
  

	
  

may alleviate the pro-inflammatory state induced by lipotoxicity through a variety of
mechanisms, including altering mitochondrial biogenesis, aiding oxidative stress systems
and regulating lipid accumulation. SIRT3 may therefore represent a potential new target
to combat lipotoxicity and its concurrent disease states.
Cardiac hypertrophy
Sirtuins and protein deacetylation have also been linked to cardiovascular health
[119]. The renin-angiotensin system (RAS) and Angiotensin II (Ang II) are common
targets in the treatment of cardiovascular disease, including hypertension, renal disease,
hypertrophy and Marfan syndrome. Ang II is pro-inflammatory and increases ROS
generation [120]. Similar to CR, knockout of Ang II Receptor (AT1R) in mice increased
lifespan by 26%, and AT1R knockouts have lower levels of cardiac fibrosis, hypertrophy
and attenuated aortic damage [121]. AT1R deficient mice also showed lower levels of
oxidative stress, and increased mitochondrial density when compared to controls. As a
possible mechanism explaining this anti-aging phenotype, it was shown that AT1R
knockouts had higher levels of both SIRT3 and the NAD+ generating enzyme
nicotinamide phosphoribosyltransferase, Nampt. Conversely, AngII treatment lowered
the expression levels of Nampt and SIRT3, with these effects being blocked by
candesartan, an AT1R blocker [121]. Further linking the sirtuins to promoting
cardiovascular health, Miyazaki et al. showed that Sirt1 attenuates AT1R expression
levels [122].
To directly investigate the role of SIRT3 in cardiac hypertrophy, Sundaresan et al.
induced cardiac hypertrophy chemically and physically; both of which enhanced SIRT3
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expression [94, 95]. SIRT3 knockout animals subjected to the same stimuli displayed an
exacerbated hypertrophic response, suggesting that the augmented SIRT3 level seen in
wild-type animals is a protective response used to combat the hypertrophic program.
Indeed, overexpression of SIRT3 attenuated the hypertrophic response both in vivo and in
vitro, preserving cardiac function [95]. Increasing exogenous levels of the SIRT3
substrate, NAD+, attenuated the hypertrophic response through SIRT3 deacetylation and
activation LKB1 and AMPK. Hsu et al. also showed that elevated NAD+, as mediated by
Nampt, induces a cardio-protective phenotype [123]. As mentioned previously, it is not
clear if the SIRT3-mediated effect on nuclear and cytosolic targets, i.e. FOXO3a and
LKB1, is a by-product of over-expression of the short form of SIRT3 that fails to localize
to the mitochondria, or if SIRT3 acts on targets outside the mitochondria through
unspecified mechanisms. An overview of the role of the mitochondrial sirtuins on redox
stress biology is schematized in Figure 2.
ALDH2 and acetaminophen - an exception to the redox-stress ameliorative role of
SIRT3
Unlike the protective role of SIRT3 in modulating redox-stress described above [86, 89,
99], it has recently been found that SIRT3-mediated mitochondrial protein deacetylation
exacerbated oxidative stress associated with acetaminophen-induced liver injury (AILI)
[124]. The level of the lipid peroxidation adduct, trans-4-hydroxy-2-nonenal (4-HNE)
was lower in SIRT3-/- mice, compared to SIRT+/+, in response to a toxic dose of
acetaminophen, in parallel with less AILI in the SIRT3-/- mice. The resistance of SIRT3-/mice to AILI was partly due to the acetylation of mitochondrial aldehyde dehydrogenase
2 (ALDH2), a dehydrogenase which functions to oxidize and detoxify aldehydes,
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Figure 2 Mitochondrial localized SIRT3 and SIRT5 regulate oxidative stress utilizing
both direct and indirect mechanisms. Deacetylating manganese superoxide dismutase
(MnSOD/SOD2) and isocitrate dehydrogenase 2 (IDH2) augments their activity,
providing a direct mechanism to regulate ROS. The deacetylation of various other
mitochondrial enzymes indirectly attenuates oxidative stress, which includes regulating
mitochondrial function, namely through deacetylation of cytochrome c and complexes of
the electron transport chain (ETC I, II and V). Another indirect mechanism is through
controlling ROS generating metabolic intermediate production by deacetylating aldehyde
dehydrogenase (ALDH2), glutamate dehydrogenase (GDH), long chain acyldehydrogenase (LCAD), carbamoyl phosphate synthetase I (CPS-1) and ornithine
transcarbamylase (OTC). Finally SIRT3 can regulate apoptosis and glucose metabolism
through its actions on cyclophilin D. The cumulative effect of this ROS regulation is to
attenuate various age-related pathologies including oncogenesis, cardiac hypertrophy,
lipotoxicity and age-related hearing loss.
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including the lipid peroxidation product 4-HNE [125]. In contrast to the known antioxidant effect of SIRT3, via the deacetylation and activation of redox scavenger
substrates, SIRT3-mediated deacetylation of ALDH2 does not change its enzyme activity
directly. Rather, the deacetylation of ALDH2 facilitates the binding of the acetaminophen
toxic metabolite, N-acetyl-p-benzoquinoneimine (NAPQI), directly to ALDH2, with a
concomitant blunting of dehydrogenase activity [124]. Taken together, this finding
suggests that the acetylation of mitochondrial proteins can also function as an allosteric
inhibitor to the binding of reactive metabolites. This mechanism is proposed to function
in the enhanced susceptibility to acetaminophen-induced injury under fasting and caloric
restricted conditions [126, 127], nutrient states known to promote the activation of sirtuin
enzymes.
Conclusions and future directions
The majority of the work carried out thus far on mammalian sirtuin proteins has
focused on SIRT1 and SIRT3. SIRT1, as the major nuclear deacetylase, plays a pivotal
role in the acetylation-based regulation of numerous proteins, including many that form
the transcriptional response to changes in redox conditions. SIRT3, as the major
mitochondrial deacetylase, acts as the in situ regulator of proteins, which ameliorate
damage in one of the major ROS-producing organelles in the cell. Our knowledge of the
functional activity of these proteins has grown exponentially over the last few years, and
will likely continue to uncover new pathways regulating the cellular response to oxidative
stress. Table 1 summarizes all the ROS modulatory proteins that are substrates of the
sirtuins and describes the functional consequences of sirtuin activation. One of the major
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fundamental areas to be tackled in this field is how intracellular redox conditions affect
the transcriptional control of SIRT1 and SIRT3 protein levels. Work in this area will help
to determine the level of feedback control inherent in this system, and will establish how
finely balanced these mechanisms are. Additionally, both in the redox field in particular,
and the sirtuin field in general, future research effort will likely turn to the other sirtuins.
While SIRTs 2,4,5,6 and 7 may have a more limited functional scope than SIRT1 and
SIRT3, it is likely that their substrate-specific activity will be crucial in the regulation of
many important pathways. As such, while they appear to be the forgotten members
currently, the future may yield much more insight into their function within the cell.
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Webster et al. Table 1
Redox-related
Gene
p53

Sirtuin

Localization

Result of Sirtuin Action

Reference(s)

SIRT1,
SIRT7

Nucleus

33,34,77

FOXO3a
LBK1

SIRT1,
SIRT2
SIRT1

Nucleus,
cytoplasm
Nucleus

Mediates transcriptional activity
depending on sirtuin expression
level
Activates transcriptional activity

45,46

PGC-1α

SIRT1

Nucleus

eNOS
HIF1α

Nucleus
Nucleus

HIF2α
14-3-3ζ

SIRT1
SIRT1,
SIRT6
SIRT1
SIRT2

Activates LBK1, leading to AMPK
phosphorylation
Activates transcriptional coactivation
Activates eNOS activity
Repression of transcriptional activity

Nucleus
Cytoplasm

IDH2
SOD2
NDUFA9

SIRT3
SIRT3
SIRT3

Mitochondria
Mitochondria
Mitochondria

SDHB

SIRT3

Mitochondria

ATP5A

SIRT3

Mitochondria

GDH

SIRT3,
SIRT4

Mitochondria

OTC

SIRT3

Mitochondria

CPS1

SIRT5

Mitochondria

CypD (PPIF)

SIRT3

Mitochondria

LCAD

SIRT3

Mitochondria

ALDH2

SIRT3

Mitochondria

Activates transcriptional activity
Upregulates 14-3-3ζ prevents
anoxia-reoxygenation mediated
apoptosis
Activates enzyme, reduces ROS
Activates enzyme, reduces ROS
Activates enzyme, upregulates ETC
activity
Activates enzyme, upregulates ETC
activity
Activates enzyme, upregulates ETC
activity
Activates enzyme (SIRT3),
represses enzyme by ADPribosylation (SIRT4)
Activates enzyme, reduces ammonia
toxicity and ROS
Activates enzyme, reduces ammonia
toxicity and ROS
Deactivates enzyme, prevents
interaction with mPTP
Activates enzyme, promotes lipid
processing
Deacetylation by SIRT3 allows
NAPQI binding to ALDH2,
reducing its activity
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37,38

47-53
57
60,61
29, 59
73
87-89
83, 95-97
98
99
84
79,100
19
102
105
19,115
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ABSTRACT
There is emerging recognition of a novel fuel and redox sensing regulatory program that
controls cellular adaptation via non-histone protein lysine-residue acetyl post-translation
modifications. This program functions in tissues with high energy demand and oxidative
capacity and is highly enriched in the heart. Deacetylation is regulated by NAD+dependent activation of the sirtuin family of proteins while acetyltransferase
modifications are controlled by less clearly delineated acetyltransferases. Subcellular
localization specific protein targets of lysine-acetyl modification have been identified in
the nucleus, cytoplasm and mitochondria. Despite distinct subcellular localizations, these
modifications appear, in large part, to modify mitochondrial properties including
respiration, energy production, apoptosis and anti-oxidant defenses. These mitochondrial
regulatory programs are important in cardiovascular biology, although how protein acetyl
modifications effects cardiovascular pathophysiology has not been extensively explored.
This review will introduce the role of non-histone protein lysine-residue acetyl
modifications, discuss their regulation and biochemistry and present the direct and
indirect data implicating their involvement in the heart and vasculature.
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Non-Standard Abbreviations and Acronyms:
AceCS2 – acetyl-coA synthetase 2; ADP – adenosine diphosphate; AMP – adenosine
monophosphage; AMPK – AMP-kinase; CREB – cyclic AMP response element binding
protein; CPS1 - carbamoyl phosphate synthetase 1, eNOS – endothelial nitric oxide
synthase; ETC – electron transfer chain; FAO – fatty acid oxidation; Foxo – forkhead
box O transcription factors; GDH – glutamate dehydrogenase; GNAT – Gcn5-related Nacetyltransferase; HAT – histone acetyltransferase; HDAC – histone deacetylase; HIF-2α
- hypoxia inducible factor alpha; ISDH2 – isocitrate dehydrogenase 2; MnSOD –
manganese superoxide dismutase; NAD – nicotinamide adenine dinucleotide; NAMPT –
nicotinamide phosphoribosyltransferase: NMN – nicotinamide mononucleotide; NMNAT
– NMN adenylyltransferase; LKB1 – serine-threonine liver kinase B1; OAADPr – Oacetyl-ADP-ribose; PTM – post translational modification; PPAR – peroxisome
proliferator activated receptor; PGC-1 – PPAR gamma coactivator 1; ROS – reactive
oxygen species; TCA – tricarboxylic acid; TIP60 – Tat-interactive protein 60.
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In the year of the bicentennial celebration of Darwin’s birth, the pursuit of
regulatory programs that underpin ‘adaptations to confer survival’ remains an important
area of scientific investigation. Adaptation to acute stressors, as opposed to evolutionary
‘pressures’, would require rapidly inducible ‘stress-sensing systems’ that could initiate
biological modifications, enabling survival advantage. As mitochondria are central to
important cellular functions, including essential pathways for energy production, reactive
oxygen species (ROS) signaling, calcium homeostasis and apoptosis, it would not be
surprising if mitochondrial adaptations are instrumental in this ameliorative
reprogramming. The heart has a high density of mitochondria with robust energetic
demands and the concept of mitochondrial adaptation in the cardiovascular system to
resist biomechanical stressors is well recognized.1-4 To date, the most extensively
explored sensing program delineated in the heart is controlled by AMP protein kinase and
this signaling network is responsive to energy depletion and rising AMP levels.5 A more
recently identified nutrient and redox sensing regulatory program, exemplified by protein
lysine-residue acetyl modification, is beginning to be investigated as an additional
homeostatic control program.
Lysine-residue acetylation is a reversible post-translational modification (PTM)
orchestrated by a diverse family of structurally unrelated enzymes collectively known as
acetyltransferases. This modification usually involves the covalent transfer of an acetyl
group from acetyl-coenzyme A to a ε-amino group on lysine. The reverse reaction is
driven by deacetylase enzymes. These lysine-modifications have been most extensively
explored in the regulation of histones to fine-tune gene transcription, and these regulatory
programs are dynamically controlled by histone acetyltransferases (HATs) and histone
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deacetylases (HDACs). The role of acetylation/deacetylation in the modification of
histones has recently been well described6 and is not the focus of this review. Initially
identified in 1997, the first non-histone protein to exhibit acetyl-lysine modification was
p53.7 A steady increase in the number of non-histone lysine acetylation modifications are
being discovered and may play a diverse role in diffuse biological processes.8 Coupled to
this, the enzymes controlling these PTMs are not confined to HATs and HDACs but
include an expanding array of lysine acetyltransferases and deacetylases.
The modulation of mitochondrial biology and function via lysine acetylation involves
proteins residing in the nucleus (mitochondrial regulatory proteins), cytoplasm
(chaperones) and within mitochondria themselves. Together, these PTMs of target
proteins contribute towards alterations in numerous mitochondrial functions including the
regulation of mitochondrial biogenesis, apoptosis, thermogenesis, metabolism and
possibly in the contribution of mitochondrial function to longevity.9 Although this field
was initially identified and characterized in non-vertebrate eukaryotes, we focus on
mammalian biology. In this review we explore: (1) the enzymes that orchestrate these
modifications; (2) identify the substrates of these enzymes; (3) investigate the regulation
of lysine acetylation; (4) describe the cardiovascular functional consequences of these
regulatory events and (5) highlight potential areas of importance that need to be
investigated to expand our understanding of the role of non-histone lysine acetylation and
deacetylation on mitochondrial biology and cardiovascular homeostasis.

Non-Histone Lysine Acetyltransferases
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Acetylation, as a process to regulate the availability of DNA for transcription, has
been described for over forty years.10 HATs remove the positive charge of lysine in the
histone tail, altering its interaction with DNA and allowing access to other DNAassociated proteins.11, 12 Since the discovery of non-histone lysine-acetylation,7 the
number of candidate proteins documented has grown steadily, with a recent proteomics
study identifying 195 new acetylated proteins in mammalian tissue.13 Strikingly, in this
study, 133 proteins with acetylated lysine residues were concentrated in mitochondria.13
These data suggest that ~20% of the mitochondrial proteome may be targeted for acetyl
modification. This concept is further supported by the finding that protein acetylation is
similarly abundant in prokaryotes.14 The functional characterization of the role of lysineresidue acetylation in the vast majority of these proteins has yet to be determined.
The non-histone lysine acetyltransferases can be loosely grouped into three main
families, though there are several other identified acetyltransferases that fall outside these
defined categories.15, 16 These include the Gcn5-related N-acetyltransferase (GNAT), the
MYST and the p300/CBP families.
The Gcn5-related N-acetyltransferase (GNAT) family contains HAT1, the first
identified histone acetyltransferase,17 along with Gcn5/PCAF and multiple Nacetyltransferase (NAT) proteins. The GNAT family share 3-4 motifs involved in acetylCoA binding and catalysis, with nuclear-localized proteins and a bromodomain to
facilitate DNA binding.18, 19 A role of Gcn5 relating to mitochondrial function is inferred
by the acetylation and inactivation of peroxisome proliferator gamma coactivator 1
(PGC-1) family members, which are known to be master regulators in mitochondrial
biogenesis and mediators of mitochondrial metabolism.20 Gcn5, activated by the steroid
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receptor coactivator SRC-3, acetylates the PGC1α and β, which inhibits their regulatory
control of mitochondrial content and metabolic functioning.21-23
The MYST family, named after the original members MOZ, YBF2, SAS2 and
TIP60, share both a ~240 amino acid core acetyl-CoA-binding domain and a C2HC zincfinger domain.24 MYST proteins are found throughout the Eukaryota and are
predominantly involved in histone acetylation, although some members are also involved
in the regulation of transcription factors such as p53.25 Tat-interactive protein 60 (TIP60)
is transiently expressed in heart tissues during early embryonic development, suggesting
that acetylation is involved in regulating cardiac myocyte differentiation.26
Finally, there is the p300/CBP (CREB binding protein) family, which are large
nuclear proteins that function as transcriptional co-regulators which have intrinsic histone
acetyltransferase activity.27, 28 It has subsequently been shown that these large multidomain proteins additionally have non-histone acetyltransferase activity and are capable
of PGC-1α acetylation.29 The presence of p300 is required for the correct formation of
several mouse tissues, with a single mutant allele being sufficient to produce major
defects in heart structure and coronary vascularization.30 p300 also acetylates the early
embryonic transcription factor GATA-4 which functions in differentiating embryonic
stem cells into cardiac myocytes and in the development of cardiac hypertophy.31, 32
Collectively, it appears that the lysine-acetyltransferases are crucial for several steps in
cardiac development, and may play a role in mitochondrial biology via this regulation of
PGC-1. Interestingly, despite the prevalence of acetylated lysine residues on numerous
mitochondrial proteins, to date mitochondrial enriched lysine-acetyltransferases have not
been identified and are therefore not discussed further in this review.
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Lysine Deacetylase Enzymes
The mammalian deacetylases are grouped according to phylogenetic analysis and
sequence homology. The mammalian class I and II enzymes are nuclear and cytosolicnuclear localized enzymes respectively that predominantly function as HDACs. To date,
one HDAC has sequence similarity to both class I and II enzymes and has been
designated as a class IV enzyme. Class I, II and IV enzymes have zinc-dependent
deacetylase activity.33 The sirtuins are designated as class III deacetylases and are NAD+dependent enzymes. The founding member of these enzymes is yeast Sir2, which silences
chromatin via deacetylation of histones.34 Sir2 enzymes have been shown to mediate
lifespan extension in yeast, worms and flies and are postulated to function, in part, via the
modulation of mitochondrial function.9 Mammals have 7 sirtuin enzymes designated as
SIRT1 through SIRT7. These have distinct tissue distributions and subcellular
localizations which together probably contribute to their distinct biological functions 35.
The mammalian sirtuins are further phylogenetically divided into five subclasses based
on the homology of their 250 amino acid core domain.36 The mitochondrial enriched
SIRT3 clusters with SIRT1 and SIRT2 in subclass I. These three enzymes show closest
homology to yeast Sir2 and exhibit the most robust deacetylase activity. The additional
mitochondrial enriched sirtuins SIRT4 and SIRT5 are assigned to subclasses II and III,
and exhibit predominant ADP-ribosyltransferase and deacetylase activity respectively.37,
38

NAD+ Biochemistry
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As sirtuin activity is dependent on NAD+, it has now been established that sirtuin
activation is directly linked to the energetic and redox status of the cell as measured by
the ratio of NAD+:NADH, by the absolute levels of NAD+, NADH, and by the NAD+
catabolite nicotinamide.39-41 Interestingly, nicotinamide itself inhibits sirtuin activity and
nicotinamide-depletion during NAD biosynthesis inversely activates sirtuins.42
The NAD biosynthetic pathways are distinct in prokaryotes and invertebrates
compared to vertebrates (reviewed43). We only briefly review vertebrate biochemistry
here. De novo biosynthesis using tryptophan and nicotinic acid as precursors is the minor
pathway for NAD generation. However, this pathway is induced by exercise and
following the administration of peroxisome proliferator activated receptor alpha
(PPARα) agonists.44, 45 The predominant pathway to generate NAD involves the salvage
of NAD using nicotinamide as the precursor. In mammals there are two intermediary
steps in NAD generation, initiated by the conversion of nicotinamide to nicotinamide
mononucleotide (NMN) via the nicotinamide phosphoribosyltransferase (NAMPT)
enzyme. Nicotinamide/nicotinic acid mononucleotide adenylyltransferase (NMNAT)
then converts NMN to NAD. These biochemical pathways are most well characterized in
the nucleus, and are pivotal for the activity of SIRT1.46 Moreover, NAMPT has been
identified as the rate-controlling step in NAD biosynthesis in that overexpression of
Nampt but not Nmnat increased cellular NAD levels.46
The investigation into the biology of NAD in the mitochondria has begun to be
explored, and the identification of a mitochondrial-enriched NMNAT isoform supports
the concept of subcellular compartment specific functioning of NAD biosynthesis.47
Moreover, mitochondrial NAD+ levels can now be measured by mass spectroscopy.48
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Using this novel technique, the metabolic stress of fasting has been shown to increase
mitochondrial NAMPT and to concomitantly induce mitochondrial NAD+ levels.48
Sirtuin Biochemistry
Sirtuins are known to deacetylate lysine residues on histone and non-histone
proteins.49, 50 This deacetylation of target residues, coupled to the cleavage of NAD+
results in the generation of nicotinamide and the metabolite O-acetyl-ADP-ribose
(OAADPr). The deacetylation of lysine residues on non-histone proteins modulates their
cognate target protein function, as evidenced by the activation of Peroxisome proliferator
activator receptor Gamma Coactivator - 1 alpha (PGC-1α) following its deacetylation by
SIRT1.29, 51 Two potential biological consequences of lysine deacetylation include the
unmasking of lysine to facilitate other PTMs, and a putative biological role following the
generation of OAADPr.
In terms of PTMs, the lysine residue is highly promiscuous, with the potential to
undergo, for example, acetylation, methylation, ubiquitinylation or SUMOylation on their
ε-amino group (reviewed16). This multi-potential capacity for individual residue
modification, the potential competition between these distinct PTMs at the same site and
the emerging data to support cross-talk between multiple protein residue modifications
highlights the emerging complexity of intramolecular signaling that may well govern
biological processes.16 The role of lysine acetylation and/or deacetylation in this complex
interplay is a challenging concept to be explored.52
Interestingly the deacetylation metabolite OAADPr itself may directly facilitate posttranslational modulatory effects following the enzymatic transfer of ADP-ribosyl groups
266	
  
	
  

	
  

to proteins.53 Although mono-ADP-ribosylation enzymes have been characterized in
prokaryotes, and in extracellular compartments in eukaryotes, identification of
intracellular enzymes in eukaryotes has been elusive.54 Sirtuins may possess the dual
functionality, as both enzymatic deacetylases, and as mono-ADP ribosyltransferases
using OAADPr as substrate for this PTM. To date, the mitochondrial- and nuclearenriched SIRT4 and SIRT6 proteins respectively, exhibit ADP-ribosyltransferase
activities.37, 55 However, the rate-constant of sirtuin ADP-ribosyltransferase activity is
5000 fold lower than classical bacterial enzymatic rates, and 500 times weaker than their
deacetylase activities.56 These data question the physiological role of sirtuins in monoADP-ribosylation, however, the development of tools to investigate this biochemistry and
to identify the target proteome57 should facilitate major advances in our understanding of
this component of NAD and sirtuin biology in the near future. A diagram depicting NAD
biosynthesis pathways are shown as the top half of figure 1.
Sirtuin Subcellular Localization
The subcellular localization of the sirtuins is probably a pivotal feature in dictating
their biological targets. Of the sirtuins known to modulate mitochondrial biology, SIRT1
has been established to predominantly reside and function in the nucleus, SIRT2, in the
cytoplasm, SIRT4 in the mitochondria matrix and SIRT5 in the inner mitochondrial
membrane58 or matrix.38 These locations are not exclusive and may be dynamic under
specific conditions. For example, SIRT1 is exclusively nuclear during cardiac
embryogenesis and then displays both nuclear and cytoplasm postnatal localization.59
Similarly, the subcellular localization of SIRT3 is predominantly in the mitochondrial
matrix,60-62 although some studies suggest that SIRT3 is exclusively mitochondrial 63
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Figure 1. Biochemistry of NAD biosynthesis and sirtuin activity. The de novo pathway is
the minor pathway and the salvage pathway the major pathway. The solid lines depict the
biochemical pathways. The white boxes with their hatched lines represent biochemical
and physiologic mediators of the NAD biosynthesis and sirtuin activation pathways. The
black box shows the consequences of sirtuin mediated deacetylation. The hatched box
represents a hypothetical modification that has not been robustly characterized.
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mononucleotide; NAMPT – nicotinamide phosphoribosyltransferase; NMNAT –
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while others show nuclear and cytosolic locations in whole tissue preparations64 and
following overexpression studies.65-67 Whether changes in the subcellular localization of
SIRT3 are associated with biological stressors, are tissue specific62, 64 or result from the
genetic manipulation studies is not completely resolved. Nevertheless, the capacity of
SIRT3 to alter its subcellular localization with compartment distinct functions is an
intriguing concept that warrants further investigation.
Biological Triggers Orchestrating Sirtuin Activity
The biochemical pathways operational in sirtuin regulation suggest that metabolic
cues are integral to their activity. Moreover, as the ratio of NAD:NADH is an important
regulator of the cellular redox state, oxidative stress signaling may similarly be
implicated in the regulation of sirtuin activity. More recently, the AMP-activated protein
kinase (AMPK), the prototypic fuel sensing signaling kinase has also been found to
modulate sirtuin activity.
Caloric restriction, which promotes cell survival and longevity functions, in part,
through increasing NAD+ levels. As such, the modulation of sirtuin levels and activity
has been investigated in response to this nutrient deficit. SIRT1, SIRT2 and SIRT3 levels
and activity are induced in multiple organs in response to caloric restriction.67-69 However,
the uniformity of this response has been questioned with the demonstration that both the
ratio of NAD:NADH and SIRT1 levels are decreased in the liver in response to caloric
restriction.70 Similarly, at least in pancreatic b-cells, SIRT4 activity is diminished in
response to caloric restriction.37
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Other modifications of nutrient exposure are also implicated in the regulation of
sirtuins. In contrast to chronic caloric restriction, fasting acutely increases NAD:NADH
ratio in the liver, activating SIRT1.71 A consequence of fasting induced SIRT1 induction
is the deacetylation and activation of PGC-1α and PGC-1β leading to the activation of
mitochondrial metabolism.22 Conversely, elevated glucose has been shown to
downregulate SIRT1 in skeletal muscle and in hepatocytes,

71

while insulin, with or

without elevated glucose, similarly downregulates SIRT1.68, 72 Although nutrient
mediated modulation of the mitochondrial enriched sirtuins has not been extensively
studied, SIRT3 is downregulated in skeletal muscle in mice with streptozotocin induced
severe hyperglycemia73 and in brown adipose tissue in various murine genetic models of
obesity.67 In human subjects SIRT3 levels have been shown to be diminished in skeletal
muscle of sedentary older individuals, while endurance training ameliorates this effect.74
By virtue of the fact that sirtuins are activated by changes in the cellular redox
state as reflected by their induction with higher levels of oxidized NAD+ or a change in
the ratio of NAD+ to its reduced NADH form, imply these enzymes as redox sensitive. To
date, all three subclass I sirtuins i.e. SIRT1, SIRT2 and SIRT3 have been shown to be
induced by oxidative stressors.64, 69, 75, 76 Interestingly, with respect to cardiac
biomechanical stressors, pressure overload and angiotensin II have been shown to
increase SIRT1 and SIRT3 levels in the heart and cardiomyocytes respectively.64, 75
A more global role of AMPK in modulating the sirtuins has not been established.
However, AMPK activates SIRT1 by increasing intracellular NAD+ levels77 and
conversely SIRT1 deacetylates and activates the AMPK kinase LKB1.78 These
observations suggest integrated biological effects of these two major nutrient and redox
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stress sensors in the cell. How these collectively modulate mitochondrial deacetylases
and organelle homeostasis, however, has not been well characterized. The biochemistry
of Sirtuin activation and the biological triggers modulating this program are schematized
in the lower half of figure 1.

Modulation of mitochondrial function via nuclear protein lysine-acetylation
The control of mitochondrial function is not restricted to regulatory events within
the mitochondria itself as exemplified by inter-genomic regulation between the nuclear
and mitochondrial genomes and due to nuclear regulation of the intrinsic mitochondrial
apoptotic program. Thus, it stands to reason that acetyl modification of non-histone lysine
residues of nuclear proteins may be operational in the control of mitochondrial integrity
and function.
The nuclear enriched SIRT1 has been shown to deacetylate numerous
transcription factors and transcriptional co-activators that are known to control
mitochondrial function. This includes the deacetylation and activation of PGC-1α.
. Activation of this transcriptional co-activator is known to upregulate mitochondrial
biogenesis and increase mitochondrial metabolism with tissue specific preference.20, 79, 80
Furthermore, SIRT1-mediated deacetylation of FoxO proteins has been linked to the
preferential activation of stress resistant targets81, 82 including the induction of
mitochondrial antioxidant defenses. The deacetylation of p53 inactivates this
transcription factor, thereby attenuating its pro-apoptotic action. Finally, the nuclear
encoded mitochondrial transcription factor A (TFAM) has been shown to undergo acetyl
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PTM, however, the regulatory enzymes controlling this reaction and its functional
significance, remains to be shown.83 In adipose tissue SIRT3 overexpression has also
been shown to upregulate PGC-1α and promote mitochondrial uncoupling.67 However,
the veracity of this data has been questioned due to the lack of alteration in thermogenesis
in SIRT3 knockout mice exposed to hypothermic stress.62

Known Mitochondrial Targets of Lysine Acetylation/Deacetylation
The suggestion that mitochondria contain acetyltransferase and deacetylase enzymes
was recognized in 1962, with the demonstration that isolated mitochondria could
reversibly acetylate carnitine.84 The biology and multiple enzymes involved in carnitine
ester formation has now been firmly established.85 However, the biochemistry and
functional role of mitochondrial protein lysine acetylation is less well characterized and
has become a recent focus of study in the context of the identification of mitochondrial
enriched lysine-deacetylases.
Whether the mitochondrial enriched sirtuins (SIRT3, 4 and 5) function as
deacetylases has recently been explored, using genetic deletion of each of these three
genes to investigate global hepatic mitochondrial protein lysine acetylation.62 While the
SIRT4 and SIRT5 knockouts showed little change relative to the control mice, the SIRT3
knockout show enhanced mitochondrial protein acetylation, suggesting that SIRT3 is a
major mitochondrial deacetylase.62 Despite these post-translational changes, no obvious
basal phenotype is evident in the SIRT3-/- mice. However, using affinity purification and
mass spectroscopic analysis multiple SIRT3 interaction proteins have begun to be
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identified and a majority of these putative interacting proteins reside and function in the
mitochondria.86
The functional characterization of individual target proteins is now being actively
investigated. The mitochondrial enzyme acetyl-CoA synthetase 2 (AceCS2) was the first
target of SIRT3 to be identified and partially characterized.87, 88 ACS2 is inactivated
following acetylation and rapidly reactivated by SIRT3-mediated deacetylation.87, 88
Interestingly, AceCS2 is abundant in the murine heart and skeletal muscle and has been
shown to be induced during ketosis.89 This implies that AceCS2 is involved in acetate
conversion for energy production under ketogenic conditions. The functional
characterization of the modulation of AceCS2 by SIRT3 in the heart has yet to be
explored. Two additional mitochondrial matrix proteins have been identified as substrates
of SIRT3 and in both instances lysine deacetylation results in increased enzyme activity.
These include glutamate dehydrogenase (GDH) which facilitates the oxidative
deamination of glutamate to alpha-ketoglutarate, and the citric acid cycle enzyme
isocitrate dehydrogenase 2 (ICDH2).58, 62 Interestingly GDH is also a substrate for SIRT4
and this interaction results in the ADP-ribosylation and inactivation of GDH.37 The
functional significance of the opposing effect of SIRT3 and SIRT4, on GDH activity,
requires further characterization. The most recent functional characterization of a
mitochondrial matrix metabolic target of the sirtuins is the interaction with, deacetylation
of, and activation of the urea cycle enzyme carbamoyl phosphate synthetase 1 (CPS1) by
SIRT5.38 This enzymes functions to detoxify and dispose of ammonia and in the SIRT5
knockout mouse, fasting results in elevated serum ammonia levels.38
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SIRT3 has also been shown to physically interact with NDUF9A, a subunit of
complex I of the electron transfer chain.90 The interaction of SIRT3 with this inner
mitochondrial membrane protein results in its deacetylation and activation and the
genetic depletion of SIRT3 accordingly compromises complex I activity and ultimately
mitochondrial oxygen consumption and ATP production.90 SIRT5 has also been shown
to associate with an electron transfer chain protein, i.e. cytochrome c, although the
functional consequences of this interaction has not to date been established.58 Figure 2
schematizes the currently identified nuclear, cytosolic and mitochondrial proteins that are
targets of sirtuin deacetylation and PTM.
Although a role of sirtuins in modulating outer mitochondrial membrane proteins has
not been functionally characterized, it has recently been shown that long chain acyl CoA
synthetase isolated from the outer membrane, also undergoes lysine-residue acetylation.91

Roles of Mitochondrial Protein Lysine Acetylation in the Heart
To date, the interrogation of the function of sirtuins in the heart has been limited,
especially with respect to mitochondrial enriched sirtuins. However, prior studies linking
sirtuins to metabolism, apoptosis, autophagy and aging suggest that altering sirtuin
activity may modulate cardiovascular function and the responses to pathophysiological
stressors. This inference is further supported by the induction of NAMPT in rat
cardiomyocytes in response to both hypoxia and serum deprivation.48 In that study,
NAMPT mediated protection against cell death via mitochondrial NAD+ salvage was
dependent on the presence of SIRT3 and SIRT4.48
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Cardiac SIRT1 levels are induced by pressure overload, in response to the
systemic administration of the oxidative stressor paraquat, with heart failure and during
aging.75, 92 Together, these changes suggest that SIRT1 is modulated in response to
cardiac biomechanical stressors. The first study to functionally characterize sirtuin
function in the heart employed SIRT1 transgenic mice.75 Low to moderateoverexpression attenuates age-associated cardiac fibrosis, apoptosis, hypertrophy and
cardiac dysfunction. Furthermore, modest SIRT1 induction protects against cardiac
oxidative stress. The mitochondrial salutary effects associated with this SIRT1 induction
include: increased FoxO dependent catalase expression; elevated cellular ATP levels and
increased mitochondrial citrate synthase activity.75 A gene-dose effect of SIRT1 is
evident in that transient overexpression of SIRT1 in cardiomyocytes prevents apoptosis
via deacetylation and inactivation of p53,92 but robust SIRT1 induction in transgenic mice
results in increased cardiac apoptosis, fibrosis and hypertrophy.75
Anoxia-reoxygenation stress in cardiac derived H9c2 cells results in the induction of
the cytoplasm enriched sirtuin, SIRT2.76 Conversely, we have previously observed, in
unpublished data, that cardiac SIRT2 gene expression is diminished by the
cardioprotective program induced by delayed ischemic preconditioning.93 To
characterize the stress-response to SIRT2 downregulation we used siRNA to genetically
deplete SIRT2 in H9c2 myoblasts.76 SIRT2 depletion upregulates the cytosolic chaperone
14-3-3ζ, which in turn sequesters the pro-apoptotic mitochondrial protein BAD in the
cytosol and augments tolerance against anoxia-reoxygenation induced cell death.76
Interestingly, the biology of SIRT2 in cellular homeostasis is not exclusively determined
by levels of this deacetylase but also appears to have opposing functions under basal and
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stress conditions.69 These divergent phenotypes are illustrated by SIRT2-mediated
induction of mitochondrial manganese superoxide dismutase via FOX3a deacetylation
with the subsequent attenuation of reactive oxygen species levels at baseline. In contrast,
under conditions of increased oxidative stress, SIRT2 promotes cell death in parallel with
the induction of the pro-apoptotic protein Bim.69 Collectively these studies show that
despite its extra-mitochondrial localization, SIRT2 modulates mitochondrial function via
the modulation of mitochondrial pro-apoptotic proteins and via mitochondrial antioxidant
enzyme regulation.
In rat neonatal cardiomyocytes SIRT3 levels are increased in response to H2O2, the
alkylating agent MNNG, serum-starvation, and in response to phenylephrine and
Angiotensin II. 64 This regulation shows similarity to SIRT1 and suggests stressresponsive functioning. In parallel, SIRT3 overexpression in cardiomyocytes enhanced
resilience to genotoxic and oxidative stress. 64 An identified target for this ameliorative
function is the deacetylation of Ku70. Ku70 is predominantly localized to the nucleus,
although it is evident as a smaller cytoplasmic pool.94 The cytoplasmic pool is proposed
to sequester the pro-apoptotic Bax protein and prevent its translocation to the
mitochondria.94 During stress Ku70 is acetylated, which facilitates the release of Bax to
promote mitochondrial-mediated apoptosis.95 Conversely, SIRT3 and SIRT1 both
deacetylate Ku70, sequestering Bax in the cytosol and reducing genotoxic cell death.64 A
recent study shows that SIRT3 knockout mice, display increased cardiac hypertrophy and
interstitial fibrosis with an increased susceptibility to the development of angiotensin IIinduced hypertrophy.96 In parallel, the cardiac restricted transgene overexpression an
SIRT3 isoform ameliorates this phenotype. The mechanism of SIRT3 mediated
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protection here is shown to be via Foxo3a mediated induction of anti-oxidant defense
enzymes suggesting, in part, a nuclear regulatory role of SIRT3 in cardiac stressmediated adaptation.96
For completeness sake, we note that a cardiac phenotype is also evident in SIRT7
knockout mouse although whether this is associated with modulation in mitochondrial
biology or function has not been investigated.97 SIRT7 resides in the nucleoli and
following its genetic depletion mice develop and die from cardiac hypertrophy and an
inflammatory cardiomyopathy.97 The absence of SIRT7 in primary murine
cardiomyocytes enhances p53 acetylation, additionally leading to increased apoptosis and
increased susceptibility to oxidative and genotoxic stressors.97
Potential Roles of Mitochondrial Protein Lysine Acetylation in Vascular Biology
Sirtuin function in the vasculature has not been directly explored; however, sirtuin
biology is beginning to be investigated in biological programs that in part modulate
vascular function, including nitric oxide biology, angiotensin signaling and hypoxia
responsiveness.
Nitric oxide (NO) is a multifunction signaling molecule with diverse vascular
functions which include the modulating of blood vessel tone, leukocyte adhesion, platelet
activation and the development of atherosclerosis.98 Interestingly, NO also regulates
mitochondrial biology through the modulation of the mitochondrial biogenesis regulatory
program and via the regulation of electron transfer chain flux.99-101 The salutary effects of
calorie restriction on mitochondrial biogenesis and metabolism has been shown to be
dependent on NO, and this molecule is furthermore implicated in the transcriptional
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induction of SIRT1.102 SIRT1 itself deacetylates and activates endothelial NOS (eNOS),
which via the generation of NO promotes endothelial dependent vasodilation.103
Together these regulatory events align with the known blood pressure lowering effect
associated with caloric restriction,104 although whether mitochondrial biology per se
and/or NO are important in these biological effects is yet to be determined.
Renin-angiotensin system (RAS) activation contributes to cardiovascular and renal
disease resulting in significant morbidity and mortality. Deletion of the Ang-II type 1a
receptor (AT1R) in mice extends their lifespan in association with blood pressure
reduction and decreased cardiac hypertrophy and fibrosis.105, 106 Interestingly AT1R
deletion leads to the upregulation of genes encoding for SIRT3 and NAMPT in the
kidney.105 Consistent with this but in contrast to the heart, angiotensin II administration
downregulates Sirt3 gene expression in cultured proximal tubule epithelial cells.105 As
the kidney is central in angiotensin II induced hypertension,107 whether the modulation of
SIRT3 and by inference mitochondrial biology plays a role in this pathophysiology is
unknown. Interestingly and of relevance to the modulation of blood pressure, the
overexpression of SIRT1 in vascular smooth muscle cells results in the downregulation of
AT1R.108 In parallel, the SIRT1 activator resveratrol represses AT1R gene transcription
and this pharmacologic compound blunts angiotensin II-induced hypertension in mice.108
Taken together, these data reveal a complex interaction between SIRT1 and SIRT3 and
the RAS system, with apparent target organ specific effects. Although intriguing, the
associations between sirtuins and hypertension-target organ biology are observational,
and mechanistic studies need to be performed to understand the role of deacetylases and
the mitochondria in this disease process.
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Hypoxia is a potent trigger for the modulation of vascular tone and to promote
angiogenesis. The latter program is orchestrated by the induction of hypoxia inducible
factors (HIFs). HIFs are transcription factors that, under hypoxic conditions, regulate the
shift in cell metabolism to glycolysis; augment cell survival through induction of antioxidant systems such as Heme-oxygenase-1 and superoxide dismutase (SOD); and
initiate the angiogenesis regulatory program. This leads to improved mitochondrial
function and cell survival.109 Hypoxia-induced redox stress stimulates SIRT1 activity,
which in turn deacetylates and activates HIF-2α.41 In keeping with the role of HIF
activation, this SIRT1 mediated deacetylation results in the upregulation of, for example,
the mitochondrial anti-oxidant enzyme SOD2, and the angiogenesis regulatory factor
VEGF.41 These data suggest that through its redox-sensing capacity, SIRT1 can modulate
vascular biology via the activation of HIF-2α.
Taken together, these studies suggest that SIRT1 and SIRT3 have modulatory effects
on numerous integrated biological programs governing vascular health and adaptation.
The study into the mechanisms orchestrating these effects, and the determination of the
physiologic role of the sirtuin program in vascular pathophysiology appears to be a
promising area for future investigation. Table 1 summarizes all of the currently identified
sirtuin protein targets and their function in the modulation of mitochondrial biology.
Conclusions/Future Directions
In this review we discuss how the nutrient and redox sensing sirtuins modulate
mitochondrial function via predominant nuclear (SIRT1), cytosolic (SIRT2) and
mitochondrial (SIRT3) mediated effects. Their roles in cardiac biology have been limited
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to date, showing that: (1) the induction of SIRT1 mediated mitochondrial antioxidant and
anti-apoptotic effects, (2) anti-apoptotic effects of SIRT2 deletion in cardiac derived cell
lines and (3) SIRT3 mediated anti-apoptotic effects in response to oxidative and
genotoxic stress in primary cardiomyocytes. A direct role of sirtuins in the vasculature
has not been established but the augmentation of SIRT1 is associated with: (1) the
downregulation of angiotensin receptor type 1, (2) lowering of blood pressure and (3)
with the induction of HIF-2α mediated angiogenesis signaling and the upregulation of
mitochondrial anti-oxidant enzymes. In addition, in the long-lived ATR1 knockout mice,
which have low blood pressure, the genes encoding for SIRT3 and NAMPT are
upregulated in the kidney. Collectively these data suggest a functional role of sirtuin
biology in the modulation of cardiovascular pathophysiologic adaptations to stressors.
Further and more direct in-vivo studies to investigate this biology are warranted.
The recognition that a large number of proteins that reside in the mitochondria
undergo lysine-acetylation PTMs,13 and that their target proteins include numerous
proteins controlling fatty acid oxidation (FAO), the tricarboxylic acid cycle (TCA) and
the electron transfer chain (ETC) question whether these PTMs play an important role in
cardiac substrate preference and utilization. Substrate preference and utilization and the
efficient integration between metabolic pathways, for example coordination between the
TCA cycle with the ETC,110 and the modulation of anaplerosis111 have begun to be
recognized as important modulators of cardiac ischemia tolerance,112, 113 cardiac
hypertrophy and the transition to heart failure.114, 115 Whether lysine acetyl PTMs are
important and operational in the modulation and integration of these metabolic fluxes are
important questions that have not been addressed.
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Table 1. Summary of subcellular targets of sirtuin deacetylation or ribosylation* and
proposed functional consequences
Sirtuin

Target

Function

PGC-1α

Promotes mitochondrial biogenesis

Foxo

Upregulation of anti-oxidant defense programs

Nuclear
Targets
SIRT1

proteins

SIRT2

eNOS

? vasodilation and/or mitochondrial biogenesis effects

p53

Inactivated by deacetylation – diminishes apoptosis

HIF-2α

Upregulates anti-oxidant enzymes and VEGF

Foxo3a

Activates anti-oxidant defense programs

Foxo3a

Activates Bim to promote apoptosis under redox stress

14-3-3 ζ

Downregulation - Bad translocation - mitochondrial
apoptosis

SIRT3

Foxo3a

Upregulates anti-oxidant enzymes

PGC-1α

Upregulates genes encoding mitochondrial proteins
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Cytosolic
Targets
SIRT1

Ku70

Sequestered Bax in cytosol to inhibit mitochondrial
apoptosis

SIRT3

LKB1

Activates AMP kinase

Ku70

Sequestered Bax in cytosol to inhibit mitochondrial
apoptosis

Mitochondrial
Targets
SIRT3

AceCS-2

Acetate conversion to acetyl-CoA

GDH

Activation - deaminates glutamate to α-KG for TCA
cycle

NDUF9a

Activation of complex I of the ETC

ISDH2

Facilitates TCA cycling

SIRT4

GDH

Inactivation by ADP-ribosylation

SIRT5

Cytochrome

? Promotes electron flux through ETC

c
CPS1

Detoxification of ammonia via urea cycle
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An additional area of research that has yet to be functionally characterized, but may
be important, is the role of sirtuin biology in type 2 diabetes mellitus and obesity
associated cardiovascular perturbations. Diabetes and obesity both associate with nutrient
excess, mitochondrial dysfunction, and a predisposition to cardiovascular pathology.116, 117
Gene expression analysis shows that SIRT3 levels are diminished with obesity and
hyperglycemia. Moreover, our understanding of how nutrient excess modulates
biological function was recently enhanced with the recognition that elevated glucose
could promote acetyl modification of proteins.118 Here, increasing concentrations of
glucose promote histone acetylation through ATP citrate lyase mediated conversion of
citrate to the acetylation precursor acetyl CoA.118 Whether excess nutrients modulates
non-histone protein lysine acetylation via increasing acetyl CoA in distinct subcellular
distributions remains to be determined119 and specifically to be evaluated in the
cardiovascular system. Figure 3, schematizes both the identified pathways modified by
sirtuin biology in the cardiovascular system and highlights areas of interest that have yet
to be explored.
The pharmacologic manipulation of the sirtuins as a potential therapeutic strategy
is being investigated. The first compound explored was the plant-derived polyphenol
resveratrol (3,5,4’-trihydroxystilbene) which has been shown to upregulate both SIRT1
and AMPK.120-122 and to induce mitochondrial biogenesis.122 Consistent with its known
pleiotropic effects resveratrol administration confers protection against cardiac ischemiareperfusion injury.120, 123 Recently SIRT1-specific small molecule activators have been
identified and are shown to promote fatty acid oxidation and mitochondrial function.124
Whether these specific SIRT1 activators can directly ameliorate cardiac stress-tolerance
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Sirtuin effects on
the heart

Sirtuin effects on
vascular pathways

• Sequestration of
mitochondrial apoptotic
proteins in the cytoplasm

• ↑ HIF2α
- ↑ glucose metabolism
- promote angiogenesis
- ↑ mitochondrial antioxidant defenses
• Activation of eNOS
- ? role in mitochondrial
respiration

• ↓ p53 mediated apoptosis
• ↑ mitochondrial antioxidant enzymes

PTMs that can potentially
modulate cardiac function
• Fuel substrate selection
- PTM of FAO enzymes
• TCA to ETC coupling
- PTM of TCA and ETC proteins
• Modification in response to fuel
overload e.g. with diabetes
obesity – increased acetyl-CoA
and/or modulation of NAD:NADH

Figure 3. Potential role of sirtuin mediated modulation of mitochondrial biology in the
cardiovascular system. The direct and indirect effects of mitochondrial function that have
been characterized are shown under the heart and vascular pathways columns. The
potential effects of mitochondrial metabolic protein modifications are shown in the
column to the right. How these may affect fuel substrate use and selection and the
adaptations to direct cardiac stressors and to metabolic stresses on the heart and
vasculature have yet to be ascertained. The speculative functions of acetyl-lysine PTM’s
is highlighted by their grey background.
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and whether these effects include the modulation in mitochondrial function need to be
investigated. No specific pharmacologic modulators of SIRT3 have been described,
however numerous SIRT2 inhibitors have been identified.125-127 One of these inhibitors
has been shown to prevent the development of Parkinson’s-like disease in neuronal
cells126 and it would be intriguing to investigate this compound in the context of cardiac
redox stress.
Although, we have discussed the actions of sirtuins slanted towards the modulation of
mitochondrial function, this family of proteins has a myriad of additional functions
including for example roles in gene transcription,128 autophagy129 and the circadian
rhythm.130 Hence, although our understanding of this important non-histone lysineresidue PTM should develop with ongoing investigations, we must be cognizant of the
fact that the complexity and hierarchy of this biology is putatively more complex than the
mitochondrial-centric focus elaborated on in this review.
In conclusion, fuel and redox sensing are important cellular commodities required
to adapt to biomechanical and metabolic stressors. The PTM of non-histone lysine
residues by acetylation/deacetylation appears to contribute to these sensing programs in
the orchestration of important nuclear, cytosolic and mitochondrial responses to augment
tolerance to injury. The investigation into this field is in its early stages and although
many gaps exist in our knowledge, initial studies suggest that the modulation of this
regulatory program may be important in controlling cardiovascular stress adaptation.
Additionally, the emerging data supporting integration between sirtuin and AMPK
adaptive programs may shed insight into the complexity of intracellular metabolic
sensing and responses to nutrient and redox stress. Overall, these findings advance the
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observations of Charles Darwin from more than 150 years ago, which were initially
directed at whole organism adaptations over the long-term, to the modern interrogation of
subcellular adaptive reprogramming to acute-stressors. The recent identification and
ongoing characterization of this acetylation-dependent stress-adaptive programming
should further enlighten us to the myriad of innate programs exploited by nature to
advance survival whether acutely and/or for the propagation and survival of species.
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ABSTRACT
Obstructive sleep apnea (OSA) is associated with cardiovascular complications including
hypertension. Previous findings from our laboratory indicate that exposure to intermittent
hypoxia (IH), to mimic sleep apnea, increases blood pressure in rats. IH also increases
endothelin-1 (ET-1) constrictor sensitivity in a protein kinase C (PKC) δ-dependent
manner in mesenteric arteries. Because phosphoinositide-dependent kinase-1 (PDK-1)
regulates PKCδ activity, we hypothesized that PDK-1 contributes to the augmented ET-1
constrictor sensitivity and elevated blood pressure following IH. Male Sprague-Dawley
rats were exposed to either Sham or IH (cycles between 21%O2/0%CO2 and
5%O2/5%CO2) conditions for 7 hours/day for 14 or 21 days. The contribution of PKCδ
and PDK-1 to ET-1-mediated vasoconstriction was assessed in mesenteric arteries using
pharmacological inhibitors. Constrictor sensitivity to ET-1 was enhanced in arteries from
IH rats. Inhibition of PKCδ or PDK-1 blunted ET-1 constriction in arteries from IH but
not Sham rats. Western analysis revealed similar levels of total and phosphorylated PDK1 in arteries from Sham and IH rats but decreased protein:protein interaction between
PKCδ and PDK-1 in arteries from IH rats compared to those from Sham, consistent with
observations that increased PKCδ-phosphorylation causes dissociation from PDK-1.
Blood pressure was increased in rats exposed to IH and treatment with the PDK-1
inhibitor OSU-03012 (33 mg/day) lowered blood pressure in IH but not Sham rats. Our
results suggest that exposure to IH unmasks a role for PDK-1 in regulating ET-1
constrictor sensitivity and blood pressure that is not present under normal conditions.
These novel findings suggest PDK-1 may be a uniquely effective antihypertensive
therapy for OSA patients.
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INTRODUCTION
Obstructive sleep apnea (OSA) occurs due to a cyclical loss of pharyngeal muscle
tone during sleep, resulting in airway collapse and subsequent arousal with disruption of
sleep and restoration of airflow. Upon air flow restoration, sleep resumes and the cycle
repeats whereas central sleep apnea is caused by loss of the central drive to breathe. In
both cases, the repeated cycles of apneic events lead to intermittent hypoxia (IH) and are
associated with increased risk for hypertension, stroke, coronary artery disease,
arrhythmias, and heart failure. It is estimated that 24% of men and 9% of women
experience at least 5 apneic episodes per hour with an estimated 80% undiagnosed for
OSA (Bradley and Floras, 2009). Studies in rodent models demonstrate that chronic
exposure to IH to mimic the apneic episodes of sleep apnea causes vascular dysfunction
that might underlie the increased cardiovascular complications observed in OSA patients
(Dematteis et al., 2008).
Previous studies from our laboratory have shown that 14 days of exposure to IH
increases mean arterial blood pressure in rats (Kanagy et al., 2001). This augmented
blood pressure is dependent on activation of the endothelin-1 (ET-1) A receptor (ETAR)
and generation of reactive oxygen species (ROS); moreover, ROS mediate increased
levels of plasma ET-1 in IH-exposed rats (Troncoso Brindeiro et al., 2007). Along with
increased levels of circulating ET-1, IH rats show augmented constrictor responses in
mesenteric arteries to ET-1 but not to phenylephrine or depolarizing concentrations of
KCl (Allahdadi et al., 2005). This increased constrictor response is dependent on greater
calcium sensitivity as opposed to greater increases in intracellular calcium levels. Arteries
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from IH rats also have increased expression of the ETAR, and the increased
vasoconstrictor sensitivity to ET-1 in IH rats can be attenuated by pharmacologically
blocking ETAR (Allahdadi et al., 2005; Allahdadi et al., 2008a). We subsequently
reported that IH-augmented vasoconstriction is mediated by the δ-isoform of protein
kinase C (PKCδ) in a calcium-independent manner and that ET-1 increases PKCδ
autophosphorylation levels (Allahdadi et al., 2008b). However, it is not clear what
increases ET-1 activation of PKCδ-dependent contraction in vascular smooth muscle
from IH-exposed rats.
Similar to all members of the protein kinase A, B, and C families, PKCδ has
multiple phosphorylation sites that differentially regulate function. PKC isoforms in
particular are phosphorylated as part of the “maturation” process. Specifically,
phosphoinositide-dependent kinase-1 (PDK-1), which activates at least 23 members of
the AGC family of protein kinases, including PKC isoforms (Le Good et al., 1998) and
Akt (Bayascas et al., 2008), phosphorylates the activation loop domain in PKC,
“priming” PKC for DAG binding, autophosphorylation, and activation (Reviewed in
(Newton, 2009)). For PKCδ, Thr505 is the PDK-1 activation site, whereas Ser643 and
Ser662 are the turn motif and hydrophobic domain autophosphorylation sites, respectively
(Kikkawa et al., 2002).
Regulation of PDK-1 activity is not as well defined as that of its downstream
targets. Of interest, ROS and insulin are two known activators of PDK-1 phosphorylation
and activity. Specifically, H2O2 increases serine and tyrosine phosphorylation of PDK-1
in cultured cells (Prasad et al., 2000), whereas Zou et al. (Zou et al., 2003) observed
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increased phosphorylation of Ser241 in bovine aortic endothelial cells following exposure
to peroxynitrite. In light of the previously reported increase in ROS levels following IH
exposure, we hypothesized that increased PDK-1 activity mediates the increased ET-1
constrictor sensitivity and elevation in blood pressure following IH exposure. To test this
hypothesis, we examined the effect of PDK-1 inhibition on ET-1-dependent
vasoconstriction in mesenteric arteries from control and IH-exposed rats and used the
orally active PDK-1 inhibitor OSU-03012 to investigate a role for PDK-1 in the IHinduced increase in blood pressure.
METHODS
Rodent Model of Sleep Apnea
Male Sprague-Dawley rats (250-275 g) were exposed to either Sham or IH conditions as
described previously (Allahdadi et al., 2005; Troncoso Brindeiro et al., 2007). Briefly, all
rats were housed in enclosed Plexiglas boxes with free access to food and water. IH
exposure consisted of cycling between room air (21% O2/0% CO2) and hypoxia (5%
O2/5% CO2), whereas Sham conditions consisted of exposure to room air only in
identical boxes that subjected control rats to sounds and airflow similar to that produced
by the hypoxia cycler. Rats were exposed to 20 hypoxic episodes/hour for 7 hours/day
during their sleep period and were maintained on a 12:12-hour light:dark cycle. We have
previously shown that this IH exposure drops arterial PO2 levels from ~70 mmHg to 35
mmHg while PCO2 levels remain unchanged (Snow et al., 2008). The Institutional Animal
Care and Use Committee of the University of New Mexico School of Medicine reviewed
and approved all animal protocols. All protocols conform to the National Institutes of
Health guidelines for animal use.
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Isolated Mesenteric Artery Preparation
At the end of the Sham or IH exposure period, rats were euthanized with sodium
pentobarbital (150 mg/kg, i.p.). Mesenteric arterial arcades were isolated and placed in
physiological salt solution (PSS; in mM: 129.8 NaCl, 5.4 KCl, 0.44 NaH2PO4, 0.83
MgSO4, 19.0 NaCO3, 1.8 CaCl2, and 5.5 glucose) at 4°C until used for contractile studies
or protein analysis. Third-order mesenteric arteries with a pressurized inner diameter of
150-250 µm were dissected from the mesenteric arterial cascades and cleared of adipose
and connective tissue. An artery segment was placed in a vessel chamber (Living
Systems Instrumentation; Burlington, VT) and secured with silk thread on glass
micropipettes. Unless noted, experiments were conducted in endothelium-intact arteries.
Endothelial disruption was performed by physically rubbing the endothelium with moose
mane in a subset of experiments. Vessels were pressurized to 60 mmHg with a peristaltic
pump (Living Systems Instrumentation) and superfused with PSS (bubbled with 21%
O2/6% CO2/balance N2 and heated to 37 °C) at a rate of 5 mL/minute.
Constrictor Studies
ET-1 constriction was assessed in isolated mesenteric arteries in the absence or presence
of the following inhibitors: the nonselective PKC inhibitor Go6983 (1µM; 3-[1-[3(Dimethylamino)propyl]-5-methoxy-1H-indol-3-yl]-4-(1H-indol-3-yl)-1H-pyrrole-2,5dione;
Biomol International; Farmingdale, NY), the classical PKC (cPKC) inhibitor Go6976 (1
µM; 5,6,7,13-Tetrahydro-13-methyl-5-oxo-12H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-12propanenitrile; Biomol International), the PKCδ inhibitor rottlerin (3 µM; 3'-[(8315	
  
	
  

	
  

Cinnamoyl-5,7-dihydroxy-2,2-dimethyl-2H-1-benzopyran-6-yl)methyl]-2',4',6'trihydroxy-5'-methylacetophenone; Biomol International), the PDK-1 inhibitor OSU03012 (10 µM; 2-Amino-N-[4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1yl]phenyl]acetamide; Cayman Chemical; Ann Arbor, MI), and the phosphoinositide 3
kinase (PI3K) inhibitor LY294002 (10 µM, 2-(4-Morpholinyl)-8-phenyl-4H-1benzopyran-4-one; Cayman Chemical). The concentration used for each inhibitor was
based on previous studies that established inhibition parameters for PKC isoform(s)
(Martiny-Baron et al., 1993; Gschwendt et al., 1994; Gschwendt et al., 1996; Zhu et al.,
2004). All inhibitors were added to the PSS superfusate for 30 minutes prior to initiation
of ET-1 concentration-response curves and remained in the superfusate throughout the
contractile studies. For vehicle studies an equal volume of the appropriate vehicle was
added to the superfusate. Baseline diameter was recorded and then vessels were exposed
to increasing concentrations of ET-1 (American Peptide; Sunnyvale, CA) from 10-10 to
10-7.5 M. The presence of active tone was verified by comparison with the maximal
passive diameter in Ca2+-free PSS (in mM: 129.8 NaCl, 5.4 KCl, 0.44 NaH2PO4, 0.83
MgSO4, 19.0 NaCO3, 5.5 glucose, and 4.5 EGTA). Constriction to the PKC activator
phorbol 12,13-dibutyrate (PDBu; Sigma-Aldrich; St. Louis, MO) in the absence or
presence of OSU-03012 was also assessed in arteries from Sham rats to determine if the
effects of OSU-03012 were mediated by non-specific effects on PKC. Additionally,
constriction to PDBu was assessed in the presence of Go6983 and rottlerin to compare
the effects of OSU-03012 with general PKC and PKCδ inhibition, respectively. All data
are expressed as percent constriction compared to baseline diameter.
PDK-1 Phosphorylation
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Phosphorylation of PDK-1 at the Ser241 residue was assessed in mesenteric arteries from
Sham and IH rats. Arteries were isolated and placed in ice-cold lysis buffer (25 mM TrisHCl [pH 7.6], 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS; Thermo
Scientific; Waltham, MA) containing 1X Halt phosphatase inhibitor cocktail (Thermo
Scientific), 2.5 mM phenylmethanesulfonyl fluoride (Sigma-Aldrich), and 1X Complete
protease inhibitor cocktail (Santa Cruz Biotechnology; Santa Cruz, CA). Tissues were
homogenized and centrifuged 10 minutes at 1,500 × g at 4°C. Supernatants containing
equal protein concentrations (15 µg; as assessed by a Pierce BCA Protein Assay Kit;
Thermo Scientific) were added to 5X sample buffer, heated to 95oC for 5 minutes,
separated on a 4-15% gradient gel (BioRad Laboratories; Hercules, CA), and then
transferred to a polyvinylidene fluoride membrane. Phosphorylated and total PDK-1
protein (58-68 kDa) were analyzed following overnight incubation with phospho-PDK-1
Ser241 (1:250; Cell Signaling Technology; Danvers, MA) and PDK-1 (1:250; Cell
Signaling Technology) primary antibodies. Proteins were visualized using a LI-COR
Odyssey Infrared Imaging System (LI-COR; Lincoln, NE). Phosphorylated PDK-1 is
expressed as a ratio of total PDK-1. Total PDK-1 levels were normalized to coomassie
blue staining.
PKCδ/PDK-1 Immunoprecipitation
Association of PKCδ and PDK-1 was evaluated using a Pierce Co-Immunoprecipitation
Kit (Thermo Scientific). Mesenteric arterial arcades were isolated from Sham- and IHexposed rats, placed into 150 µL lysis buffer (25 mM Tris, 150 mM NaCl, 1 mM EDTA,
and 1% NP-40; Thermo Scientific), homogenized, and centrifuged as described above.
Following centrifugation, lysates (100 µg) were incubated overnight at 4oC in an
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immunoprecipitation column prepared with a PKCδ antibody (AbCam; Cambridge, MA)
according to the manufacturer’s protocol. Samples were eluted and prepared for Western
blotting as described above using 50 µg of protein for each sample. Blots were incubated
overnight with a PKCδ (1:250; Cell Signaling Technology) or PDK-1 (1:250; AbCam)
primary antibody at 4oC. Data are expressed as the ratio of PDK-1 (58-68 kDa) to PKCδ
(78 kDa). Total PKCδ levels were normalized to coomassie blue staining.
Blood Pressure Measurements
Blood pressure was measured by radiotelemetry in a second group of rats exposed to
Sham or IH conditions. Telemetry transmitters (Data Sciences International; St. Paul,
MN) were surgically implanted under isoflurane anesthesia with the catheter placed in the
abdominal aorta via the femoral artery; rats were allowed to recover for at least 7 days.
Baseline blood pressure was recorded for 3 days after the recovery period and then Sham
or IH exposure was initiated as described above. The IH exposure was extended to 21
days to allow for pressure to reach a plateau, as previously described (Kanagy et al.,
2001). After 21 days of Sham or IH cycling, rats received either vehicle (transgenic
dough diet; Bio-Serv; Frenchtown, NJ) or the PDK-1 inhibitor OSU-03012 (33 mg/day in
dough diet [based on a previous study (Gao et al., 2008)]; Cayman Chemical) for 3 days
with continued measurement of blood pressure and continued exposure to Sham or IH
conditions.
Statistical analysis
Concentration-response curves were analyzed by two-way repeated-measures ANOVA
and Student-Newman Keuls post hoc analysis was used to detect differences between
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groups. Western blot densitometry levels and blood pressure changes were compared by
student’s T-tests. The blood pressure response over time was compared between Sham
and IH by two-way ANOVA. Data are expressed as mean ± SEM. A p-value of <0.05
was considered statistically significant.
RESULTS
ET-1-mediated Constriction in Mesenteric Arteries
A comparison of ET-1 constriction under various conditions in mesenteric arteries
from Sham and IH rats is shown in Table 1. ET-1-mediated vasoconstriction was greater
in endothelium-intact mesenteric arteries from IH-exposed rats compared to arteries from
Sham rats (Figure 1). Pan-PKC inhibition with the non-isoform-selective inhibitor
Go6983 had no effect on ET-1-mediated vasoconstriction in mesenteric arteries from
control rats (Figure 2A) but attenuated constriction in arteries from IH rats (Figure 2B).
In contrast, Go6976, a selective cPKC inhibitor, had no effect on ET-1-induced
constriction in arteries from either Sham or IH rats (Figure 2C and 2D). These results
confirm that PKC activation contributes to ET-1-mediated vasoconstriction following IH
exposure and that the PKC isoform(s) involved is not a cPKC isoform. Much like the
non-selective PKC inhibitor Go6983, the PKCδ inhibitor rottlerin attenuated ET-1mediated constriction in arteries from IH-exposed rats but was without effect in arteries
from Sham rats (Figure 3). It has been demonstrated that rottlerin can inhibit PKCε, but
ET-1-mediated constriction was unaffected by the PKCε inhibitor V1-2myr (data not
shown). Taken together, these results suggest that PKCδ is involved in the heightened
constriction to ET-1 following IH exposure.
Effects of PDK-1 Inhibition on ET-1-mediated Constriction
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Table 1. Characteristics of Concentration-response Curves.

Group

-LogEC50

Emax

Sham

8.64 ± 0.09

70.1 ± 1.1

IH

8.70 ± 0.05

77.4 ± 0.7 *

Sham + Go6976

8.88 ± 0.10

69.2 ± 1.0

IH + Go6976

8.68 ± 0.05

74.4 ± 2.2

Sham + Go6983

8.80 ± 0.07

69.0 ± 2.2

IH + Go6983

8.70 ± 0.11

49.1 ± 3.7 *#

Sham + Rottlerin

8.64 ± 0.08

65.7 ± 2.0

IH + Rottlerin

8.45 ± 0.06

43.2 ± 4.6 *#

Sham + OSU-03012

8.41 ± 0.05

71.7 ± 1.72

8.41 ± 0.15 #

57.2 ± 2.0 *#

IH + OSU-03012

*P<0.05 vs. respective Sham treatment, #P<0.05 vs. IH.
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Figure 1: Exposing rats to two weeks of intermittent hypoxia (IH) leads to increased
constrictor sensitivity to endothelin-1 (ET-1) in endothelium-intact mesenteric arteries
when compared to arteries from Sham controls. Values are expressed as percentage of
constriction as compared to baseline lumen diameter. * denotes p < 0.05 vs. Sham;
n=10/group.
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Figure 2: Pan-PKC inhibition with Go6983 (1 µM) had no effect on ET-1-mediated
vasoconstriction in mesenteric arteries from Sham rats (A) but attenuated constriction in arteries
from IH rats (B). Go6976 (1 µM), a selective classical PKC inhibitor, did not affect ET-1induced constriction in arteries from either Sham (C) or IH (D) rats. * signifies p < 0.05 vs.
respective vehicle treatment; n=5-6/group.
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Figure 3: The PKCδ inhibitor rottlerin (3 µM) was without effect on the ET-1 constrictor
response in arteries from Sham rats (A) but attenuated constriction in response to ET-1 in
mesenteric arteries from IH-exposed rats (B). * p < 0.05 vs. vehicle treatment; n=5/group.
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Similar to the effect of the PKC inhibitors rottlerin and Go6983, ET-1-mediated
constriction in mesenteric arteries from IH rats was greatly reduced after exposure to the
PDK-1 inhibitor OSU-03012 (Figure 4). In contrast, OSU-03012 had no effect on ET-1mediated constriction in arteries from Sham rats, suggesting that ET-1 does not normally
signal through PDK-1 to constrict mesenteric arteries. PKC-mediated vasoconstriction
was measured in the absence and presence of Go6983, rottlerin, and OSU-03012 using
the PKC activator PDBu in arteries from Sham rats to verify that PKCδ can contribute to
constriction in control arteries if activated and that the effects of OSU-03012 were not
due to non-specific inhibition of PKC. As shown in Figure 4C, OSU-03012 had no effect
on PDBu-mediated vasoconstriction. Conversely, inhibition of PKCδ (rottlerin) greatly
blunted PDBu-mediated constriction while the non-selective PKC inhibitor (Go6983)
completely blocked constriction. These results suggest that OSU-03012 does not
attenuate ET-1 constriction through inhibition of PKCδ and that PKCδ can mediate
vasoconstriction in mesenteric arteries from control rats if it is activated.
It is not clear whether augmented PDK-1/PKCδ signaling in arteries from IH rats
is unique to ET-1 signaling. However, constriction to the alpha adrenergic receptor
agonist phenylephrine was similar in arteries from Sham and IH rats and was not
differentially affected by administration of OSU-03012, rottlerin or Go6983, inhibitors of
PDK-1 and PKC, respectively (data not shown).
Effects of PI3K Inhibition on ET-1-mediated Constriction
PI3K is a potential upstream regulator of PDK-1 activity; thus, the effect of PI3K
inhibition on ET-1 vasoconstriction was assessed. The PI3K inhibitor LY294002 had no
effect on ET-1-mediated constriction in mesenteric arteries from IH rats (Figure 5B);
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Figure 4: Mesenteric arteries were incubated with the phosphoinositide-dependent
protein kinase 1 (PDK-1) inhibitor OSU-03012 (OSU; 10 µM), and constriction to ET-1
was assessed. As with PKCδ inhibition, ET-1-mediated vasoconstriction was unaffected
by PDK-1 inhibition in arteries from Sham rats (A), but constriction was attenuated in
arteries from IH-exposed rats (B). (C) Constriction to the PKC activator phorbol 12,13dibutyrate (PDBu) in arteries from Sham rats was similar in the absence or presence of
PDK-1 inhibition but was diminished by non-selective PKC inhibition with Go6983 (1
µM) or inhibition of PKCδ with rottlerin (3 µM). * denotes p < 0.05 vs. vehicle
treatment; n=6-10/group.
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however, PI3K inhibition augmented ET-1-mediated constriction in arteries from Sham
rats (Figure 5A). To determine whether the augmented ET-1 constriction in the presence
of PI3K inhibition in arteries from Sham rats was due to an effect on some endothelial
factor, ET-1 constriction was evaluated in the presence of LY294002 in endotheliumdisrupted arteries. The augmented ET-1 response in arteries from Sham rats was largely
abolished by endothelial disruption, with only a slight, although significant, difference
between vehicle- and LY294002-treated arteries (Figure 5C), suggesting that PI3K may
activate both an endothelial pathway and have an additional inhibitory effect in vascular
smooth muscle. PI3K inhibition had no effect in endothelium-disrupted arteries from IH
rats (Figure 5D). Overall these data suggest that the contribution of PDK-1 to augmented
ET-1 constrictor sensitivity in IH is independent of PI3K activity.

PDK-1 Phosphorylation and Interaction with PKCδ
Phosphorylation of PDK-1 at the Ser241 residue was measured as one indication of
PDK-1 activity. There were no detectable differences in phosphorylation levels between
mesenteric arteries from Sham and IH rats (Figure 6A-B), indicating that phosphorylation
of this residue is not differentially regulated by exposure to IH. ET-1 stimulation of
arteries did not affect PDK-1 phosphorylation (data not shown). Total levels of PDK-1
were not altered by IH exposure (Figure 6C).
Interactions between PKCδ and PDK-1 in mesenteric arteries from Sham and IH
rats were assessed by measuring co-immunoprecipitation of these proteins (Figure 7)
because the degree of their interaction can be used as an indirect indication of PKCδ
activation—PKCδ phosphorylation by PDK-1 decreases its association with PDK-1 (Gao
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Figure 5: LY294002 (10 µM), an inhibitor of phosphoinositide 3 kinase, augmented
vasoconstriction in endothelium-intact mesenteric arteries from Sham rats (A) but had no
effect in arteries from IH rats (B). Treatment with LY294002 in endothelium-disrupted
arteries diminished the augmented constrictor response in Sham arteries (C) and had no
inhibitory effect in IH arteries (D). * p < 0.05 vs. respective vehicle group; n=5/group.
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Figure 6: Total and phosphorylated PDK-1 (58-68 kDa) was measured in mesenteric
artery homogenates from Sham and IH rats. Representative images are shown in (A) and
the average ratios of densitometry values of phosphorylated to total PDK-1 are shown in
(B). When expressed as a ratio of total PDK-1 protein, PDK-1 phosphorylation at Ser241
was similar between Sham and IH. Total PDK-1 was normalized to coomassie blue
staining and was not altered by IH exposure (C). The images shown include tissue from 4
rats/group and are representative of 3 replicates. (A.U. is arbitrary units.)
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Figure 7: Mesenteric artery homogenates from Sham and IH rats were
immunoprecipitated with PKCδ (78 kDa) antibody and probed for PDK-1 (58-68 kDa).
There was diminished interaction between PDK-1 and PKCδ in arteries from IH rats
compared to those from Sham rats. Total PKCδ levels were normalized to coomassie
blue staining and were not affected by exposure to IH. * p < 0.05 vs. Sham. The images
shown include tissue from 4 rats/group and are representative of 3 replicates. (A.U. is
arbitrary units.)
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et al., 2001). PKCδ was immunoprecipitated from mesenteric artery lysates and levels of
PKCδ-bound PDK-1 were assessed. The ratio of PDK-1 to PKCδ was lower in arteries
from IH rats compared to those from Sham rats (Figure 7A-B), demonstrating that IH
treatment results in decreased protein:protein interaction between PDK-1 and PKCδ and
suggesting enhanced PDK-1 phosphorylation of PKCδ. Total PKCδ levels were similar
between arteries from Sham and IH rats (Figure 7C).
PDK-1 Contribution to Blood Pressure
Blood pressure was measured continuously at baseline and throughout the Sham
or IH exposure period. Blood pressure was elevated after exposure to IH was initiated,
but Sham exposure had no effect on blood pressure (Figure 8). Three days of treatment
with the PDK-1 inhibitor OSU-03012 significantly decreased blood pressure in IH rats
compared to pressure prior to beginning treatment with OSU-03012; however, PDK-1
inhibition did not affect blood pressure in Sham rats. Treatment with OSU-03012 did not
affect plasma concentrations of ET-1 in Sham or IH rats. These results provide evidence
of a role for PDK-1 in the IH-induced increase in blood pressure.
DISCUSSION
The findings of this study demonstrate that PDK-1 and PKCδ contribute to the
observed increase in ET-1 vasoconstrictor sensitivity in a rodent model of sleep apnea.
Furthermore, PDK-1 contributes to the elevated blood pressure observed following
chronic exposure to IH to mimic sleep apnea. These results provide the first evidence of a
novel role for PDK-1 in blood pressure regulation and ET-1 constrictor sensitivity that is
not present under normal conditions but is unmasked after exposure to IH.
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Figure 8: Blood pressure was monitored by telemetry at baseline and throughout Sham
and IH exposure protocols (A). The gray box indicates the period of vehicle or OSU03012 (OSU; 33 mg/day) treatment. The change in mean arterial pressure compared to
baseline is shown in (B). Exposure to IH caused an increase in blood pressure, but Sham
conditions did not. (C) Treatment with the PDK-1 inhibitor OSU caused a decrease in
blood pressure in IH but not Sham rats. * p <0.05 vs. Sham; n=4-6/group.	
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In agreement with previous findings using endothelium-disrupted mesenteric
arteries (Allahdadi et al., 2008b), this study demonstrates that augmented ET-1-mediated
vasoconstriction is dependent on PKCδ in endothelium-intact mesenteric arteries. This
PKCδ-dependent mechanism does not appear to be present in all vascular beds since
isolated aortic segments from Sham- and IH-exposed rats both show attenuated
vasoconstriction in response to pan-PKC and cPKC inhibitors but PKCδ inhibition has no
effect (Allahdadi et al., 2008b). Furthermore, inhibition of PDK-1, a kinase activator of
PKCδ, with OSU-03012 attenuates ET-1-mediated vasoconstriction in arteries from IH
rats, not in those from Sham rats.
Previous studies from our laboratory showed that 2-week exposure to IH
increased blood pressure with a corresponding augmentation of vasoconstrictor reactivity
to ET-1 (Kanagy et al., 2001; Allahdadi et al., 2005). Circulating concentrations of ET-1
are increased following exposure to IH, and both increased ET-1 expression and
increased blood pressure were attenuated by in vivo treatment with the antioxidant
tempol, suggesting that the IH-induced increase in blood pressure is oxidative stress
dependent (Troncoso Brindeiro et al., 2007). We also reported that the IH-induced
increase in blood pressure is prevented or reversed by ETAR antagonists (Kanagy et al.,
2001; Allahdadi et al., 2008a).
Our results indicate that PKC inhibitors that block PKCδ activity inhibit ET-1mediated constriction in mesenteric arteries from IH rats, but those that do not inhibit this
isoform are without effect. Therefore, even though rottlerin has non-PKCδ targets
(Soltoff, 2007) the selective attenuation of ET-1 constriction in arteries from IH rats,
suggests that one or more targets of rottlerin —PKCδ or others—is activated by ET-1
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only in IH arteries. Taken together with the finding that OSU-03012 attenuates ET-1
constrictor sensitivity only in arteries from IH rats, our results suggest that exposure to IH
unmasks a novel ET-1 constrictor pathway that includes both PDK-1 and PKCδ that is
not present under normal conditions.
Results of the current study highlight a novel role for PDK-1 in regulating
cardiovascular function following exposure to IH. The majority of studies using the
PDK-1 inhibitor OSU-03012 have focused on cancer therapy and the drug’s ability to
block Akt signaling rather than using it as a tool to inhibit PKC signaling (Zhu et al.,
2004; Gao et al., 2008). Thus, the current finding that PDK-1 can regulate constrictor
sensitivity to ET-1 and blood pressure following exposure to IH is the first suggestion
that this kinase may play a role in blood pressure regulation under some conditions.
The increase in blood pressure following IH exposure likely involves multiple
pathways rather than simply being a result of increased PDK-1/PKCδ activity. Previous
studies from our laboratory have demonstrated that inhibiting the ETAR (Allahdadi et al.,
2008a) or scavenging of ROS (Troncoso Brindeiro et al., 2007) completely prevent or
reverse the IH-induced increase in blood pressure, suggesting that pathways contributing
to elevated blood pressure are downstream of these mediators. Additionally, PDK-1 has
multiple targets, including Akt. It is possible that a 3-day treatment with the PDK-1
inhibitor OSU-03012 impairs Akt and NO signaling to mitigate blood pressure lowering
in the Sham rats.
As described above, PDK-1 can be activated by binding to phosphoinositides,
such as phosphoinositol 3,4,5-tris-phosphate (PIP3) generated by PI3K. However, PI3K

333	
  
	
  

	
  

inhibition with LY294002 did not affect ET-1-induced constriction in mesenteric arteries
from IH rats even though PI3K inhibition augmented vasoreactivity in endothelium-intact
arteries from Sham rats. This augmented constriction in the Sham group could be due to
inhibition of PI3K/PDK-1/Akt activation of endothelial nitric oxide synthase (eNOS)
(Dimmeler et al., 1999; Zeng et al., 2000; Xiao-Yun et al., 2009). This is supported by
the observation that disrupting the endothelium greatly attenuated the effect of PI3K
inhibition in arteries from Sham rats but has not been confirmed by direct measurement
of nitric oxide (NO) production or eNOS activity. The lack of effect of LY294002 in the
arteries from IH rats suggests that these arteries have lower basal NO production or some
other form of endothelial dysfunction that may contribute to the hypercontractile state
mediated by ET-1 and PKCδ as shown in Figure 3. This potential loss of a PI3Kdependent dilator effect following IH warrants further investigation.
PDK-1 can be activated by conformational changes following binding of lipid
products such as PIP3 at the pleckstrin homology (PH) domain. However the lack of
effect on ET-1 vasoreactivity by LY294002 in IH vessels suggests that the augmented
PDK-1/PKCδ contribution to ET-1-induced constriction apparent after IH exposure is not
caused by increased PIP3 production. Indeed, other studies demonstrated that lipid
binding at the PH domain does not affect PKC phosphorylation levels (Bayascas et al.,
2008), and PDK-1 phosphorylates PKC even when the PH domain is mutated
(Sonnenburg et al., 2001). Our results are thus more consistent with PDK-1 relying on
PI3K-generated PIP3 to activate Akt and eNOS but phosphorylating PKC independently
of PIP3 binding to its PH domain.
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Interestingly, our data suggest that IH exposure diminishes the physical
association of PKCδ and PDK-1. Gao and colleagues (Gao et al., 2001) demonstrated that
PDK-1 preferentially binds unphosphorylated PKCβII over the phosphorylated form and
concluded that PDK-1 not only phosphorylates the activation loop of PKCβII and
upregulates PKCβII autophosphorylation, but it is the release from PDK-1 that primes
PKCβII for autophosphorylation. Therefore, the decreased association of PDK-1 and
PKCδ observed in mesenteric arteries from IH-exposed rats is consistent with the
previous observation of increased PKCδ autophosphorylation (Allahdadi et al. H920H927), and thus increased PKCδ activation.
The mechanism by which IH exposure leads to dysregulation of PDK-1 and its
downstream target PKCδ is not yet defined. We have previously shown that arteries from
IH rats have increased levels of ROS (Troncoso Brindeiro et al., 2007) and ROS have
been shown to activate PDK-1 (Prasad et al., 2000; Zou et al., 2003), raising the
possibility that IH-induced elevations in ROS may contribute to the aberrant PDK-1
signaling in mesenteric arteries from IH rats. Block et al. (Block et al., 2008) showed that
increased ROS in mesangial cells activate the tyrosine kinase Src, which phosphorylates
PDK-1, increasing its activity. Tyrosine kinases such as Src have also been shown to
activate PKCδ (Rybin et al., 2007) and may contribute to IH-mediated increases in PDK1 and PKCδ activity, and future studies examining the effects of ROS on PDK-1 activity
and phosphorylation of its target PKCδ may provide insight into the mechanism of IHinduced dysregulation of PDK-1 signaling. Of interest, constriction to phenylephrine and
PDBu is similar in arteries from Sham and IH rats and vascular expression of PDK-1 and
PKCδ is not increased by IH. Thus it appears that IH augments ET-1 constriction by
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facilitating coupling of the ETAR to PKCδ in a PDK-1-dependent manner and that the
blood pressure lowering effect of OSU-03012 in IH but not Sham rats, similar to our
earlier findings with ETAR antagonists, is consistent with a selective effect of IH on ET-1
constriction.
In conclusion, our results indicate that exposure to IH increases constrictor
sensitivity to ET-1 in a PDK-1- and PKCδ-dependent manner. This pathway is not active
under normal conditions, as evidenced by the lack of effect of PDK-1 and PKCδ
inhibitors in control conditions, but is unmasked by IH exposure. Although PDK-1 does
not appear to regulate blood pressure under normal conditions, our results provide novel
evidence that PDK-1 contributes to the IH-induced elevation in blood pressure. The
intriguing role of PDK-1 in various pathologies such as cancer, diabetes, and insulin
resistance, and now OSA-induced hypertension, suggests that this kinase plays a pivotal
role in vascular smooth muscle cell biology. With a PDK-1 inhibitor already in clinical
trials, PDK-1 may provide a novel therapeutic target for blood pressure regulation in
OSA patients.
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